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ABSTRACT
This project was performed in order to determine whether exercise-induced 
increases in plasma cortisol concentrations may be responsible for enhanced 
lymphokine activated killer (LAK) cell activity. Secondly, this project included 
preliminary experiments which were designed to test the hypothesis that stimulatory 
effects of cortisol on LAK cell activity may be due to cross-talk between signalling 
systems important to glucocorticoid effects and stimuli which act through nuclear 
activator protein-1 (AP-1).
Blood samples were collected from resting horses in order to determine 
whether the animals had normal plasma glucocorticoid concentrations. All horses 
included in these experiments had 10'7 to 10'8M cortisol concentrations and samples 
collected over a 24 hour period exhibited a normal diurnal rhythm.
Plasma cortisol concentrations were measured before and after injection o f 
cortisol or vehicle and the beginning o f exercise stress. Radioimmunoassayable 
cortisol concentrations were increased (P<0.05) in cortisol treated animals. Vehicle 
injection did not affect cortisol concentrations. Exercise-stressed horses had higher 
(P<0.05) basal cortisol concentrations compared to vehicle or cortisol-treated horses. 
Exercise significantly increased plasma cortisol at all time points. Cortisol injections 
did not elevate plasma cortisol to concentrations measured in exercise-stressed horses.
Extracts from PBMCs were analyzed to determine if they contained 
immunoreactive (ir) AP-1 protein and glucocorticoid receptors (GR). Cell extracts 
were resolved by SDS-PAGE and blotted onto nitrocellulose membranes. Primary GR
x v
antibody bound to a single band and the size (-100KD) was similar to that reported for 
characterized GR from other species. Dot blots were used to detect ir-Fos and Jun in 
extracts from equine PBMCs. Extracts containing at least 90 ng of protein contained 
specifically labeled Fos and Jun.
The last experiment cultured PBMCs with media, IL-2, IL-2 plus phorbol ester 
(TPA) or IL-2 plus cortisol. As compared to the media control, LAK cell activity was 
stimulated by IL-2 and inhibited by TPA and high dose cortisol. Immunoreactive-Jun 
was increased by TPA and this effect was abolished by 10‘4M cortisol.
These experiments indicate that stimulatory effects of exercise on LAK cell 
activity are unlikely to be due to cortisol actions or to stimuli which act through 
protein kinase C/AP-1 messenger systems.
x v  i
CHAPTER 1: INTRODUCTION
Projects on neuroendocrine-immune interactions in the equine species were 
initiated by various researchers in the School o f Veterinary Medicine at Louisiana 
State University (LSU) early in the 1990s. Results from the initial studies, and 
published reports from many other laboratories, were responsible for design of 
experiments summarized in this dissertation. Four main points were particularly 
important to design of these experiments. Firstly, work with a wide variety o f species 
indicated that stress may have detrimental or beneficial effects on the initial response 
to infection or traumatic injury, the progression o f various diseases, severity of 
symptoms associated with a particular disease and the severity of undesirable side- 
effects related to therapeutic regimes used to treat existing diseases. It was not clear 
why a particular stressor may have beneficial effects or why another stress might have 
detrimental effects. It had also been reported that a stress which normally benefited 
health might be detrimental if it was started at a different time relative to exposure to 
infectious organisms or the progression o f a disease.
Experiments performed at LSU indicated that a defined exercise stress 
enhanced lymphokine activated killer (LAK) cell activity. These exercise stressors 
resulted in a significant increase in plasma cortisol concentrations and in vitro 
experiments with equine peripheral blood mononuclear cells (PBMCs) suggested that 
cortisol may stimulate or inhibit LAK cell activity. In vitro experiments with human 
and rodent immune cells suggested that inhibitory effects of cortisol were due to 
classically defined genomic effects o f this steroid. The stimulatory effects of cortisol
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were reported to be due to cross-talk between glucocorticoid receptors and stimuli 
which controlled expression and activity of activator protein-1 (AP-1). Since 
generation o f LAK cell activity involves activation and proliferation, we hypothesized 
that AP-1 played an important role in IL-2 induced LAK cell activity and that the 
stimulatory effects o f glucocorticoids on equine LAK cell activity were due to an 
interaction between AP-1 proteins and glucocorticoid receptor.
This project was divided into several experiments. In the first set of 
experiments endpoints were collected in order to demonstrate that horses used for 
recovery of PBMCs had a normal endocrine profile relative to glucocorticoid secretion. 
This set o f experiments also characterized circulating cortisol concentrations at various 
time points in resting horses as an indirect means o f determining whether the 
hypothalamo-pituitary-adrenal (HPA) axis in these animals was functioning in a 
manner consistent with that previously described for the equine species. This was 
believed to be important since we wanted to analyze endocrine-immune interactions 
for PBMCs collected from horses without endocrine abnormalities. Specific objectives 
o f the experiments were to determine whether horses used in these experiments had 
normal mean concentrations o f plasma glucocorticoids; characterize the diurnal rhythm 
of plasma cortisol in horses used in these experiments; determine whether there was a 
gender effect on concentrations of plasma glucocorticoids; and establish the basal 
physiological range o f plasma glucocorticoid concentrations to be used in subsequent 
in vitro experiments.
The second set o f experiments of this project tested effects o f intravenous (IV) 
cortisol injections on radioimmunoassayable plasma steroid concentrations. The 
treatment used for this experiment was expected to increase measurable concentrations 
o f cortisol in plasma to peak concentrations measured during exercise stress. 
Collaborators on this experiment utilized various immunological assays in order to 
determine if  IV cortisol injection produced effects on immune function which were 
similar to that which occurred during exercise stress.
The third set of experiments was conducted in order to determine whether 
equine PBMCs contained immunoreactive (ir) proteins necessary for a functional 
interaction between hormone-bound glucocorticoid receptors (GR) and protein subunits 
o f AP-1. Specific objectives o f this experiment were to determine if ir-GR could be 
detected in extracts of PBMCs; estimate the molecular weight o f ir-GR in order to 
determine if the ir-material was similar in size to GR from other species; determine 
whether PBMCs collected from resting horses contained detectable ir-Jun and/or ir- 
Fos; establish the number of equine PBMCs and the amount o f cell protein that were 
needed to consistently detect ir-Jun and/or ir-Fos; establish the sensitivity of assays 
used to detect ir-Jun and ir-Fos by using known amounts o f commercially available 
standards; determine whether the detection of ir-Jun and ir-Fos in extracts from equine 
PBMCs would be abolished by pre-absorbing primary antibodies with excess amounts 
o f purified Jun and Fos standards; and determine if the immunoreactivity of Jun and 
Fos standards and extracts from equine PBMCs was abolished by heat treatment.
The final experiment in Chapter 6 of the project was performed in order to 
determine whether phorbol ester or cortisol treatments act individually or together to 
modify LAK cell activity o f equine PBMCs stimulated with 250 U o f IL-2 per ml of 
media. We also characterized ir-Jun in equine PBMCs in order to determine whether 
any treatment effects were related to differences in the amount o f this nuclear protein. 
Specific objectives o f this experiment were to treat equine PBMCs with phorbol ester 
concentrations that would induce a significant increase in ir-Jun; determine whether 
cortisol treatments effected the amount o f ir-Jun in nuclear extracts from PBMCs; 
determine whether ir-Jun concentrations induced by phorbol ester treatment were 
modified by various doses of cortisol; characterize the effect o f phorbol ester, cortisol 
or cortisol and phorbol ester treatments on detectable ir-Jun measured at various time 
points during generation o f equine LAK cell activity; determine the effect o f phorbol 
ester treatment on IL-2 induced LAK cell activity; verify stimulatory effects of low 
cortisol dosages and the inhibitory effects of high dose cortisol treatment on LAK cell 
activity; and determine whether combined treatment with phorbol ester and cortisol 
alters effects of the individual compounds on LAK cell activity.
CHAPTER 2: LITERATURE REVIEW
A. Introduction
Research on the endocrine systems and the immune system initially 
concentrated on studying each system separately. However, multicellular organisms 
must have some means o f coordinating the activity o f various systems in order to 
maintain homeostasis. In the last few decades it has become increasingly obvious that 
neuroendocrine-immune interactions may be particularly important to the incidence 
and progression of various diseases. It is noteworthy that bi-directional 
communication between the neuroendocrine and the immune systems may have 
detrimental or beneficial effects on the initial response to injection or traumatic insults. 
Bi-directional communication between these system may also inhibit or enhance 
progression o f various diseases and effect the severity of symptoms associated with a 
particular disease. Finally, it appears that neuroendocrine-immune interactions may 
reduce or increase detrimental effects o f therapeutic regimes used to treat various 
diseases. The latter interaction appears to be particularly important to cancer patients 
who require chemotherapy or radiation treatments.
Our current understanding o f neuroendocrine-immune interactions is very 
limited. Most contemporary research projects are only beginning to define compounds 
which act in bi-directional communication and the basic in vitro actions that effective 
compounds may have on various immune cells. Another primary area for current 
research has continued to demonstrate that the central nervous system (CNS), 
peripheral endocrine systems and various immune tissues and cells produce many of
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the same biologically active compounds. In particular, various hormones that were 
originally believed to be secreted only from endocrine cells have been found as 
transcripts and biologically active secretory products o f various cells and tissues of the 
immune system. Similarly, numerous cells in the CNS, the adrenal medulla and 
various endocrine tissues may synthesize and secrete large amounts of various 
cytokines.
Our ability to define neuroendocrine-immune interactions is confounded further 
by the rapid evolution o f methods for elucidating complex processes important to 
specific cell functions. Relative to experiments performed as part of this research 
project, it has recently been demonstrated that traditional explanations for 
glucocorticoid effects on target cells are extremely simplistic. The traditional model 
for steroid effects on cells also largely ignores the fact that individual cells in 
multicellular organisms must have evolved the means for coordinating multiple 
stimuli. Experiments described in this dissertation were done to determine whether 
stimuli which act to produce their effects through regulation of AP-1 proteins may 
interact with glucocorticoids to regulate LAK cell activity generated from equine 
PBMCs.
As already noted, our understanding of glucocorticoid effects involved in a 
particular immune response is incomplete. The following literature review reflects the 
current state of our knowledge. In many cases, review articles have been cited in an 
attempt to limit the length of this text.
This review is divided into sections which summarize data on glucocorticoids, 
the proto-oncogene/AP-1 family, interactions between glucocorticoid receptors and 
AP-1 proteins and LAK cell activity. The glucocorticoid section includes literature on 
factors important to normal glucocorticoid concentrations in the circulation, 
glucocorticoid receptors (GR) and glucocorticoid effects on various cell types. Review 
o f literature for the AP-1 proteins describes chemical structures, mechanism o f action, 
factors regulating AP-1 protein expression and the function o f AP-1 dimers in cell 
proliferation, differentiation and transformation. Sections on glucocorticoids and AP-1 
proteins necessarily include a considerable amount of chemistry needed to understand 
interactions between these two cell signals. In addition, this information was included 
so that we may be able to explain results from the proposed experiments.
The third section o f the literature review considers publications which have 
defined treatment interactions for GR and AP-1 proteins. The fourth section of the 
review summarizes published literature on LAK cell activity in various species.
B. Glucocorticoids
1. Concentrations of Circulating Glucocorticoids
Circulating levels o f glucocorticoids are determined by the rate of synthesis and 
release from the adrenal gland and the rate of clearance from plasma. The primary 
glucocorticoids secreted by the adrenal cortex include cortisol, corticosterone and 
cortisone. In humans, the adrenal cortex secretes much more cortisol than other 
steroids and the concentration o f plasma cortisol is normally much greater than 
concentrations o f plasma corticosterone and cortisone (Table 1) (Wayne, 1989). Most
8Table 1: Normal Concentration of Plasma Glucocorticoids in a Variety o f Species
Species CBG
(g/1)
Plasma Cortisol 
(ng/ml)
Plasma Corticosterone 
(ng/ml)
Human 0.037 135.0 ± 35.0f 5.0 ± 3.0f
Horse — 70.0 5.0
Dog — 17.8 + 1.32+ —
Cat — 17.0 ± 2.8* —
Cattle — 11.2 ± 0.75 * 2.8 ± 0.15*
Swine — 13.7 ± 4.0f 2.4 ± 0.8f
Rat — --- 20.0-200.0
Plasma glucocorticoid concentrations in a variety of species were reported in a review 
article published by Wayne (1989). Values marked with an * are listed as the mean ± 
SD and values marked with f  were reported as the mean ± SE. CBG = cortisol- 
binding-globulin. The presence of a straight line in any column indicates that data for 
that endpoint were not available.
of the cortisone in the bloodstream of humans is derived from metabolism of cortisol 
by peripheral tissues (Bailey & West, 1969; Srivastava et al., 1973). In horses, the 
adrenal synthesizes and secretes large amounts o f cortisol, less corticosterone and a 
very small amount of cortisone (Freestone & Melrose, 1995). In contrast to humans 
and horses, other mammals, including cattle, sheep and rats, synthesize and secrete 
lower levels o f cortisol (Table 1).
Steroidogenic cells do not store significant amounts o f steroid hormones 
(Simpson & Waterman, 1989). Therefore, regulation of steroid hormone secretion 
occurs primarily at the level of steroid hormone synthesis. The hypothalamo-pituitary- 
adrenal (HPA) axis is the principal regulator of glucocorticoid synthesis (Figure 1). 
Corticotropin-releasing factors, including corticotropin-releasing hormone (CRH) and 
arginine vasopressin (AVP), are secreted by hypothalamic neurosecretory cells (Rivier 
et al., 1990). Releasing factors reach the anterior pituitary via the portal vessels in 
order to stimulate the synthesis and release of adrenocorticotropic hormone (ACTFI) 
from corticotropes. Adrenocorticotropic hormone in the general circulation acts on the 
adrenal gland to stimulate the synthesis and release of glucocorticoids. The HPA axis 
controls basal synthesis and secretion of glucocorticoids in the adrenal cortex and it 
also mediates glucocorticoid release elicited by various stressors (Rivier et al., 1990).
Corticotropin-releasing hormone is the most important factor involved in 
control of the HPA axis. Neurosecretory cells containing CRH are located within the 
dorsal medial parvicellular subdivision of the paraventricular nucleus (PVN) in the 
hypothalamus (Littlefield-Chabaud, 1994; Littlefleld-Chabaud & Melrose, 1991).
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Figure 1: The Hypothalamo-Pituitary-Adrenal (HPA) Axis. This schematic illustration 
shows the basic relationships important to function of the HPA axis. Areas of the 
basal forebrain including the hypothalamus contain neurons which release regulatory 
compounds (CRH, AVP) from their axon terminals. These axon terminals are outside 
of the blood brain barrier and hypothalamic peptides enter fenestrated capillaries. 
Releasing factors are transported through median eminence and pituitary portal 
vasculature to the anterior pituitary gland. Releasing factors stimulate synthesis and 
secretion of various pituitary hormones including ACTH and other pro- 
opiomelonocortin peptides which increase synthesis and release of glucocorticoids, 
mineralocorticoids and androgens by the adrenal cortex. Heavy solid arrows indicate 
that a large change is induced by the stimulus and light solid arrows indicate a 
pathway that is not as markedly affected. Dashed lines with arrows depict inhibitory 
feedback effects. ACTH = adrenocorticotropic hormone; AVP = arginine vasopressin; 
CRH = corticotropin-releasing hormone.
These cells have axons projecting to the portal capillary plexus in the external zone of 
the median eminence (Whitnall et al., 1985). The same neurons also produce AVP 
(Sawchenko et al., 1984). Corticotropin-releasing hormone and AVP stimulate the 
synthesis and release o f ACTH from corticotropes in the pituitary by different 
mechanisms (Aguilera et a l,  1983). Corticotropin-releasing hormone acts, at least in 
part, by binding to receptors linked to the protein kinase A (PKA) pathway.
Therefore, it stimulates the production o f intracellular cyclic-adenyl-mono-phosphate 
(cAMP). Arginine vasopressin enhances CRH-induced ACTH release by increasing 
intracellular calcium concentrations.
Adrenocorticotropic hormone is a linear chain polypeptide o f 39 amino acids. 
This hormone is derived from a large precursor molecule referred to as 
pro-opiomelanocortin (POMC) (Freestone & Melrose, 1995; Miller et al., 1983; 
Whitfeld et al., 1982). The major function of ACTH is to stimulate steroid 
biosynthesis in cells o f the adrenal gland. Cortisol and corticosterone are the major 
glucocorticoids produced by the adrenal cortex in response to ACTH stimulation. 
Stimulatory effects o f ACTH on glucocorticoid synthesis are mediated by intracellular 
cAMP (Simpson & Waterman, 1989). Binding of ACTH to high affinity membrane 
receptors results in activation of adenyl cyclase, leading to increased cAMP which 
leads to activation o f cAMP-dependent protein kinases. Increased activity o f protein 
kinases mediates both acute and long-term effects on steroidogenesis. The acute 
actions occur in seconds or minutes. Long-term effects o f ACTH on glucocorticoid 
synthesis require hours or days.
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Acute effects of ACTH (Figure 2) primarily involve intramitochondrial 
reactions which result in increased conversion of cholesterol to pregnenolone (Hall, 
1985). Specifically, activated protein kinases cause phosphorylation o f a labile protein 
factor which stimulates the transfer of cholesterol to the inner mitochondrial membrane 
and binding o f cholesterol to cytochrome P-450. In addition, ACTH stimulates 
receptor-mediated uptake o f low density lipoprotein (LDL) cholesterol, cholesterol 
ester hydrolase activity and HMGCoA reductase activity by way o f a cAMP-dependent 
protein kinase.
Chronic effects o f ACTH on steroidogenesis (Figure 2) are associated with 
most, if  not all, o f the steps o f glucocorticoid synthesis due to increased synthesis of 
steroidogenic enzymes (Hum, et al. 1993; John et al., 1986). Activated cAMP- 
dependent protein kinases induce the expression o f a steroid hydroxylase-inducing 
protein (SHIP) which causes an increase in the level of mRNA encoding each o f the 
steroidogenic forms of cytochrome P-450, including mitochondrial steroidogenic 
enzymes, P-450scc and P-450up, and microsomal enzymes P-450]7aand P-450C2,. It has 
been demonstrated that increased mRNA encoding each of the steroidogenic P-450s is 
the result o f increased transcription of the respective genes, rather than activation of 
pre-existing mRNA (Simpson & Waterman, 1989). However, mechanisms involved in 
the effect of SHIP on the transcription of each steroid hydroxylase gene have not been 
elucidated.
Cortisol is intermittently secreted by the adrenal throughout the day for periods 
lasting only a few minutes (Weitzman et al., 1971). Between each pulse of steroid
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Figure 2: Action of Adrenocorticotropic Hormone (ACTH) on Glucocorticoid 
Synthesis. See text for a detailed description o f acute and chronic effects of ACTH on 
glucocorticoid synthesis and secretion. CE = cholesterol esters; CEH = cholesterol 
ester hydrolase; Choi = cholesterol; FFA = free fatty acids; HMGCoA = 3-hydroxy-3 - 
methylglutaryl coen2yme A; LDL = low density lipoprotein; PK = protein kinase; 
SHIP = steroid hydroxylase-inducing protein.
secretion the adrenal cortex does not secrete any cortisol for several minutes or hours. 
Each pulse o f cortisol release is characterized by a very rapid rise in circulating 
cortisol concentrations, followed by a slower decline. Most mammals exhibit a peak 
in mean plasma glucocorticoid concentrations at the onset o f the normal period of 
wakefulness and a trough 12 hours later. This diurnal rhythm in plasma cortisol is 
related to a higher frequency o f pulsatic cortisol release in the early morning hours.
In horses, mean plasma concentrations o f cortisol are elevated in the morning and 
lower in the afternoon and evening (James et al., 1970).
Physiological processes which control diurnal secretion of glucocorticoids are 
complex and poorly understood. Current literature suggests that mechanisms involve 
intrinsic hypothalamic rhythmicity which regulates the synthesis and secretion o f CRH, 
light-dark cycles, feeding cycles and inherent rhythmicity of steroid secretion by the 
adrenal which may be mediated by sympathetic innervation.
The mRNA for CRH and CRH peptide content in CRH neurons fluctuate in a 
diurnal manner due to neuronal or intrinsic cell processes (Krieger, 1979). Further, 
ACTH is released episodically in pulses every 30 to 120 minutes throughout the day 
in animals continuously infused with CRH and there is no diurnal change in 
responsiveness of the pituitary to CRH (Krieger, 1979). In animals with a normal 
HPA axis, the diurnal rhythms o f CRH, ACTH and cortisol are generally correlated. 
However, cortisol secretion occasionally occurs when pulses o f CRH and ACTH are 
not measured and not all pulses of ACTH release are followed by pulses of cortisol 
release (Fehm et al., 1984). Accordingly, it seems that the diurnal rhythm of
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glucocorticoid secretion is not completely dependent upon an intrinsic rhythm of CRH 
release and other factors must affect the diurnal rhythm of cortisol secretion.
The diurnal rhythm of plasma cortisol concentrations and light-dark cycles 
have been correlated in humans (Krieger, 1979). Frequency o f nocturnal secretory 
episodes increases between the third and fifth hours o f sleep. The largest secretory 
bursts in hormone release occur after 6 to 8 hours of sleep and during the first several 
hours o f wakefulness. When individuals shift light-dark and feeding schedules 
congruently, the circadian rhythm of cortisol changes slowly over the course of 2 to 3 
weeks. Thus, in addition to light-dark cycles, feeding cycles may influence the diurnal 
rhythm of cortisol secretion in humans. Concentrations o f cortisol are generally 
highest before breakfast and increased hormone concentrations appear to be correlated 
with lunch and supper (Follenius et al., 1982). In horses, there is no clear relationship 
between sleep-wake cycles and the diurnal rhythm of plasma cortisol (James et al., 
1970).
The adrenal gland releases glucocorticoids in a diurnal rhythm in the absence 
o f ACTH stimulation (Dallman, 1984). This may reflect inherent rhythmicity in 
synthetic functions or it may reflect sympathetic regulation o f the adrenal gland 
(Dallman, 1984). In hypophysectomized animals continuously infused with ACTH, 
plasma glucocorticoid concentrations still exhibit a diurnal rhythm. Furthermore, 
spinal transection above the level o f adrenal innervation abolishes the diurnal rhythm 
o f cortisol secretion in hypophysectomized rats (Dallman, 1984).
Cortisol is relatively insoluble in water and is solubilized by binding to carrier 
proteins. In humans, about 6% of cortisol is unbound and approximately 90 to 97% of 
the circulating cortisol is transported in the bloodstream by reversibly binding to 
plasma proteins including an a 2-globulin named cortisol-binding globulin (CBG) and 
albumin (Ballard, 1979; Freestone & Melrose, 1995; Simpson & Waterman, 1989). 
Concentrations of CBG in the systemic circulation depend on the species, individual 
variations within a species and hormone status. Humans have relatively high levels of 
CBG which are increased during pregnancy (Feldman, 1989; Meikle, 1989). Horses 
do not have any significant amount o f CBG (Freestone & Melrose, 1995). Thus, in 
horses, most cortisol is likely to be free or loosely bound by albumin. Only free 
cortisol is biologically active at the tissue and cellular level. Free glucocorticoids 
enter the cell by simple diffusion and the physiological processes (HPA axis) that 
control plasma cortisol concentrations respond to free cortisol rather than to total 
cortisol concentrations.
Metabolism o f adrenal steroids occurs primarily in the liver and this 
metabolism is responsible for clearance o f steroid hormones from the plasma (Peterson 
et al., 1971). In hepatic cells, steroids undergo enzymatic modification that transforms 
them into inactive substances with increased water solubility so that they can be 
removed more readily. Cortisol has a half-life of 80 to 120 minutes in humans and 
about 130 minutes in horses (Slone et al., 1983).
Cortisol undergoes side-chain cleavage and A-ring reduction to form 
dihydrocortisol which is rapidly converted to tetrahydrocortisol (THF). Some THF is
reduced to form cortols. Only a small part of cortisol is metabolized to 17- 
ketosteroids through side chain cleavage. As with cortisol, cortisone is reduced to 
tetrahydrocortisone (THE) and cortolone. In the periphery, cortisol can be converted 
to cortisone. This reaction is reversible and the equilibrium favors cortisol by a ratio 
o f 10:1. Due to this interconversion, cortisol and cortisone share metabolic pathways 
and have common major metabolic products, including THF, THE, cortols and 
cortolones.
Plasma glucocorticoid concentrations are also influenced by stress. Stress is 
defined as any external stimulus that causes a change in homeostasis. Homeostasis is 
a stable state o f equilibrium of the body's interior environment (Selye, 1973). Various 
physiological, psychological and environmental stressors may have short-term and/or 
long-term effects on wide range of physiological processes. Stressors typically result 
in an increase in plasma glucocorticoid concentrations. The magnitude of the 
glucocorticoid response to stress may be influenced by various factors, such as time of 
day, age o f the animal, and the previous stressors. After exposure to a stressor, 
plasma glucocorticoids may begin to increase within minutes. The stress-induced 
elevation o f plasma glucocorticoids (Figure 3) is mediated by the HPA axis (Harbuz & 
Lightman, 1992). Stress stimulates the cerebral cortex o f the brain to produce 
neurological impulses which simultaneously activate the autonomic nervous system 
(ANS), the hypothalamus and the HPA axis. Activation of the HPA axis leads to 
increased plasma cortisol concentrations. Activation of the ANS results in an increase 
in plasma levels o f catecholamines. Plasma catecholamines may increase due to
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Figure 3: Stress Response and the Hypothalamo-Pituitary-Adrenal (HPA) Axis. ACTH 
= adrenocorticotropic hormone; CRF = corticotropin-releasing factors; EN = 0- 
endorphin. The dark horizontal line with an arrow on both ends indicates that 
stimulatory effects of stress may originate in either area of the central nervous system 
(CNS). Dark solid arrows that project toward the bottom of the page represent 
primary stimulatory effects. Thin solid arrows correspond to processes that are less 
responsive to stress. Dark solid arrows that project up and then to the right outline 
feedback effects o f cytokines on the stress response and they also represent the fact 
that cytokine release following various infections is thought to be an important signal 
that stimulates the CNS and HPA axis to help ward off various diseases. See text for 
additional details.
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norepinephrine released from sympathetic nerve endings and from the adrenal medulla 
as well as epinephrine release from the adrenal medulla. Increased catecholamine 
release results in the 'flight-fight' reaction commonly associated with stress (Selye, 
1973).
2. Receptors and Mechanisms of Action
a. Types and Tissue Distribution of Glucocorticoid Receptors. There 
are three types of glucocorticoid receptors. High affinity type I, "mineralocorticoid 
receptors" (MR), are also known as "corticosterone-preferring receptors" (CR). Type I 
receptors have a low affinity for synthetic glucocorticoids such as dexamethasone, but 
are selectively activated by aldosterone or corticosterone (Kd ~ 0.5 nM) (Reul & de 
Kloet, 1985, 1986). These receptors were initially localized in the kidney and colon.
In the CNS, type I receptors are preferentially located in the limbic system, mainly in 
the hippocampus and lateral septum, where they mediate tonic feedback effects of 
glucocorticoids on the HPA axis (de Kloet & Sutano, 1989; Reul & de Kloet, 1985, 
1986: Reul et al., 1989). The ability o f some type I receptors to respond to 
aldosterone, in spite o f higher circulating levels of glucocorticoids, is due to tissue- 
specific expression o f 11-beta hydroxysteroid dehydrogenase that converts 
glucocorticoids to their 11-keto mineralocorticoid metabolites (Funder et al., 1988; 
Lakshmi et al., 1991; Stewart, 1987). This enzyme is present at high concentrations in 
CNS areas that selectively respond to aldosterone, such as the circumventricular organs 
(Moisian et al., 1990).
Low affinity type II, "glucocorticoid receptors" (GR) have a higher affinity for 
dexamethasone (Kd ~ 3.0 nM) than for corticosterone (Reul & de Kloet, 1985). In 
addition to their distribution in liver, adipose and muscle tissues, type II receptors are 
widely distributed throughout the CNS. These receptors are almost completely 
unoccupied when corticosteroid concentrations are at basal levels and are saturated 
during stress. These receptors also become occupied when glucocorticoids increase to 
their highest concentration diurnally. Thus, type II receptors may act to regulate gene 
transcription and mediate effects of higher concentrations of glucocorticoids during 
stress or corticosteroid concentrations at the peak of the diurnal rhythm (de Kloet & 
Sutano, 1989).
The third type of glucocorticoid receptor is the GABAA/benzodiazepine (BZP) 
receptor-chloride channel complex. This membrane receptor has separate binding sites 
for barbiturates, BZP and steroids (Majewska et al., 1985; Marrow et al., 1991; 
McEwen, 1991; Puia et a l ,  1990). Glucocorticoid metabolites bind to this receptor in 
order to mediate rapid effects on neural depolarization or release of corticotropin- 
releasing factors (CRF). Although the physiological role o f this cell surface receptor 
in glucocorticoid feedback on the HPA axis has not been clarified, it is reasonable to 
speculate that it is involved in fast, rate-sensitive inhibition o f the HPA axis by 
glucocorticoids.
b. Subcellular Distribution of Glucocorticoid Receptor (GR). The
subcellular distribution o f GR is still controversial. Early studies on subcellular 
localization o f GR were based on cell fractionation and autoradiography (Jensen et al.,
1968). Results from these experiments suggested that hormone receptor which was 
not bound to steroid was soluble in the cytoplasm of cells. The hormone-bound 
receptor was reportedly activated through a temperature-sensitive process before being 
transported into the nucleus (Groudy et al., 1982). This proposal led to development 
o f a two step model for steroid hormone action. Application of alterative techniques 
led to the conclusion that unoccupied GR was present in the cytoplasm and the 
nucleus (Sheridan et al., 1979). The two step model was then replaced by an 
equilibrium model which stated that subcellular distribution of bound and soluble 
receptors was determined solely by receptor concentrations in a particular compartment 
(Martin & Sheridan, 1986). However, some immunolocalization experiments 
suggested that several steroid hormone receptors may be localized in the cell nucleus 
at all times (King & Greene, 1984).
Current literature indicates that cytosolic localization o f receptors in cell 
extracts is due to artifactual redistribution o f receptors during cell- or tissue- 
homogenization. Unoccupied and hormone-bound steroid receptors are now believed 
to be nuclear proteins that interact with lipophilic ligands capable of traversing the 
plasma membrane and nuclear envelope in order to bind to their respective receptors. 
Published data also suggests that GR may be associated with microtubules during 
different stages of the cell cycle (Akner et al., 1990; Wikstrom et al., 1987).
c. Structure of Glucocorticoid Receptors. The glucocorticoid receptor 
is a single chain acidic phosphoprotein. In humans, it is composed o f 777 amino acids 
and it has a molecular weight o f about 94 KD (Holenbeg et al., 1985). Receptors
isolated from various species contain at least three different domains including a 
ligand binding domain, the DNA binding domain and the transactivation domain 
(Figure 4) (Danielsen et al., 1986; Giguere et al, 1986; Holenbeg et al., 1985). The 
hormone binding domain lies at the carboxyl-terminus o f the receptor. This domain 
extends from residue 518 or 499 to the carboxyl-terminus in rats and humans 
(Carlstedt-Duke et al., 1987). Folding o f this domain is believed to result in a 
hydrophobic surface which interacts with the steroid. Stoichiometric analysis of 
purified GR has suggested that the steroid-binding domain contains one single binding 
site for glucocorticoids (Wrange et al., 1986). This domain is also involved in 
receptor association with heat shock protein (hsp) 90 (Dalman et al., 1991; Housley et 
al., 1990; Howard et al., 1990), nuclear localization of receptors (Cadepord et al., 
1992; Picard & Yamamoto, 1987) and dimerization of receptors (Dahlman-Wright et 
al., 1991; Eriksson & Wrange, 1990; Luisi et al., 1991; Wrange et al., 1989).
The DNA binding domain was originally defined using proteolytic digestion 
with a-chymotrypsin and trypsin. It was mapped to a central sequence including 110 
residues numbered 390 to 500 in humans and 410/414 to 517 in rats (Carlstedt-Duke 
et al., 1987; Wrange & Gustafsson, 1978). This domain contains 10 highly conserved 
cysteine and many basic residues which form two zinc finger motifs (Freedman et al.,
1988). In each zinc finger motif one zinc ion is associated with four cysteine residues 
to stabilize two peptide loops. Both zinc fingers are required for efficient DNA 
binding and are responsible for the specific binding o f receptors to DNA sequences
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Figure 4: Structure of the Glucocorticoid Receptor Protein in Humans and Rats. This figure was made based on review articles 
by Gustafsson and coworkers (1987) and Beato (1989). See text for a discussion of characterized structural components. HSP 
heat shock protein.
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(Danielsen et al, 1989; Schena et al., 1989). They also mediate dimerization o f the 
receptors (Dahlman-Wright et al., 1990).
The transactivation domain is highly variable among the steroid receptors.
The major transactivation activity o f GR in humans has been mapped to the amino 
terminus between residues 77 and 262 (xl) and a weaker transactivation function was 
found between residues 526 and 556 (x2) in the region between the DNA- and ligand- 
binding domain o f the receptor (Hollenberg & Evans, 1988). The xl domain contains 
a relatively high proportion o f glutamic and aspartic amino acids and therefore may be 
a member o f the acidic activators. In vitro cell free transcription studies have shown 
that the xl domain interacts directly with the general transcriptional apparatus and that 
it determines tissue specificity o f glucocorticoid effects (McEwan et al., 1993).
A "hinge" region between the hormone- and DNA-binding domains contains a 
short stretch of highly basic amino acids (Rusconi & Yamamoto, 1987). This region 
has been implicated in nuclear localization of the rat GR (Picard & Yamamoto, 1987) 
and it is homologous to sequences required for nuclear localization o f other proteins 
(Markland et al., 1987).
d. Ligand-Binding and Activation of Receptors. Binding o f hormone 
causes dissociation of hsp 90 from the receptor, receptor dephosphorylation and 
conformational modifications. These changes result in activation of the receptor so 
that it may bind to DNA in order to regulate gene expression.
Heat shock protein 90 is a highly conserved, ubiquitous and abundant protein 
that is associated with steroid receptors in cytosolic extracts (Baulieu, 1987; Pratt et
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al., 1992). It exists as a homodimer and is associated with the steroid receptor at a 
ratio o f at least 2:1 (Bresnick et al., 1990). Although the actual biological activities of 
this protein are unknown, several potential functions for hsp 90 have been suggested. 
Firstly, binding of hsp 90 is required for ligand binding activity o f glucocorticoid 
receptors and it is believed to promote tertiary structure that facilitates ligand binding 
(Bresnick et al., 1989; Nemoto et al., 1990). Secondly, hsp 90 helps to regulate 
receptor activation since it modifies protein kinase activity (Miyata & Yahara, 1992).
Once hormone binding occurs, hsp 90 dissociates from the receptor complex. 
Hormone-dependent dissociation o f hsp 90 is a temperature sensitive process. In vitro 
experiments have demonstrated that elevated temperatures (25-37° C) will lead to 
dissociation o f hsp 90 from receptor complexes even in the absence o f hormone, but 
lower temperatures will inhibit dissociation.
Phosphorylation of the receptor complexes has been demonstrated both in vitro 
and in intact cells (Housley & Pratt, 1983). It occurs on serine residues o f the 
receptor and is mediated by a protein kinase which uses adenosine triphosphate as the 
phosphate donor. In contrast, dephosphorylation is mediated by phosphatase (Matic & 
Trajkovic, 1986; Reker et al., 1987).
e. Translocation of Activated Receptors. Translocation of GR into the 
nucleus requires specific signal sequences and specific receptor proteins. The nuclear 
localization signal (NLS) is a short amino acid sequence that directs the GR to the 
nucleus. The NLS has a high content o f basic residues and is often flanked by proline 
and acidic amino acid residues. In most nuclear proteins NLSs share a consensus
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sequence of four amino acids, Lys-Arg/Lys-X-Arg/Lys, in which X is limited to a few 
preferred amino acids.
Glucocorticoid receptor contains two independent NLSs (Picard & Yamamoto, 
1987). The first signal (NLS1) is located just at the C-terminal side of the DNA- 
binding domain. It is functionally repressed when the steroid binding domain is 
present, but it becomes constitutively active when the GR-domain is truncated. The 
second signal (NLS2) lies within the steroid binding domain. Multiple NLSs 
cooperatively mediate nuclear translocalization o f the receptor and none of them are 
sufficient on their own. Two nuclear pore complex proteins, with molecular weights 
of 60 KD and 76 KD, have been suggested to be the candidate receptors for the NLS. 
They have central domains consisting o f a series repeat structure and may interact with 
nuclear localization signals of the GR (LaCasse & Lefebvre, 1991).
Once bound by the hormone, GR undergoes a conformational change which 
unmasks the NLSs. The interaction of NLSs with specific receptors on the nuclear 
envelope results in internalization o f receptor complex. This transport process appears 
to play a role in control of the activity of the glucocorticoid receptor.
f. DNA Binding and Gene Transactivation. Once translocated to the 
nucleus, the activated GR may form dimers (Tsai et al., 1988; Wrange et al., 1989) 
which bind to specific glucocorticoid response elements (GREs) and stimulate or 
inhibit gene expression (Figure 5, Schematic A). The GREs were first identified in 
DNA binding studies with the mouse mammary tumor virus long-terminal repeat 
(MMTV LTR) (Payvar et al., 1983). Glucocorticoid-inducibility was found to be
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Figure 5: Molecular Mechanisms of Glucocorticoid Actions. The cell membrane is 
illustrated as a shaded vertical bar in the left-hand portion of this figure. Compounds 
which are illustrated to the left of the membrane are in the plasma. The cytoplasm is 
on the right-hand side of the membrane and the nuclear compartment is outlined by 
the dark solid line. Capital letters (A, B, C, D), to the right of each schematic, 
illustrate different mechanisms for glucocorticoid effects in various cell types. See 
text for additional details. C = carrier; G = glucocorticoid; GRE = glucocorticoid 
response element; nGRE = negative GRE; R = receptor; TRE = TPA response 
element. Triangles to the left o f the nucleus represent "heat shock protein 90" and 
circles correspond to phosphate groups bound to glucocorticoid receptor.
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mediated through a 15 base-pair partially palindromic sequence that consists o f two 
hexameric half-sites separated by three bases. A similar sequence was discovered in 
the regulatory region of genes for human metallothionein Ila, chicken lysozyme and 
rat tyrosine aminotransferase (Beato, 1989). Based on these and other characterized 
GREs, a functional GRE consensus sequence was proposed to include 
5'-GGTACAnnnTGTTCT-3' where n can be any nucleotide (Beato, 1989).
Glucocorticoid response elements have been found either upstream, as far as 
several kilobases from the promoter, or downstream from the initiation site of 
transcription (Beato, 1989; Pay vat et al., 1983). They function as a classic enhancer 
which acts independent o f orientation and distance from the transcription start site. 
There is a relatively weak interaction between the GR and the GRE due to a limited 
number o f protein/DNA contact sites. The association constants for GR binding to the 
GRE and GR binding to non-specific sites are 10'8 M and 10'6 M, respectively.
Dimerization of the GR is required for DNA binding (Dahlman-Wright et al.,
1990). Dimerization involves a interaction between the hormone-binding domain and 
the DNA-binding domain. Studies using purified DNA-binding domain (DBD) protein 
o f the GR have shown that two DBD proteins interact with DNA cooperatively. This 
co-operativity was eliminated by changes in the spacing between the half sites or by 
changing their relative orientation, but it was not affected by inserting a nick in the 
DNA between the two half sites. Thus, it has been suggested that co-operativity 
results from a protein-protein interaction between the two bound DBDs (Dahlman- 
Wright et al., 1990). Furthermore, dimerization activity was mapped to a five amino
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acid segment at the base o f the second zinc finger in a region known as the D-box 
(Dahlman-Wright et al., 1991a). However, the GR DBD bound DNA with 10-fold 
lower affinity as compared to binding of intact receptor (Dahlman-Wright et al., 1992). 
Receptor derivatives that included the C-terminal steroid-binding domain partially 
restored binding affinity.
Due to protein-protein interactions between two DNA-binding domains and two 
steroid binding domains, two monomers of the GR form a homodimer in a head to 
head orientation and they interact with each half o f the palindromic GRE 
cooperatively. Binding of the first GR to the DNA facilitates binding o f the second 
GR molecule due to a change in the structure of DNA which results from binding of 
the first GR molecule and an interaction between the two GR molecules (Dahlman- 
Wright et al., 1990) .
Target gene specificity o f GR is determined by residues at the N-terminal helix 
o f the first zinc finger in the DNA-binding domain (Alroy & Freedman, 1992; Mader 
et al., 1989). Studies using in vivo transactivating assays showed that changing three 
amino acids clustered in the first zinc finger o f the GR to amino acids at same 
position in the estrogen receptor completely changed specificity so that the mutant 
preferentially bound an estrogen response element (ERE) (Zilliacus et al., 1991). 
Studies on crystal structure o f GR DBD-DNA complexes have demonstrated that only 
one residue o f the triplet (Gly-Ser-cys-lys-Val) makes a base contact (Luisi et al.,
1991). The Val residue makes a favorable van der Waals contact with the 5-methyl 
group o f the T in the GRE half site TGTTCT and the ERE has an A at the
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corresponding position. Substitution o f Val with Ala decreases GR binding affinity for 
a GRE by a factor o f ten, but does not increase its affinity for an ERE. Thus, this 
residue functions both in a positive and a negative selective role.
Subsequent to its interaction with DNA, multiple GRs synergistically activate 
gene expression by facilitating the formation o f a productive transcription complex at 
the promoter due to interactions with general transcriptional factors (McEwan et al., 
1993; Wright & Gustafsson, 1991) and/or by modulation o f chromatin structure 
(Cordingley et al., 1987).
g. Interaction With Other Nuclear Proteins and Gene Inhibition. 
Glucocorticoids not only induce transcription of many genes but also are able to 
repress expression o f some genes, including those for prolactin, glycoprotein, the a- 
subunit of several pituitary hormones, collagenase, proliferin and POMC. Negative 
regulation o f gene expression by glucocorticoids is mediated by interactions with other 
nuclear proteins. Several different mechanisms have been suggested to be responsible 
for the interaction between the GR and other nuclear proteins (Figure 5).
One hypothesis is that binding of the receptor to a negative GRE (nGRE) site 
on the DNA interferes with the association o f the other positive transcription factors to 
a common or overlapping site, resulting in negative regulation o f the target gene 
(Figure 5, Schematic C). In the gene for the a-subunits of glycoprotein hormones, a 
set o f GR-binding sites are found overlapping cyclic AMP response elements (CRE) in 
the promoter region (Akerblom et al., 1988). Reduced expression o f this gene 
following glucocorticoid treatments is apparently mediated by competition for the
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DNA sequences since expression of this gene in pituitary and placental cells are 
dependent on cAMP levels, inhibitory effects o f glucocorticoids on expression o f this 
gene are dependent on cAMP-induced changes in gene expression and glucocorticoid 
effects require the DNA-binding domain but not the transactivation domain of the GR 
(Oro et al., 1988). This type o f effect would be similar to that schematically 
illustrated for GR interactions with the TRE/AP-1 binding sites (Figure 5, Schematic 
C).
Another hypothesis suggests that a composite GRE exists in the promoter 
region o f some target genes. Selective function o f the composite GRE is determined 
by cooperative interactions between both bound proteins, but not by the mutual 
exclusion o f one or the other DNA-binding protein (Diamond et al., 1990; Miner & 
Yamamoyto, 1991) (Figure 5, Schematic D). For example, in the mouse proliferin 
promoter and bovine prolactin gene, the GR interacts with a region that includes an 
AP-1 site (Mordacq & Linzer, 1989). It is suggested that the co-localization of these 
two elements is required for phorbol ester stimulation and glucocorticoid repression of 
gene expression.
Inhibitory effects of glucocorticoids on collagenase gene expression have been 
related to receptor interactions with other nuclear proteins which occur independent of 
DNA binding (Schule & Evans, 1991) (Figure 5, Schematic B). It was demonstrated 
that GR antagonized AP-1-induced expression of the collagenase gene without binding 
to the AP-1 site. Further, the over-expression o f AP-1 proteins, c-Jun and c-Fos, may 
be blocked by activation o f glucocorticoid-responsive genes even through AP-1 does
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not bind to GRE (Jonat et al., 1990; Schule, 1990; Yang-Yen et al., 1990a). Thus, it 
has been proposed that protein-protein interactions between the GR and AP-1 
prevented either nuclear factor from associating with DNA on various target genes.
h. Regulation of GR Expression. In some cells, the sensitivity to 
glucocorticoids is directly proportional to the GR concentration (Bourgeois & Newby, 
1979; Gehring et al., 1984; Vanderbilt et al., 1987). Many factors influence the 
intracellular concentration of GR, including the cell cycle, state o f development, aging, 
receptor heterogeneity and endocrine status (Chang & Roth, 1979; Munck et al., 1972; 
Svec & Rudis, 1981). Among these factors, the most intensively studied is the effect 
o f endogenous glucocorticoid concentrations on GR expression.
In most cells, glucocorticoids cause a decrease in GR levels by homologous 
down regulation (Burnstein & Cidlowski, 1992). The hormone-induced, receptor- 
mediated down regulation of intracellular GR levels generally results in a 
corresponding decrease in glucocorticoid sensitivity (Bellingham et al., 1992). It has 
been suggested that ligand-induced down regulation represents a common negative 
feedback mechanism enabling a cell to protect itself from the continued stimulation 
elicited by ligand. Autoregulation of the GR is a very complex process involving 
transcriptional, post-transcriptional and post-translational mechanisms. Evidence has 
indicated that down regulation is independent o f protein synthesis and involves an 
increase in GR protein turnover rate, a decrease in GR mRNA synthesis and changes 
in GR mRNA stability. However, the signal pathways and molecular mechanisms 
responsible for these effects have not been elucidated.
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3. Functions
Glucocorticoids are 21-carbon steroids characterized by an oxo group at 
carbons 3 and 20; a 2-carbon side chain on carbon 17; a hydroxyl group on carbon 11; 
the presence or absence o f a hydroxyl group at carbon 17; and a double bond between 
carbons 4 and 5 (Feldman, 1989; Simpson & Waterman, 1989). The double bond 
between carbons 4 and 5, and the presence o f the keto group at carbon 3 o f the A 
ring, are essential for the biological activities o f glucocorticoids (Feldman, 1989; 
Simpson & Waterman, 1989).
a. Effects On Intermediate Metabolism. Glucocorticoids influence 
carbohydrate, lipid, protein and nucleic acid metabolism and synthesis (Freestone & 
Melrose, 1995; Feldman, 1989). Glucocorticoids were named for their glucose- 
regulating activities. They are secondary to insulin in regulating glucose metabolism 
in humans and conserve glucose in times o f starvation to protect against glucose 
deprivation (Feldman, 1989; Oletsky, 1989; Rousseau & Baxter, 1979).
Glucocorticoids increase hepatic glycogen deposition by increasing glycogen synthesis, 
inhibiting glycolytic enzymes and promoting the capacity of the liver to carry out 
gluconeogenesis with substrates derived from degradation o f proteins and fats in 
extrahepatic tissues. In muscle, glucocorticoids decrease protein synthesis and increase 
protein breakdown to amino acids which are transported to the liver to be used as 
substrates for gluconeogenesis. In fat, glucocorticoids increase lipolysis, thereby 
releasing glycerol for gluconeogenesis and fatty acids for energy generation via 
oxidative phosphorylation. In addition, glucocorticoids decrease glucose uptake and
34
utilization in peripheral tissues. The overall result of these actions is an increase in 
blood glucose levels. These actions have been related to clinically adverse effects of 
glucocorticoid therapy or to long-term effects of stress which precipitate diabetes 
mellitus and causes hyperglycemia in non-diabetic persons (Feldman, 1989; Olefsky,
1989), horses and ponies (Freestone & Melrose, 1995).
As part o f their function to conserve glucose at the expense of other substrates, 
glucocorticoids exert inhibitory actions on many tissues (Feldman, 1989; Freestone & 
Melrose, 1995). For example, they decrease synthesis and increase breakdown o f 
proteins, fat and nucleic acids not only in muscle but also in connective tissues and 
lymphoid cells. Immunosuppressive and anti-inflammatory actions of glucocorticoids, 
as well as inhibition o f wound healing and osteoporosis caused by glucocorticoids, 
may have evolved from the aforementioned effects on cellular availability o f various 
substrates. However, some tissues, such as the heart and the brain are less sensitive to 
the detrimental effects of glucocorticoids.
b. Feedback Effects of Glucocorticoids. Circulating glucocorticoids 
exert negative feedback on hypothalamic neurosecretory cells and pituitary 
corticotropes in the HPA axis. Feedback inhibition by circulating glucocorticoids is an 
important mechanism for controlling activity of the HPA axis, especially during stress. 
Glucocorticoids may act on the HPA axis at various loci. Firstly, glucocorticoids can 
act directly on CRH neurosecretory axons in the median eminence to exert rapid and 
rate sensitive feedback effects (Edwardson & Bennett, 1974; Jones et al., 1977a). 
Secondly, cortisol may act directly on CRH perikarya during stress and when peak
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cortisol concentrations are expressed diurnally since CRH neurosecretory cells in the 
PVN contain type II GR (Agnati et al., 1985; Ahima et al., 1991). However, it has 
been proposed that tonic glucocorticoid feedback to the hypothalamus is less 
significant than glucocorticoid feedback on the limbic system (de Kloet & Sutano, 
1989; Kovacs & Makara, 1988). The septum and hippocampus are the major tissues 
required for tonic feedback effects o f glucocorticoids. In rats, these tissues contain 
very high concentrations of type I MR and a low concentration o f type II GR (Reul & 
de Kloet, 1985, 1986). Activation o f type I receptors can enhance neuronal 
excitability in hippocampal pyramidal neurons which exert an inhibitory effect on 
CRH neurons in the PVN via relays which pass through the bed nucleus o f the stria 
terminalis (de Kloet & Sutano, 1989; Kovacs & Makara, 1988).
Glucocorticoids may also block the HPA response to stress by inhibiting 
afferent CNS pathways that produce these responses. In particular, type II GR have 
been co-localized in catecholaminergic, serotonergic and neuropeptide Y-containing 
neurons that innervate various areas of the hypothalamus (Fuxe et al., 1985;
Harfstrand et al., 1986; Hisano et al., 1988). Anatomical studies on organization of 
CRH and catecholaminergic neurons in the equine CNS have demonstrated that 
organization o f these cell groups is similar to that described for most mammals 
(Littlefield-Chabaud, 1994). This suggest that control of the HPA axis in the equine 
species probably functions in a manner similar to that described for other experimental 
models.
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c. Immunosuppressive and Anti-inflammatory Actions.
Glucocorticoids have profound effects on the immune system. They act on multiple 
target cells, tissues and organ systems through multiple mechanisms. High 
concentrations and doses o f glucocorticoids suppress a wide variety of nonspecific 
inflammatory responses and specific immunologic processes, including the growth, 
differentiation and functions o f immune cells, the distribution of cellular subsets and 
the production of cytokines. Physiological concentrations o f cortisol are considered to 
be necessary for the development and maintenance o f normal immunity.
Major targets for anti-inflammatory effects o f glucocorticoids include non­
lymphoid cells, leukocytes, neutrophils, eosinophils, basophils, endothelial cells and 
fibroblasts. Glucocorticoids decrease circulating cell numbers, inhibit the 
accumulation o f these cells at inflammatory sites and inhibit release o f inflammatory 
mediators histamine and leukotriene C4 from basophils (Sternberg & Wilder, 1993). 
Glucocorticoids also inhibit neutrophil functions, such as lysosomal enzyme release 
and the respiratory burst.
Endothelial cells are critical regulators of the inflammatory cascade. They 
form the barrier between the blood and tissues which affect homeostasis, vascular 
permeability and trapping and exudation of leukocytes in inflammatory sites. By 
inhibiting the activation and subsequent function of the endothelial cells, 
glucocorticoids may reduce vascular permeability and suppress exudation of cells and 
plasma (Sternberg & Wilder, 1993). Further, glucocorticoids may affect inflammatory 
responses by suppressing the proliferation o f fibroblasts and the growth factor-induced
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DNA and protein synthesis, including synthesis of collagen (Aronow, 1979).
Inhibitory actions o f glucocorticoids on fibroblasts lead to easy bruising and poor 
wound healing.
It has been suggested that anti-inflammatory effects of glucocorticoids are 
mediated by lipocortin-1 through putative lipocortin-1 receptors. Lipocortin-1 is a 
37KD protein which is a member of the annexion family of calcium-binding proteins 
(Crumpton & Dedman, 1990; Flower & Blackwell, 1979; Wallner et al., 1986). In 
humans, lipocortin-1 is restricted to specialized epithelia of lung, medullary and 
cortical epithelia o f the thymus, ductal epithelia in prostate, basal keratinocytes o f the 
epidermis (Fava et al., 1989) and endothelial cells (Romisch el al., 1992). Synthesis 
o f lipocortin-1 in monocytes and differentiated macrophage-like cell lines can be 
induced by glucocorticoids (Ambrose et al., 1992; Wong et al., 1991). Even 
physiological concentrations of lipocortin-1, in the absence of inflammation, are 
regulated by glucocorticoids (Vishwanath et al., 1992). Receptor-like lipocortin-1 
binding protein has been identified on the surface o f peripheral blood monocytes and 
polymorphonuclear leukocytes (Goulding et al., 1990). This has led to the hypothesis 
that glucocorticoid effects on lipocortin-1 serves to regulate inappropriate 
inflammatory and autoimmune responses at specific sites in the body (Goulding & 
Guyre, 1992). Induction o f lipocortin-1 by glucocorticoids during inflammation 
causes suppression of phospholipase A2 activity. Suppression o f phospholipase A2 
activity results in a decrease in arachidonic acid synthesis and a subsequent decrease 
in prostaglandins and neutrophil functions.
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In addition to the anti-inflammatory effects, glucocorticoids inhibit specific 
immune responses. The major targets of glucocorticoid effects on the immune system 
are lymphocytes and monocytes or macrophages. Glucocorticoids antagonize 
differentiation of monocytes/macrophages and they inhibit functions o f these cells by 
depressing myelopoiesis, inhibiting expression of class II major histocompatibility 
complex antigens induced by interferon-y (INF-y), decreasing Fc and C3 receptor 
expression, inhibiting chemotaxis, suppressing synthesis and release o f prostaglandins 
and blocking the release o f numerous cytokines, such as interleukin-1 (IL-1), 
interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a). Glucocorticoids also reduce 
the production and release o f inflammatory prostaglandins and leukotrienes and 
depress tumoricidal and microbicidal activities of activated macrophages (Sternberg & 
Wilder, 1993). Inhibition o f IL-1 release is reported to be of primary importance for 
immunosuppressive effects o f glucocorticoids on the normal function o f various 
immune cells (Kern et al., 1988).
Glucocorticoids may exert direct effects on lymphocytes. It has been 
demonstrated that glucocorticoids may affect trafficking of lymphocytes. In humans, a 
single dose of glucocorticoids produces a marked but transient lymphocytopenia 
involving all lymphocyte subpopulations (Fauci & Dale, 1974). The mechanism o f the 
lymphopenia involves redistribution of circulating lymphocytes to other lymphoid 
compartments, particularly the bone marrow (Fauci et al., 1976). Changes in the 
expression o f adhesion molecules may also be responsible for the redistribution of 
lymphocytes (Croustein et al., 1992).
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Glucocorticoids may affect the activation, proliferation and functions o f T-cells 
by regulating the production o f IL-2. Glucocorticoids inhibit multiple steps involved 
in IL-2 synthesis and secretion, including the transduction o f signal that induces IL-2 
gene expression [tyrosine phosphorylation and Ca2+-dependent protein kinase 
(Paliogianni et al., 1993c)]; the transcriptional activation of IL-2 genes via interaction 
with transcriptional factors AT and AP-1 (Paliogianni et al., 1993a); and the 
degradation o f IL-2 mRNA (Boumpas et al., 1991). Glucocorticoids block the 
activation, proliferation and function of T-cells by inhibiting IL-2 production and 
interfering with IL-2-dependent phosphorylation o f several intracellular proteins 
(Paliogianni et al., 1993b). In addition to the aforementioned effects, glucocorticoids 
inhibit the production of several other cytokines, including IL-3, IL-4, IL-10 and TNF- 
(3 (Kunicka et al., 1993).
Glucocorticoids affect thymocyte maturation and differentiation (Cotman et al., 
1987; Dardenne & Savino, 1992; Goetzl & Spector, 1989). The development of 
antigen-specific thymocytes is mediated by positive and negative selection based on 
the ability of T cell receptors (TCRs) to bind to major histocompatibility complex 
(MHC) antigens. Thymocytes with high affinity TCRs for self MHC antigen undergo 
apoptotic cell death. Cells with low affinity receptors also die. Only thymocytes with 
moderate avidity receptors for self MHC antigens can survive. Data suggest that 
glucocorticoids play an important role in regulating apoptotic cell death by regulatory 
affinity o f TCR.
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The thymus synthesizes and secrete multiple hormones including CRH (Aird et 
al., 1993; Ekman et al., 1993; Muglia et al., 1993; Redel, 1992) and ACTH (Batanero 
et al., 1992). Recent studies have demonstrated that thymic epithelial cells also 
contain steroidogenic enzymes and synthesize corticosteroids, particularly during the 
fetal and neonatal periods (Vacchia et al., 1993). Thus, there is a complete HPA axis 
in the thymus of fetal and adult rats. Furthermore, blocking the local effect of 
glucocorticoids in thymus with RU486, a glucocorticoid receptor antagonist, enhances 
TCR-mediated-specific deletion o f immature thymocytes. Thus, glucocorticoids 
derived from the thymus or the adrenal gland may antagonize TCR-mediated apoptotic 
cell death (Vacchia et al., 1993). Published data have also suggested that 
glucocorticoids may stimulate apoptosis o f immature thymocytes. In rodents and 
humans, pharmacological doses o f corticosteroids reportedly induce apoptosis of 
thymocytes (Nieto et al., 1992). Stressors that increased plasma glucocorticoid 
concentrations have been related to increased thymocyte apoptosis and this effect was 
blocked by RU486 (Gruber et al., 1994). Further, adrenalectomy of adult rats resulted 
in a remarkable enlargement o f the thymus. Therefore, corticosteroids can apparently 
either stimulate or antagonize apoptosis of T cells depending on their maturation state, 
the nature of co-stimulatory signals and the concentration of glucocorticoids.
Differentiation and functions o f T helper-type 1 (TH1) and T helper-type 2 
(TH2) subsets may be another process regulated by glucocorticoids. Glucocorticoids 
inhibit production o f cytokines (IL-2, y-interferon) by TH1 cells (Vacca et al., 1992) 
and IL-4 produced by TH2 cells (Daynes & Araneo, 1989). Interleukin-2 tends to
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block glucocorticoid-induced apoptosis o f TH1 cells and IL-4 blocks glucocorticoid- 
induced apoptosis o f TH2 cells (Zubiaga et al., 1992). In addition, glucocorticoids 
induce production of transforming growth factor-beta (TGF-P) and this protein is a 
potent inhibitor o f TH1-mediated immune functions (Ayaniar et al., 1991). Thus, it is 
likely that glucocorticoids inhibit differentiation of TH1 and TH2 cells by blocking or 
reducing the production o f various growth factors.
In contrast to T cells, B cells are relatively resistant to the immunosuppressive 
effects o f glucocorticoids. Glucocorticoids inhibit the proliferation of B cells, but have 
little effect on the differentiation o f B cells into immunoglobulin-secreting plasma cells 
(Cupps et al., 1985). The most important effect o f glucocorticoids on B cells relates 
to antibody production. Low doses of glucocorticoids do not affect antibody synthesis 
in vivo. However, daily treatment with high doses of glucocorticoids will reduce 
serum immunoglobulin levels with maximal suppression observed 2 to 4 weeks after 
the beginning o f treatment (Butle & Rossen, 1973). This suppression is the result of 
an initial increase in immunoglobulin catabolism followed by decreased synthesis 
which could result from decreased accessory or helper T-cell activities.
Glucocorticoids mediate stress-induced immunosuppression. The primary 
function o f stress-induced elevations in plasma glucocorticoids is to prevent over­
reaction o f the body's responses to stress, such as excessive or unstrained 
amplifications o f immune and inflammatory processes (Munck et al., 1984). These 
steroids inhibit stress-induced increases in the release and/or production of IL-1, IL-2, 
IL-3, IL-5, IL-6, IL-8, TNF and granulocyte-macrophage colony-stimulating factor
(GM-CSF) (Goetzl & Spector, 1989; Lee et al., 1988). However, glucocorticoids have 
been found to increase receptors for these factors in various tissues, including IFN-y 
receptor on human monocytes (Strickland et al., 1986), IL-1 receptors on human 
peripheral blood lymphocytes (Akahoshi et al., 1988) and a glioblastoma cell line 
(Gottschall et al., 1991), IL-6 receptor in human epithelial cells (Snyers et al., 1990), 
VP and CRH receptors in the rat pituitary (Lutz-Bucher et al., 1986; Wynn et al.,
1985) and serotonin receptor in the cerebral cortex o f rats (Kuroda et al., 1993). The 
increase in these receptors have been suggested to account for permissive enhancement 
and suppressive actions of glucocorticoids on various immunological functions 
(Munck, 1992).
C. Proto-Oncogene: AP-1 Family
1. Origin
Activator protein-1 was first identified as a transcriptional factor that binds to 
the 12-O-tetradecanoylphorbol 13-acetate (TPA) response element (TRE). A TRE in 
the human metallothionein ria  (hMTTIa) promoter is required for optimal basal activity 
o f the hMTITa promoter in vivo and in vitro (Angel et al., 1987a; Lee et al., 1987a). 
The AP-1 protein was purified from extracts of HeLa cells using affinity columns 
which was constructed by coupling synthetic oligodeoxynucleotides corresponding to 
the AP-1 sites o f hMTTla to agarose beads. Several distinct polypeptides o f the jnn 
and fa s  gene families were specifically bound to these columns (Angel et al., 1987a, 
1988a; Bohmann et al., 1987, 1988; Chiu et al., 1988; Franza et al., 1988; Lee et al., 
1987a; Rauscher et al., 1988; Sassone-Corsi et al., 1988c).
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As one of the jun gene family, c-jun is a proto-oncogene which is the cellular 
counterpart of the \-jun  oncogene carried by avian sarcoma virus 17 (Cavalieri et al., 
1985; Maki et al., 1987; Vogt et al., 1987). Analysis of nucleotide sequence and the 
predicted amino acid sequence o f \-jun  has identified a 60 amino acid sequence at the 
C-terminus that is 40% homologous to the DNA-binding domain o f yeast transcription 
factor GCN4 (Maki et al., 1987). The DNA-binding domain of GCN4 can be replaced 
by the C-terminus o f c-Jun and this chimeric gene can complement yeast strains 
deficient in GCN4 (Struhl, 1987). The relationship between c-Jun and AP-1 was 
investigated since the optimal consensus sequence for GCN4 recognition sites is 
essentially identical to the AP-1 consensus sequence (Bohmann et al., 1987; Hope & 
Struhl, 1986, 1987).
The c-fos proto-oncogene was first isolated as the cellular homologue o f two 
viral fo s  oncogenes encoded by the Finkel-Biskis-Jenkins (FBJ) murine sarcoma 
viruses (MuSV) (Curran & Teich, 1982a). This virus was isolated from a spontaneous 
bone tumor and it induces osteosarcomas in rats and mice (Finkel et al., 1966, 1975; 
Van Beveren et al., 1983). Helper virus RNA related to FBJ-MuSV virus sequences 
have been used as fo s  probes (Curran et al., 1982c). These fo s  probes facilitated 
cloning o f c-fos genes from mice (Van Beveren et al., 1983), humans (Van Straaten et 
al., 1983), rats (Curran et a l,  1987), chickens (Fujiwara et al., 1987; Molder et al., 
1987) and frogs (Mohun et al., 1989). Subsequent studies have shown that the c-fos 
gene is an immediate early gene and that it encodes a nuclear phosphoprotein (c-Fos) 
which is associated with chromatin and acts as a subunit of AP-1 (Angel & Karin,
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1991; Chiu et al., 1988; Curran & Franza, 1988; Distel et al., 1987; Herrlich et al., 
1989; Lucibello & Muller, 1991a; Morgan & Curran, 1989; Muller, 1986; Renz et al., 
1987; Sambucetti & Curran, 1986).
Three additional fo s -related genes were identified in the late eighties and early 
nineties. Cross-hybridization o f conserved DNA fragments led to isolation o f the fosB  
gene (Zerial et al., 1989). Immunological cross-reaction o f c-fos and fo sB  encoded 
gene products resulted in isolation o f Fos related antigens (Franza et al., 1987). These 
have been named Fos related antigen-1 (fra-1) (Cohn & Curran, 1988) and the Fos 
related antigen-2 (fra-2) (Matsui et al., 1990; Nishina et al., 1990).
2. Structure and Characteristics
The AP-1 proteins have two major functional domains including the DNA 
binding domain and the transactivation domain (Figure 6). In Jun proteins, the 
transactivation domain is located within the N-terminal half o f the protein while the 
DNA binding domain is located at the C-terminus. The Jun proteins belong to the 
family o f "acidic-blob"-type transcription factors since the transactivation domain 
contains an abundance of acidic amino acids that are essential for activity (Angel et 
al., 1989; Oehler & Angel, 1992). However, in contrast to other members o f the 
acidic-blob group, the transactivation domains o f Jun proteins do not seem to form an 
extensive a-helical structure probably because these regions also contain single or 
multiple proline residues known to disrupt a-helical structure.
The DNA binding domain o f Jun proteins contains two functionally 
independent sub-regions including the basic region and the leucine zipper region. The
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Figure 6: Structure o f AP-1 Proteins (Angel & Herrlich, 1994). Nomenclature 
for AP-1 protein subunits are listed to the right o f each illustration. The hatched 
box ( B  ) represent the "leucine zipper" region. The cross-hatched boxes (HI 1 
represents the "basic domain". In Jun proteins, the solid boxes ( H )  represent 
transactivation regions and the shaded boxes ( □  ) represents the glutamine and 
proline rich regions. See text for additional information.
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basic region is rich in basic amino acids and it is responsible for the binding o f Jun 
proteins with DNA. The leucine-zipper is a structural motif that forms an a  helix in 
which every seventh amino acid is a leucine. The leucine side chains protrude from 
one side o f the a  helix to form a hydrophobic surface that mediates dimerization 
(Landschulz et al., 1988).
Transactivation domains of Fos proteins have not been fully characterized. 
Evidence suggests that the N-terminal half in Fos contains at least two domains 
important for activation of TRE-dependent transcription. One domain is between 
amino acids 40 and 110 and the other is directly adjacent to the basic region (amino 
acids 116-139). The latter domain primarily contains acidic amino acids and that are 
conserved in all four Fos proteins (Abate et al., 1991; Lucibello et al., 1991b).
Another two motifs (HOB1, HOB2) have recently been identified in Fos c-terminus 
(amino acids 226-236 and 267-276) (Sutherland et al., 1992). Transactivation 
triggered by FIOB1 and HOB2 is efficient whereas their independent action is 
relatively low.
The DNA binding domain of Fos is located near the center of the protein and 
it contains two clusters of basic amino acids forming a leucine zipper motif. Binding 
of Fos to DNA depends on the two basic regions and an alanine spacer (Gentz et al., 
1989; Turner & Tjian, 1989, Neuberg et al., 1989b). Moreover, DNA binding by Fos 
requires complex formation with Jun proteins and this is mediated by interactions 
between residues in the leucine zipper region (Neuberg et al., 1989a, b).
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In addition to the DNA binding and transactivation domains, AP-1 transcription 
factors also contain specific regions responsible for interaction with cellular proteins 
other than components of the RNA polymerase initiation complex. They also have 
domains related to nuclear translocation and regulation o f protein stability. Regions 
that interact with other cellular proteins and mediate nuclear localization signals in 
both Jun and Fos have been identified. However, specific regions involved in the 
rapid degradation of Jun and Fos proteins have not been identified.
3. Dimerization
Dimer formation is a prerequisite for DNA-binding. The Jun proteins can form 
both homo- and heterodimers with other Jun or Fos proteins while Fos can only 
associate with Jun proteins to form stable heterodimers (Angel & Herrlich, 1994). 
Site-directed mutagenesis experiments have demonstrated that dimerization o f Jun and 
Fos proteins occurs via hydrophobic interactions between their so-called 'leucine- 
zipper' regions. However, hydrophobic interactions alone do not seem to account for 
the specificity in dimer formation among leucine-zipper proteins. Some dimerization 
specificity is believed to be due to formation o f salt-bridges which increase stability of 
the dimers (O'Shea et al., 1992). In the leucine zipper region o f Fos proteins, there 
are acidic amino acids that are likely to cause electrostatic repulsion which may 
explain why Fos is not able to form stable homodimers. In contrast, efficient 
dimerization between the Jun and Fos proteins is likely to be promoted by ionic 
interactions between the positively charged residues in Jun with the negatively charged
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residues in Fos. The number o f such putative interactions is lower in Jun 
homodimers, resulting in reduced stability (O'Shea et al., 1989).
The Jun protein can form homo- and heterodimers, so the Jun can bind to DNA 
in the absence o f Fos (Angel & Herlich, 1994). The Fos proteins can not form 
homodimers, therefore they do not bind DNA in the absence of c-Jun. However, the 
Fos proteins can associate with any o f the Jun proteins to generate more stable 
heterodimers that have higher DNA-binding activity and bind to DNA more efficiently 
than the Jun homodimer.
4. DNA Binding
AP-1 proteins bind to DNA in a sequence-specific manner. The core sequence 
elements recognized by AP-1 factors are quite variable and fall into two classes, 
including an asymmetrical 7-mer TRE (5'-TGA G/C TCA-3') and an 8-mer 
symmetrical cAMP response element (CRE). In vitro binding studies have 
demonstrated that Jun/Fos heterodimers prefer binding to TREs while Jun homodimers 
prefer binding to CRE sequences (Nakabeppu & Nathans, 1989; Ryseck & Bravo, 
1991). AP-1 binding sites mediate gene activation through protein kinase C (PKC)- 
dependent pathways (Angel & Karin, 1991). Functional TREs are identified in the 
regulatory regions of more than 20 different genes. Most o f the AP-1 binding sites are 
located in the proximal promoter region of genes.
The sequence specificity of AP-1 binding to DNA is determined by basic 
residues in the DNA binding domain of AP-1 proteins (O'Neil et al., 1990; Vinson et 
al., 1989). Alpha-helices of dimerized proteins bifurcate beyond the leucine zipper as
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a consequence o f the positive charges in basic regions, forcing the two basic regions to 
track along the major groove o f the DNA (scissorgrip model) (Vinson et al., 1989).
5. Transactivation
The AP-1 complex stimulates transcription by binding to elements in enhancer 
and promoter regions of various genes. Both Jun and Fos contribute to transactivation 
o f the AP-1 complex (Figure 7). In vivo competition experiments have suggested that 
transactivation of AP-1 requires a coactivator which interacts with the transactivation 
domain o f c-Jun and links Jun to the pre-initiation complex (Angel et al., 1989; Oehler 
& Angel, 1992). The coactivator proteins are shared by other transcription factors 
whose transactivation domains are characterized by an abundance o f acidic amino 
acids. These acidic-blob-type transactivators can reduce physical interactions between 
Jun and coactivators, thereby interfering with c-Jun-specific transactivation. The 
interaction between c-Jun and c-Fos plays an important role in regulating various cell 
functions. Transcription of c-jun and c-fos genes is induced by TPA and other 
activators o f PKC (Angel & Herlich, 1994). The c-Fos protein and c-Fos mRNA have 
shorter half-lives than c-Jun protein and c-Jun mRNA. Therefore, composition of the 
AP-1 complex changes from predominantly Jun homo- and heterodimers, before 
induction, to mostly Jun-Fos heterodimers immediately after induction by PKC. 
Formation o f the Jun:Fos heterodimer is primarily responsible for initiating the 
induction response while c-Jun homodimers are involved in maintaining expression of 
various genes.
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Figure 7: Model of Transcriptional Activation of AP-1-Dependent Genes. The TATA 
binding protein (TBP), TBP-associated factors (TAF), RNA polymerase II and basal 
transcription factors (TFUA, -B, -E, -F, -H and -I) make up the RNA polymerase II 
preinitiation complex. In Jun-Fos heterodimers, the transactivation domain o f  Jun 
interacts with a coactivator to make contact with the preinitiation complex. See text 
for a detailed description of this model. TRE = TPA/phorbol ester response element.
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6. Regulation of AP-1 Activity
AP-1 activity can be regulated at the level of transcription as well as by post- 
transcriptional modifications (Angel & Herrlich, 1994). Transcription o f c-jun genes 
can be induced rapidly and transiently by mitogenic stimulations that activate PKC. 
Pharmacological agents and regulators which act through PKC include phorbol esters, 
serum, epithelial growth factor (EGF), platelet-derived growth factor (PDGF), 
transforming growth factor-alpha (TGFa), TGF(3, TNFa, nerve growth factor (NGF), 
IL-6 and retinoic acid (RA). The transient induction of c-jun mRNA lasts 
considerably longer than c-fos induction and part o f this difference is probably due to 
higher stability o f c-jun transcript.
Increased transcription o f the c-jun gene is mediated by different response 
elements in the promoter region (Angel et al., 1988b). In the promoter o f the human 
c-jun gene (Figure 8), there are two TATA-like sequences (5'_34AGATAAG 283', 
5'.58TATTTTTA.523') which are located 24 to 30 base pairs upstream of the 
transcription initiation sites. The upstream TATA-like sequence is overlapped by a 
related serum responsive factor (RSRF) binding site (Han et al., 1992). Two TRE-like 
sequences have been found upstream of the distal TATA-like sequence. One is 
located between positions -72 and -63 and functions as a high-affmity AP-1 binding 
site (Angel et al., 1988a). Another AP-l-like sequence was identified further upstream 
between -190 and -183 residues (Stein et al., 1992; Van Dam et al., 1990). A CAAT- 
box (5'.9IGCAAT 873') and a GC-box (5'.I23GGGCGGGCCCGCCCC ,093') have been 
found further upstream and these elements are recognized by the transcription factors
RERE
AP-1 NF-Jun SP1 CTF AP-1 RSRF
Y t  Y t
-183 -131 -107 -87 -64 -50 -28 +1 + 9 7 6
&
c-Jun coding sequence
TTACCTCA GGGCCCGCCCCCCT GCCAAT
TGGAGTCTCCA
TTACCTCA TATTTTTA AGATAA
AP-1 site GC box CAAT AP-1 site TATA like box Start site 
box
Figure 8: Organization of the Promoter Region of the c-jun Gene in Humans. See text for description of nucleotide segments and 
regulation of this gene. AP-1 = activator protein-1; CTF = CAAT-binding transcription factor; NF-Jun = nuclear factor-Jun; 
RSRF = related serum responsive factor; RSRE = related serum responsive element; SP1 = specific protein 1.
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CTF and SP1, respectively (Angel et al., 1988b). The presence of AP-1 sites within 
the c-jun promoter suggests a positive autoregulatory effect o f c-Jun on subsequent 
transcription o f the c-jun gene (Angel et al., 1988b). Autoregulatory stimulation o f c- 
Jun leads to signal amplification o f transient effects that occur following PKC 
activation. It has been proposed that autoregulatory effects may be responsible for 
long term transcriptional responses associated with increased AP-1 proteins (Angel et 
al., 1988a). This positive autoregulation seems to play an important role in different 
pathways by amplifying the magnitude and timing of responses to an initial signal. As 
shown by transfection experiments, the first AP-1 binding site plays a key role in 
induction of human c-jun transcription after stimulation o f cells by serum or TPA 
(phorbol ester). In response to TPA and growth factors, the pre-existing c-Jun protein 
is rapidly dephosphorylated on specific residues located directly upstream of the basic 
DNA binding domain. This results in an increase in the DNA binding activity o f c- 
Jun. Alternatively, phosphorylation of c-Jun within the transactivation domain may 
enhance transactivational functions o f c-Jun. The proximal AP-1 site is also essential 
for c-jun activation by DNA damaging agents such as UV irradiation or H20 2 (Devary 
et a l ,  1991).
Increased cAMP levels in NIH3T3 cells (Mechta et al., 1990), HeLa cells 
(Angel et al., 1988a) and thymocytes (Reuse et al., 1991) has been related to increased 
PKA activity and a decrease in both basal and TPA-induced c-jun expression. The 
inhibitory effect on c-jun expression occurred at the transcriptional level but the target 
elements have not been clearly defined. The cAMP responsive element binding
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protein (CREB) recognized the -72/-63 AP-1 binding site located in the c-jun 
promoter. This suggests that there may be competition between c-Jun protein and 
CREB binding to the DNA.
The transcription o f c-fos genes can be induced in different types of cells by 
various stimuli (Cohen & Curran, 1989). As an immediate early gene, transcriptional 
activity o f c-fos is rapidly induced to maximum when quiescent cells are stimulated by 
the addition o f serum or growth factors (Kruijer et al., 1984; Muller et al., 1984). 
Induction o f the c-fos gene does not require de novo protein synthesis (Greenberg et 
al., 1986).
Stimuli may induce c-fos by acting through a number of different transduction 
pathways. Multiple c/.v-elements are present in the promoter of the c-fos gene 
including the TATA element, the -60 region, the direct repeats at -95, the -170 region 
and the serum response element (SRE) at -310 (Figure 9) (Cohen & Curran, 1989; 
Fisch et al., 1987; Gilman et al., 1986; Lucibello et al., 1991b; Rivera et al., 1990; 
Runkel et al., 1991).
The SRE is the major regulatory element in the c-fos promoter. The core o f 
the SRE consist o f a palindromic DNA sequence [CC (A/T)6 GG (or a CArG box)]. 
This cis-element was originally identified as the binding site for serum response factor 
(SRF) (Gilman, 1988; Greenberg et al., 1986; Treisman, 1985, 1987, 1992a).
However, many different proteins specifically interact with SRE (Treisman &
Ammerer, 1992b), which may help to explain the apparent variation in regulation o f c- 
fo s  in various cell types. Although the SRE primarily mediates stimulatory effects of
SIF SRF NF 1 ? CREB
▼ ▼ ▼ f t
-346 -310 -170 . 9 5
c-fos coding sequence
SIE SRE NF1-like site DRs CRE TATA box Startsfe
Figure 9: Organization o f the Promoter Region of the c-fos Gene in Humans. See text for description of the nucleotide residues 
and a consideration of the literature describing processes that regulate the expression of c-fos. CRE = cAMP response element; 
CREB = cAMP response element binding protein; DRs = direct repeats; NF1= nuclear factor-1; SIE = v-sis conditioned medium 
induction element; SIF = v-sz's-inducible factor; SRE = serum response element; SRF = serum response factor.
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serum on c-fos gene transcription it also mediates the stimulation by a variety of other 
growth factors as well as phorbol esters. Further, it mediates auto-inhibitory effects of 
c-Fos (Cohen & Curran, 1989).
Serum response factors (SRFs) are ubiquitous nuclear phosphoproteins (Misra 
et al., 1991; Norman et al., 1988; Treisman, 1986, 1987) which form dimers and 
specifically recognize and bind to SRE. Phosphorylation o f SRF enhances the 
exchange rate of SRF with the SRE but has little affect on the overall DNA binding 
affinity (Marais et al., 1992). The binding o f SRF to SRE is stabilized by a ternary 
complex factor (TCF) which forms a stable complex with SRF and SRE (Shaw et al., 
1989; Schroter et al., 1990). This ternary complex represents a target within the c-fos 
promoter for the signal transduction cascade (Shaw et al., 1989). The signal triggered 
by serum, growth factors or TPA may activate both PKC-dependent and PKC- 
independent pathways which in turn activate MAP kinase (MAPK) (Leever &
Marshall, 1992). The MAPK increases phosphorylation of SRE-interacting proteins, 
SRF and leads to c-fos activation. In contrast, the activation o f phosphatase may 
cause dephosphorylation o f SRF, resulting in inhibition of the c-fos gene.
In addition to SRE, other elements play a role in regulating c-fos expression. 
For example, the -60 element contains a sequence resembling a CRE that can be 
bound by the CREB (Berkowitz et al., 1989; Sassone-Corsi et al., 1988b). This 
element is essential, but not fully sufficient, for c-fos stimulation by both cAMP and 
increased cell Ca2+ concentrations. The v-sis conditioned medium induction element
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(SIE), located upstream of the SRE at -340, mediates PDGF-induction o f the c-fos 
gene (Wagner et al., 1990).
Induction o f the c-fos gene is transient. Rapid return to the pre-stimulation 
levels is seen within 30 minutes after induction. Down-regulation o f c-fos is mediated 
principally by the autoregulatory effect of c-Fos (Sassone-Corsi et al., 1988a). The C- 
terminal sequences and their functions are conserved in Fos-related proteins and are 
sufficient for mediating autoregulatory effects (Gius et al., 1990). The 
phosphorylation o f the C-terminal domain on several sites also appears to be essential 
for autoregulatory shut-off since C-terminal Fos mutants that are lack of 
phosphorylation sites and display increased protein stability are defective in 
autoinhibition (Ofir et al., 1990). Several studies have suggested that autoinhibitory 
effects o f c-Fos are mediated by binding o f Fos to SRE (Rivera et al., 1990).
Recent literature indicates that TCF activity is affected by phosphorylation 
events that correlate with c-fos promoter activity (Zinck et al., 1993). This could 
explain the requirement for SRE-SRF interaction in Fos-mediated autorepression and 
provide new clues to understanding the mechanism for down regulation of c-fos.
In addition to transcriptional regulation, post-transcriptional regulation plays a 
major role in determining Fos/Jun DNA binding and transactivation activity (Angel & 
Herrlich, 1994). Alterations in the activity o f pre-existing AP-1 are required for 
subsequent transcriptional activation o f immediate early genes, including c-jun and c- 
fos. Post-transcriptional modifications of pre-existing AP-1 include phosphorylation, 
glycosylation, oxidization and interaction with other nuclear proteins.
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Phosphorylation is the most common form o f the post-transcriptional 
modification o f proteins. Phosphorylation of Jun homodimers may occur at the cluster 
o f residues (# 231, 239, 243, 249) near the c-Jun DNA binding domain and this may 
be mediated by glycogen synthase kinase-3 (GSK-3) (Boyle et al., 1990), casein 
kinase I (CKI) or casein kinase II (CKII) (Lin et al., 1992). Phosphorylation decreases 
DNA binding activity and, therefore, has an inhibitory effect on transcriptional 
activation. In contrast, the phosphorylation of Ser63 and Ser73 in c-Jun can cause 
increased activity of the AP-1 complex without having an effect on DNA binding 
(Binetruy et al., 1991). It seems that the kinase involved in phosphorylation o f the 
serines at positions 63 and 73 is distinct from the kinases phosphorylating Jun in vitro 
(Pulverer et al., 1991). Exposure o f cells to TPA causes dephosphorylation o f Ser243 
and phosphorylation of Ser63 and Ser73 in c-Jun, resulting in an increase o f AP-1 
activity.
Reduction-oxidation also has been shown to regulate DNA binding activity of 
AP-1 in vitro (Abate et al., 1990). Reduction-oxidation regulation of AP-1 DNA 
binding activity is mediated by a conserved cysteine residue in the c-Jun DNA binding 
domain. Reduction o f this cysteine residue stimulates AP-1 DNA binding whereas 
oxidation or chemical modification inhibits AP-1 DNA binding. When this cysteine is 
replaced with a serine residue, reduction-oxidation control of DNA binding is lost, 
resulting in increased DNA binding.
Activator protein-1 activity may be regulated by sequestering cytoplasmic 
transcription factors (Roux et al., 1990). It has been shown that the c-Fos protein was
59
anchored in the cytoplasm when cells were maintained in the absence of serum.
Serum induced an active nuclear translocation of c-Fos. This regulated nuclear 
transport was specific for the c-Fos protein since the v-Fos protein was constitutively 
present in the nucleus.
Furthermore, AP-1 activity may be altered by interaction with other proteins. 
Cross-family dimerization between bZip transcription factors of the Fos-Jun and ATF 
groups (Hai & Curran, 1991; Ivashkiv et a l,  1990), as well as occupation o f the AP-1 
site by repressor factors which do not dimerize with AP-1 proteins (Foulkes et al., 
1991; Masquilier & Sassone-Corsi, 1992), can block AP-1 mediated transcription. The 
interaction between AP-1 and several members of the steroid hormone receptor gene 
family may also alter DNA binding activity of AP-1 (Gaub et al., 1990; Jonat et al., 
1990; Schule et al., 1990; Yang-Yen et al., 1990).
7. Functions
a. Roles of AP-1 in C ellular Proliferation and Differentiation.
Several lines of evidence indicate that AP-1 proteins play a role in cell differentiation. 
Firstly, it has been reported that non-differentiated F9 embryonal carcinoma (EC) cells 
express very low levels of c-jun mRNA. Addition of RA triggers the differentiation o f 
these cells into a primitive epithelial cell type along with induction o f c-jun 
transcription which requires the AP-1 site (Ryder & Lanahan, 1989; Yang-Yen et al., 
1990b). The AP-1 site appears to be involved in amplifying the initial response to RA 
which is then maintained by newly synthesized c-Jun protein binding to the AP-1 site, 
rather than playing a primary role in the induction response. Such transcriptional
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activation o f the c-jun gene has also been demonstrated for P I9 EC cells (De Groot & 
Sutano, 1990). However, a repressing function of AP-1 may occur during 
differentiation of pre-adipocytes into adipocytes and during differentiation o f the 
mammary gland (Distel et al., 1987). The ability o f AP-1 to activate or repress gene 
expression may depend on differences in activity o f the promoter in a specific cell 
type.
The AP-1 complex also controls the expression of genes involved in cellular 
proliferation. Expression o f both c-jun and c-fos is rapidly increased in many cell 
types in response to mitogens such as serum, EGF, TGF, PDGF and other growth 
factors (Brenner et al., 1989; Lamph et al., 1988; Quantin & Breathnach, 1988; Ryder 
& Nathan, 1988). Logarithmically growing cells contain higher levels of c-jun mRNA 
than serum starved cells (Angel et al., 1988a). Further, microinjection o f anti-Fos 
antibodies, or transfection with c-fos antisense RNA, inhibits DNA synthesis or cell 
proliferation in cultured fibroblasts (Riabowol et al., 1988). However, some 
researchers have reported AP-1 has a negative effect on cell proliferation. For 
example, AP-1 is reportedly involved in the autogenous induction o f TGFp-1 which 
acts as a growth inhibitor for various cell types (Roberts et al., 1985). Phorbol ester 
treatment induces the expression of TGFp-1 which stimulates the expression o f both 
c-jun and c-fos in order to amplify its expression. These observations suggest that the 
function of the AP-1 complex may be to activate transcription of a variety of target 
genes in response to stimulation of cell surface receptors that are connected to several 
different signal transduction pathways. The down-stream target genes might then
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mediate a variety of responses to hormones and growth factors including proliferation, 
differentiation and/or neuronal activity. Outcome of the cellular response to c-Jun and 
c-Fos induction and increased AP-1 activity would then be likely to depend, on the 
specific cellular environment.
b. Roles of AP-1 in Transformation. As immediate genes, the 
expression of c-jun and c-fos is induced in response to carcinogens and tumor 
promoters, growth factors and cytokines. Then AP-1 proteins regulate the expression 
various genes. Changes in gene expression initiate DNA synthesis and may eventually 
affect mitosis or the formation o f  differentiated cells. Aberrant function o f any 
component involved in these cascades may have dramatic consequences, leading to 
loss o f growth control and neoplastic transformation (Bishop, 1987; Rozengurt, 1986; 
Weinberg, 1985).
D. Interaction Between Glucocorticoid Receptors and AP-1 Proteins
The first report which suggested that glucocorticoids regulate AP-1 activity 
came from studies on inhibition of inflammatory processes and the proliferative 
response o f cells involved in wound healing. It was known that dexamethasone 
inhibited induction o f collagenase gene expression during cell proliferation and 
inflammation. Characterization of the collagenase promoter identified an AP-1 binding 
site as a target for inhibitory effects of dexamethasone (Jonat et al., 1990; Yang-Yen 
et al., 1990a). This finding suggested that AP-1 activity might be inhibited by 
glucocorticoids. This possibility was confirmed by the fact that fusion o f an AP-1 
binding site to a heterologous promoter is sufficient to confer both TPA induction and
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dexamethasone inhibition o f the collegenase gene (Jonat et al., 1990; Lucibello et al., 
1990; Schule et al., 1990; Yang-Yen et al., 1990a).
Studies using different cell lines suggested that various mechanisms may 
mediate inhibition o f GR on AP-1 transactivation function. Studies on the repression 
o f the human collagenase gene by glucocorticoids demonstrated that the ability of 
glucocorticoids to affect TPA induction was specific for AP-1 and that inhibition was 
not restricted to TPA-induced AP-1 activity but also affected basal activity o f the AP- 
1 complex. Inhibition of collagenase gene expression was ligand dependent and the 
effect required expression of GR. Inhibition of collagenase gene expression occurred 
in the absence o f gene transactivation induced by GR. Finally, glucocorticoid 
inhibition o f collagenase gene expression did not require protein synthesis. These 
results suggest that repression of the collagenase gene is mediated by the GR and not 
by another glucocorticoid-inducible gene product.
Classically defined GREs have not been found in regulatory regions for the rat 
a-fetoprotein and mouse proliferin genes. Instead, negative GREs (nGRE) are found 
overlapping the AP-1 binding site in the promoters or enhances for these genes. 
Transfection experiments with HeLa cells have shown that the promoter is activated 
by GR in the absence o f c-Jun, but activation is inhibited by GR when the intracellular 
concentration of c-Jun and c-Fos are elevated. These results suggest that the 
overlapping AP-1 binding site and the nGRE form "composite response elements" 
(CREs). In addition, GR and AP-1 may compete for the same binding sites (Diamond 
et al., 1990; Mordacq and Linzer, 1989).
63
DNA sequence analysis of the collagenase gene has also suggested that the AP- 
1 site may be different from GREs in regulatory regions of particular genes (Konig et 
al., 1992). Purified GR does not bind to the AP-1 binding site, nor does AP-1 bind to 
the GRE. Results from gel retardation assays have shown that GR formed a specific 
complex with GRE and that this GR-GRE complex was efficiently displaced by an 
excess o f unlabeled GRE, but not by AP-1 sequences found in the collagenase 
promoter. In addition, there was no GR binding site overlapping the AP-1 site in the 
promoter region o f the collagenase gene. Thus, competition between the GR and AP- 
1 for their respective binding sites can not explain inhibitory effects of glucocorticoids 
on transcription o f collagenase. Using in vivo footprinting analysis, Konig and 
coworkers (1992) demonstrated that occupancy o f the AP-1 binding site on the 
collagenase gene was not altered under the same conditions that inhibit AP-1 action. 
This result implies that hormone bound GR is tethered to DNA-bound AP-1 at the 
collagenase regulatory element without binding directly to DNA. In support to this 
model, the wild type c-Jun protein can be directly cross-linked to GR and in vitro 
translation followed by immunoprecipitation showed that antibodies to c-Jun co­
precipitate GR in the presence and absence o f protein cross-linkers.
Other studies on GR-dependent inhibition of AP-1 regulation of the collagenase 
gene suggest a direct protein-protein interaction between GR and AP-1 subunits. It has 
been proposed that this results in mutual inhibition of DNA binding of GR and 
AP-1 and loss o f their transactivation functions (Schule et al., 1990; Yang-Yen et al.,
1990a). Results from these laboratories demonstrated that incubation of purified GR
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with an excess o f purified c-Jun inhibited binding of GR to a simple palindromic GRE 
and incubation of c-Jun with excess GR reduced the binding of c-Jun to a simple 
collagenase AP-1 binding site.
Some investigators claim that there is no real difference among the 
aforementioned models. Questions have been raised as to whether DNA binding in 
the superimposition model is required since recent studies have demonstrated that the 
nGREs are bound by three molecules of GR rather than the GR dimer that binds to 
classic GREs (Drouin et al., 1993). It is possible that on a nGRE the initial binding 
by the receptor dimer serves only to tether the third receptor molecule to make the 
appropriate protein-protein interaction with AP-1. The inhibitory GR monomer may 
not be needed to bind DNA in order to inhibit AP-1 activity. However, GR mutants 
that do not bind DNA do not interfere with AP-1 regulation o f the collagenase gene. 
There is also some doubt about the conclusion that the AP-1 site in the collagenase 
gene is only inhibited by GR.
Proliferin gene expression may be enhanced or repressed by GR depending on 
the composition of AP-1 dimers present in cells. Because cell lines used for study of 
A P-l-G R interactions may contain various levels o f c-Fos, c-Jun and related oncogene 
proteins, the results obtained from different cell types may not agree with one another. 
Studies using murine teratocarcinoma F9 cells have shown that collagenase gene 
expression is stimulated by GR in the presence o f a c-Jun. Thus, glucocorticoid 
effects on gene expression may be mediated by a common mechanism which is 
modified by the individual cell environment.
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The interaction between GR and AP-1 proteins requires the DNA binding 
domain o f both GR and AP-1 protein (Angel & Herrlich, 1994). This is supported by 
the fact that expression o f excess intact c-Jun prevents inhibition o f AP-1 by 
dexamethasone whereas truncated c-Jun protein, lacking the DNA binding domain, can 
no longer interfere with the inhibition o f AP-1 activity. Further, mutant analysis has 
revealed that the DNA binding domain is necessary and sufficient for repression of 
GR activity. In contrast, although the DNA binding domain o f the GR is required for 
this interaction it is not sufficient. Thus, other regions o f the receptor must also be 
involved in the interaction with AP-1 proteins and it has been proposed that the 
inhibitory effects of GR are related to intramolecular contact involving several regions 
o f the receptor (Heck et al., 1994).
E. Lymphokine Activated Killer Cells
1. Definition, Origin and Characteristics
Lymphokine activated killer cells were originally defined as cytotoxic 
lymphocytes capable o f lysing fresh autologous solid tumor target cells in short-term 
51Cr-release assays (Grimm et al., 1982; Yang et al., 1986). Lymphokine activated 
killer cell activity is a MHC-nonrestricted cytotoxicity in contrast to MHC-restricted 
cytotoxicity mediated by antigen-specific cytotoxic T lymphocytes (CTL). Generally, 
it is limited to killing by lymphocytes as measured in short-term (4 hr) chromium 
release assays. Therefore, LAK cell activity excludes cytotoxicity mediated by 
cytocidal macrophage, natural cytotoxic cells, or extracellular killing by
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polymorphonuclear leukocytes because each of them requires longer periods to elicit 
activity.
Since the original description o f LAK cell activity, numerous studies have been 
published regarding the phenotypic characteristic o f cells mediating LAK cell activity 
in mice, rats and humans. Early studies suggested that cells with LAK cell activity 
represented a novel type of lymphocyte distinct from classical natural killer (NK) cells 
or cytotoxic T lymphocytes (Grimm et al., 1983). This suggestion was based on 
several findings. Firstly, LAK cell activity was functionally distinct from NK activity 
since LAK cells lyse NK-resistant tumor cells. Secondly, LAK cell activity could be 
generated from tissue sites that contain few, if any, active NK cells. In addition, LAK 
cell activity is distinguished from CTL activity since LAK cell activity is MFIC- 
nonrestricted and LAK cells can lyse any tumor target cell, including those derived 
from syngeneic, allogeneic or xenogeneic sources regardless of whether the targets 
express MHC antigens. Finally, early surface marker studies indicated that murine 
LAK cells expressed a high density of Thy 1.2 (a marker historically considered T cell 
specific) but not Lyt2 markers (a marker unique to murine CTL). These early studies 
indicated that LAK cell activity was mediated by lymphoid cells derived from a 
unique lineage and that the various lytic activities could be derived from separate and 
unrelated lineages (Balias, 1986). However, extensive and exhaustive cell fraction 
studies, together with extensive surface marker analyses using more selective 
monoclonal antibodies, have demonstrated that the vast majority of LAK cell activity 
is derived from the NK population.
67
In humans, the majority o f LAK cell precursor activity is contained within the 
large granular lymphocyte (LGL) population, which contains virtually all active NK 
cells (Herberman et al., 1987) and these cells express surface markers 
characteristically associated with human NK cells, including CD56 (Leu-19) (Hercend 
et al., 1985; Ortaldo et al., 1986; Philips & Lanier, 1986) and CD16 (Leu-11) (Itoh et 
al., 1985; Lanier et al., 1985). Few, if any, LAK cell precursor cells from humans 
express the T-cell-associated CD3 or CD5 surface markers (Ortaldo et al., 1986;
Philips & Lanier, 1986). Monocytes or B cells can not generate LAK cell activity. 
Because of the granular nature of LAK cell precursors, the generation of LAK cell 
activity can be significantly depressed by removal o f granular lymphocytes with the 
lysosomotrophic amine L-leucine methyl ester (L-LME) (Shau & Golub, 1985).
As with human LAK cell precursors, data from mice also indicate that the 
majority of LAK cell precursor activity is derived from NK cells. These precursor 
cells all express NK1.1, a marker closely associated with mouse NK cells (Koo et al., 
1982). Most of these cells are part of the asialo GM1+ population and this marker is 
characteristically associated with murine NK cells (Salup et al., 1987; Yang et al.,
1986). Although a portion o f LAK cell precursor activity is associated with Thy-1 + 
cells, this is due to the heterogeneity of Thy-1 expression on subsets of murine NK 
cells. No LAK cell activity was associated with Lyt-1, Lyt-2, L3T4 positive murine 
cells (Salup et al., 1987; Yang et al., 1986).
Nearly all LAK cell activity in rats is contained within the LGL population and 
it is sensitive to treatment with L-LME (Vujanovic et al., 1988a). Using positive and
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negative selection methods, these cells were found to express 0X 8 (CD8), asialo GM1 
and the LGL-specific surface marker NKR-P1, while no LAK cell precursor activity 
was found in cells expressing CD3, CD4, CD5, CD25, 0X41 (monocyte cell markers) 
or slg. Thus, it is clear that virtually all LAK cell activity is derived from LGL 
populations containing active NK cells and no LAK cell activity is generated from 
purified resting T cells, B cells or monocytes.
In the equine species, LAK cell activity is associated with the EqT3+ 
population which includes small T cells and LGL fractions o f peripheral T 
lymphocytes (Hormanski et al., 1991). While both populations gave rise to LAK 
cells, the LGL fraction requires less IL-2 to achieve maximal cytolytic activity and 
also exhibits more potent cytotoxic activity on a per cell basis.
It is clear that the majority o f LAK cell activity is derived from IL-2-activated 
LGL/NK cells whereas little or no activity is generated from resting T cells.
However, LAK cell activity has been generated from cell populations or lymphoid 
organs virtually devoid o f active LGL/NK cells, such as lymph nodes, thymus, or 
thoracic duct lymph. Evidence for a lineage continuum among pre-NK cells (LAL), 
mature NK cells (LGL) and IL-2-activated LAK cells may help to explain these 
findings.
Using a purification scheme that results in highly enriched populations of LAL 
from rat spleen cells, it was demonstrated that a lineage continuum does exist among 
large agranular lymphocytes (LAL), LGL/NK cells and LAK cells and this 
continuation is controlled exclusively by IL-2 (Maghazachi et al., 1988). Large
69
agranular lymphocytes can be enriched from resting spleen cells by Ficoll-hypaque 
centrifugation to remove B cells and monocytes/macrophages, treatment with cytotoxic 
pan T-cell antibody plus complement to remove T cells and treatment with L-LME to 
remove LGL/NK cells (Maghazachi et al., 1988). The resulting population represents 
a very small percentage (<5%) o f the total spleen cell population and it is highly 
enriched in cells morphologically resembling LAL. These enriched LAL cells do not 
exhibit NK activity nor can NK activity be elicited by short-term (4 hr) treatment with 
IL-2 or interferon-a/p, even though the cells express surface markers similar to mature 
LGL/NK cells or LAK cells. When cultured with a low level o f IL-2 (50 U/ml), 
enriched LAL preparations from rats respond in 12 to 24 hours by generating LGL 
with NK activity (YAC-1 killing only). When IL-2 induced, LGL/NK cells were then 
cultured with high levels of IL-2, LAK cell activity was generated and this activity 
was eliminated when LGL/NK cells were treated with L-LME.
A developmental and/or activation pathway o f LAL, LGL/NK cells and cells 
with LAK cell activity has been proposed (Maghazachi et al., 1988). Initially, LAL 
are cytolytically inactive but appear to be the immediate precursor cells for 
development o f LGL with NK cell activity. Further, LGL morphology and NK cell 
activity are closely associated, with the functional activity becoming detectable at the 
same time as the appearance o f detectable granules. In the presence o f high 
concentrations o f IL-2, large granular lymphocytes with NK cell activity can further 
differentiate and/or become activated to develop LAK cell activity. Some surface 
markers on LAL are commonly associated with LGL/NK cells or LAK cells but LAL
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are distinguished from LGL/NK cells by the weak or undetectable expression of 
characteristic NK cell markers such as 0X 8 or asialo GM1. However, as LAL are 
activated by IL-2 to generate LGL with NK cell activity, these NK-associated markers 
are expressed. Activation o f LGL by higher levels of IL-2 increases expression of 
some NK markers and expression of additional markers not found on LAL or LGL/NK 
cells. Thus, the generation of LAK cell activity from cell populations or lymphoid 
organs virtually devoid o f active LGL/NK cells can be explained by a lineage 
continuum among LAL, NK cells and LAK cells.
Lymphokine activated killer cell cytolytic activity is primarily directed against 
malignant tumor cells, including freshly isolated autologous or allogeneic tumor cells, 
cultured tumor cell lines, leukemic blasts and xenogeneic tumor cells (Grimm et al., 
1982; Hiserodt et al., 1987; Vujanovic et al., 1988b). It is not clear whether LAK 
cells are capable o f reacting with benign tumor cells or whether malignant 
transformation is necessary for efficient LAK cell recognition. Freshly isolated normal 
cells, including hepatocytes, peripheral blood leukocytes (PBL), bone marrow cells and 
thymocytes, are essentially resistant to LAK cell activity. However, in some case, 
monocytes, macrophages and normal cells that have been chemically modified by 
trinitrophenol treatments can be recognized and lysed by LAK cells (Djeu &
Blanchard, 1988)
2. Induction and Regulation
Lymphokine activated killer cell activity is induced from populations of 
normal, resting lymphoid cells by culturing these cells in media containing crude or
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recombinant IL-2 (Grimm et al., 1982; Grimm & Rosenberg, 1984; Rosenberg & 
Lotze, 1986). The induction o f LAK cell activity by IL-2 involves two processes, 
activation and subsequent proliferation (Hormanski et al., 1992; Siegel et al., 1987). 
However, how IL-2 induces LAK cell activity is not very clear. Previous studies have 
shown that NK cells constitutively express the p70 chain o f IL-2 receptor (IL-2R) 
(Bich-Thuy et al., 1987). Monoclonal antibodies to the (3 subunit of IL-2R efficiently 
inhibit IL-2 mediated activation of NK cells and the generation o f LAK cell activity. 
Interleukin-2 stimulation does not induce the expression o f the a-subunit of IL-2R. 
Thus, IL-2-induced LAK cell activity is probably mediated by the p subunit o f IL-2R 
so that a high dose o f IL-2 is needed to generate LAK cell activity (Phillip el al., 
1989). However, other studies have demonstrated that stimulation of LAK cells with 
subunit-specific IL-2 analogs results in increased expression of IL-2Ra on the cell 
membrane (Heaton et al., 1993). These authors reported that stimulation o f the 
intermediate affinity IL-2RPy was sufficient for generation of LAK cell activity from 
human PBMCs; however, interaction o f IL-2 with the high-affmity receptor complex 
was necessary to obtain maximal proliferation and generation o f LAK cell activation.
As with all cell-mediated effector mechanisms, the generation of LAK cell 
activity is subject to regulation by soluble and cellular control mechanisms. The cells 
which affect generation o f LAK cell activity include alveolar or peritoneal 
macrophages, neutrophils and red blood cells (Shau & Golub, 1988; Shau et al., 1989; 
Sone et al., 1987; Roth & Golub, 1989). Macrophages are the most effective 
inhibitors o f LAK cell activity and their effect requires direct cell-to-cell contact and
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this action is independent o f prostaglandin E2 or cytokines produced by macrophages. 
Further, it has been suggested that macrophage inhibition of LAK cell induction is 
associated with a failure of the generated LAK cells to develop sufficient levels of 
surface transferrin receptors needed to proliferate in response to IL-2. The 
biochemical basis for suppression of the neutrophils and enhancement o f the red blood 
cells is unknown.
In addition to the regulatory effects o f macrophage and other cells, soluble 
factors can influence LAK cell activation. One major regulator of LAK cell activation 
is the B-cell growth factor, IL-4. In humans, IL-4 can not generate LAK cell activity 
from freshly isolated lymphocytes but it blocks the generation o f LAK cell activity 
induced by IL-2 (Peace et al., 1988). Once activated by IL-2, human cells can 
generate LAK cell activity in response to IL-4 alone. The concomitant presence o f IL- 
2 and IL-4 generates enhanced lytic activity. Besides IL-4, TNF-a, IL-1 and 
interferon-y have been reported to enhance the generation of LAK cell activity without 
influencing the proliferative response o f developing LAK cells (Ochoa et al., 1987; 
Owen-Schaub et al., 1988). In contrast, TGF-p can potently suppress the induction of 
LAK cell activity from human PBL (Grimm et al., 1988). The suppressive effect of 
TGF-P can be partly reversed by adding TNF-a. It has also been reported that high 
dose cortisol inhibits LAK cell activity while low dose cortisol may enhance LAK cell 
activity (Keadle, 1992; Keadle et al, 1993; Melrose et al., 1993; Vetto et al., 1987).
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3. Mechanisms Involved in Recognition and Killing by LAK cells
Killing by LAK cells is initiated by Mg2+-dependent target cell adhesion, 
antigen recognition and signal transduction. Target cell adhesion by LAK cells is 
dependent on CD11, CD 18 and CD2 and their reciprocal target ligands, ICAM-1 and 
LFA-3 (Timonen et al., 1988). The specification of interactions between adhesion 
molecules correctly distinguishing between tumor cells and normal cells.
It is known that antigen recognition of target cells by LAK cells is not 
restricted by or directed against products of MHC. This MHC-nonrestricted 
recognition does not involve classical T-cell receptors or the CD3 complex since NK 
cells do not express these receptors and LAK cell activity is not influenced by 
antibodies against their TcR or CD3 molecules (Ortaldo et al., 1986; Phillips &
Lanier, 1986). Studies have identified one receptor termed NKR-P1 that is capable of 
mediating a transmembrane signal for cytotoxicity of NK and adherent LAK cells 
(Chambers et al., 1989). These authors have reported that NKR-P1 is an integral 
membrane protein belonging to the lectin family of receptors, which are composed of 
disulfide-linked 30-KD monomers. This protein expressed on NK cells, LAK cells 
and neutrophils, but not on the majority o f T cells and it is not found on B cells or 
monocytes. Removal o f NKR-P1 by trypsinization of adherent LAK cells leads to a 
rapid loss o f cytolytic activity. Thus, this receptor may play a role in recognition and 
activation.
Lymphokine-activated killer cells show Ca2+-dependent lytic function including 
granule reorientation, granule exocytosis and target cell membrane perforation by the
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granule-associated pore-forming proteins (PFP). In addition, LAK cells express a 
toxic glycoprotein structure on their plasma membrane (Felgar & Hiserodt, 1992; 
Hiserodt, 1991). This membrane-associated toxin (M-CTX), exhibits potent lytic 
activity against nucleated tumor cells and it induces rapid Ca2+-dependent apoptotic 
cell death in target cells.
4. Clinical Applications
Based on their efficient MHC-nonrestricted cytolytic activity against a broad 
range o f fresh autologous or cultured tumor cells, LAK cells along with IL-2 have 
been used in adoptive immunotherapy in an attempt to control established metastatic 
tumors in animal models and a variety o f cancer patients. The cumulative results of 
clinical trials indicate that the adoptive transfer o f LAK cells and IL-2 can be effective 
in reducing established metastatic disease for a variety o f cancers.
In addition to their potent MHC-nonrestricted killing of tumor cells, LAK cells 
also exhibit strong in vitro antiviral activity against a number of viruses (Bukowski et 
al., 1989). Studies using HIV-infected target cells have shown that adherent LAK 
cells are effective at causing target cell lysis and viral inactivation. These results 
suggest that LAK cells could be used in the treatment o f various viral diseases 
including HIV infections.
F. Closing Remarks
This review has summarized literature important to our current understanding 
o f glucocorticoid effects on the immune system as well as molecular mechanisms that 
are known to be involved in glucocorticoid effects on various cell types from different
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species. Clearly our current understanding of how glucocorticoids act at the molecular 
level in various cell types requires further study. Their effects on immune function 
and the clinical importance of related steroids suggests that a better understanding of 
glucocorticoid effects is likely to provide necessary data to improve our ability to 
manage stress-dependent effects on immunity and the incidence of disease as well as 
the selective use o f therapeutic regimes aimed at managing various health problems.
The classic model for steroid effects on various cell types was based on the 
premise that hormone-bound steroid receptor simply bound by itself to DNA in 
regions which controlled expression of various genes. It is now clear that 
glucocorticoids may also act via multiple mechanisms to effect the response o f cells to 
compounds constitutively expressed by the cells and the response to cellular 
constituents that change in response to other stimuli. Cross-talk between various 
nuclear transcriptional factors and glucocorticoid receptors is a contemporary research 
area that has generated a great deal of interest. Studies on these kinds o f interactions 
in immune cells have generally been limited to in vitro analysis of cells collected from 
humans, mice and rats. Available literature suggests that interactions between AP-1 
protein or subunits of AP-1 protein may be particularly important to benificial 
glucocorticoid effects on the immune system. The experiments included in this project 
were aimed at determining whether interactions between AP-1 protein or AP-1 protein 
subunits and glucocorticoid receptors might be involved in regulating LAK cell 
activity of equine PBMCs. As noted in the literature review, very little is known 
about cell processes important to generation of LAK cell activity. Before this project
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was started we did not know whether equine LAK cell activity would be effected by 
increased AP-1 protein concentrations in the cell. However, data available from other 
species suggested that it was reasonable to hypothesize that an AP-1 interaction with 
GR would be measured in equine PBMCs and that this interaction was likely to be 
related to a specific effect on equine LAK cell activity.
The text in the remainder o f this document was divided into chapters including 
all information that will appear in related publications. This was done since the 
individual experiments were performed as part o f a large collaborative study that 
generated results from multiple investigators. Experimental endpoints characterized in 
Chapter 3 were collected in order to demonstrate that horses used for recovery of 
PBMCs had a normal endocrine profile relative to glucocorticoid secretion. This 
chapter also characterized circulating cortisol concentrations at various time points in 
resting horses as an indirect means o f determining whether the HPA axis in these 
animals was functioning in a manner consistent with that previously described for the 
equine species. This was believed to be important since we wanted to analyze 
endocrine-immune interactions for PBMCs collected from horses without endocrine 
abnormalities.
The experiments described in Chapter 4 were aimed at characterizing exercise- 
induced changes in circulating cortisol concentrations. We also injected cortisol or 
vehicle into the jugular vein of resting horses in order to reproduce peak plasma 
cortisol concentrations measured in exercise-stressed horses. Collaborators who 
worked on this experiment measured various immunological endpoints to determine if
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cortisol injection modified selected immune functions in a manner similar to that 
measured for exercise-stressed horses.
Experiments described in Chapter 5 were done to determine whether equine 
PBMCs contained immunoreactive (ir)-proteins necessary for a functional interaction 
between hormone-bound GR and protein subunits of AP-1. Chapter 6 experiments 
were performed in order to characterize any relationship between AP-1 protein 
expression and glucocorticoid effects on LAK cell activity. These experiments also 
analyzed the effect o f phorbol ester treatment on LAK cell activity and the combined 
effects o f phorbol eater and glucocorticoid treatments on LAK cell activity and AP-1 
protein subunit expression.
The summary and conclusion of the dissertation considers significance of 
results generated during the course of this project. It also notes some experiments 
which might be done to continue to define mechanisms important to glucocorticoids 
effects and to elucidate processes which may be involved in regulating equine LAK 
cell functions.
CHAPTER 3: NORMAL CONCENTRATIONS OF PLASMA 
GLUCOCORTICOIDS MEASURED IN THE HORSES INCLUDED
IN THIS PROJECT 
A. Objectives
This part o f the project was designed to characterize basal concentrations of 
plasma glucocorticoids in horses used to investigate in vitro effects of glucocorticoid 
and phorbol ester treatments on expression of AP-1 protein subunits and/or 
lymphokine activated killer (LAK) cell activity.
Specific objectives of the experiments were to:
1. Determine whether horses used in these experiments had normal 
mean concentrations o f plasma glucocorticoids.
2. Characterize the diurnal rhythm of plasma cortisol in horses used 
in these experiments.
3. Determine whether there was a gender effect on concentrations of 
plasma glucocorticoids.
4. Establish the basal physiological range of glucocorticoids to be used 
in subsequent in vitro experiments.
B. Materials and Methods
Procedures related to the use and care of animals assigned to experiments 
described in experiments of this project were evaluated and approved by the LSU 
Animal Care and Use Committee. Horses were maintained on pasture or housed in 
open air box stalls. They are fed 10 quarts of Omelene pellets at 8 AM and 4 PM. 
Water was provided ad libitum. Regular veterinary care was provided by Dr. John
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Freestone or Dr. Dennis French. The animals received regular vaccinations and they 
were dewormed based on recommended schedules. Regular farrier work and physical 
examinations were provided for or supervised by the aforementioned clinicians.
Single blood samples were collected into heparinized tubes by jugular 
venipuncture. An indwelling catheter was inserted into the jugular vein when multiple 
blood samples were collected at various time points. The specific number o f animals 
used and their sex and age are summarized in the following text.
To determine whether there was a diurnal effect on plasma cortisol 
concentrations, peripheral blood samples were collected from the jugular vein o f four 
unconditioned horses every hour for 24 hours starting at 6 AM. The plasma was 
separated from blood samples by centrifugation and plasma was extracted using 
acetone (500 pi acetone per 100 pi). Extracts were evaporated and reconstituted in 2 
milliliters (ml) o f phosphate buffered saline (PBS)-gel buffer [0.005 M NaH2P 0 4,
0.005 M Na2H P04, 0.9% (w/v) NaCl, 0.2% (w/v) gelatin]. Concentrations o f cortisol 
in the reconstituted samples were measured by radioimmunoassay (RIA), as previously 
described (Thompson et al., 1988). One hundred microliters of the reconstituted 
samples were assayed in triplicate using tritiated cortisol (Amersham Life Science Inc, 
Arlington Heights, Illinois) and anti-cortisol antibody which was kindly provided by 
Dr. Don Thompson Jr. (Louisiana State University, Baton Rouge, LA). Specificity of 
the cortisol antibody used in these assays has been characterized previously 
(Thompson et al., 1988). Antibody cross-reactivity with corticosterone is 4.4% and 
less than 0.02% for all other common steroids. Extracted plasma samples resolved by
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thin layer chromatography contained a single compound which bound 94.3% of the 
total immunoreactivity and the primary immunoreactive compound in samples was 
found at the same rf  value as tritiated cortisol.
Tubes were incubated overnight at 4°C. Then the free 3H-cortisol was removed 
by adding 500 pi o f 1% (w/v) charcoal in PBS-gel buffer and centrifugation at 3200 
rpm for 20 minutes at 0°C. Supernatants were transferred to plastic vials and 2.5 ml 
of liquid scintillation cocktail was added to each vial. Bound radioactivity was 
quantitated using a P-counter (LKB, Gaithersburg, MD). Samples from each horse 
and/or each experiment were run in a single assay. Intra- and inter-assay variation 
was 6 and 12%, respectively. Mean (± SD) cortisol concentrations were calculated in 
ng/ml and as a percentage of the baseline concentration. Data were analyzed using 
ANOVA for repeated measures and means from samples collected at various time 
points were compared using pairwise comparisons.
To determine whether there was an effect of gender on plasma cortisol 
concentrations, peripheral blood samples were collected from seven horses (4 mares, 3 
geldings) at 6 AM and at 5, 10, 15, 30, 45, 60 and 120 minutes after collection o f the 
first sample. Plasma was extracted and plasma cortisol concentrations were measured 
as described above. Data for each gender were transformed to a percentage o f the 
hormone concentration measured at 6 AM. Cortisol concentrations in ng/ml were also 
recorded and statistically analyzed for each gender. Results were analyzed using 
ANOVA for repeated measures and means were compared by pairwise comparisons.
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C. Results
Measurement of plasma cortisol concentrations at hourly intervals over a 24 
hour period showed that the mean (± SD) plasma cortisol concentration in these horses 
was 45.9 ± 19.9 ng/ml. Mean plasma cortisol concentrations for individual animals 
were 36.7 ± 14.0 ng/ml for horse # 9, 57.4 ± 22.8 ng/ml for horse # 15 and 52.9 ±
18.8 ng/ml for horse # 18.
A main effect o f time (P<0.05) was detected for cortisol concentrations in 
samples collected over a 24 hour period. Figure 10 illustrates mean (± SD) cortisol 
concentrations measured at hourly intervals in this experiment. The highest level 
(P<0.05) o f circulating cortisol was measured at 6, 7, 8 and 9 AM. Low levels of 
plasma cortisol were measured at 6, 7, 10 and 11 PM. Circulating concentrations of 
plasma cortisol in the evening were significantly lower than the plasma concentrations 
measured in the morning. The mean concentration of circulating cortisol from 6 AM 
to 9 AM was 67.7 ± 18.2 ng/ml which was significantly greater than the mean 
concentration of circulating cortisol measured in samples collected at 6, 7, 10 and 11 
PM (29 ± 11 .5  ng/ml).
There was no main effect of gender (P>0.05) or time (P>0.05) on plasma 
cortisol concentrations measured in mares and geldings when data were analyzed as a 
percentage o f the concentration o f cortisol measured at 6 AM (Figure 11). However, 
plasma cortisol concentrations in ng/ml were significantly affected by gender (Table 
2). The mean (± SD) plasma cortisol concentration for mares (n = 4) was 7.3 ± 3 .4  
ng/ml and plasma cortisol in geldings (n = 3) was 12.6 ± 9.2 ng/ml. Mean (± SD)
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Figure 10: Diurnal Rhythm o f  Plasma Cortisol in Unconditioned Horses. Peripheral blood samples were collected from four 
unconditioned horses every hour for 24 hours. Concentrations o f  plasma cortisol were measured using radioimmunoassay (RIA). 
Data were analyzed using ANO VA for repeat measures and means were compared with pairwise comparison. Plasma cortisol 
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Figure 11: Effect of Gender on Plasma Cortisol Concentrations. Peripheral blood samples were collected from seven 
unconditioned horses (4 mares, 3 geldings) at 0, 5, 10, 15, 30, 45, 60 and 120 minutes from 6 AM to 8 AM. Concentrations of 
plasma cortisol were measured by radioimmunoassay (RIA) and data are presented as a percentage of the plasma cortisol 
concentration measured at 0 minutes (6 AM). Data were analyzed with ANOVA for repeated measure. There was no main effect 
of gender (P > 0.05) or time (P > 0.05) on concentrations of plasma cortisol. Error bars represent the standard deviation.
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Table 2: Plasma Cortisol Concentrations in Mares and Geldings
Time (minutes)
Cortisol Concentration (ng/ml)
P ValueMare Gelding
0 5.8 ± 1.7 14.9 ± 16.5 P < 0.05
5 8.5 ± 4.2 13.0 ± 13.6 P > 0.05
10 7.6 ± 3.7 16.9 ± 12.8 P < 0.05
15 9.2 ± 5.9 15.5 ± 11.2 P < 0.05
20 9.5 ± 7.6 12.9 ± 10.6 P > 0.05
25 6.4 ± 1.5 12.6 ± 9.1 P < 0.05
30 6.0 ± 1.8 9.0 ± 4.1 P > 0.05
45 6.0 ± 0.6 8.9 ± 4.1 P > 0.05
60 7.4 ± 1.0 11.9 ± 9.9 P > 0.05
120 7.5 ± 1.5 10.2 ± 7.5 P > 0.05
Peripheral blood samples were collected from seven unconditioned horses (4 mares, 3 
geldings) at 0, 5, 10, 15, 30, 45, 60 and 120 minutes beginning at 6 AM. 
Concentrations o f plasma cortisol were measured by radioimmunoassay (RIA). Data 
were analyzed with ANOVA for repeated measure. There was a main effect o f gender 
(P<0.05) on concentrations of plasma cortisol but no significant main effect of time on 
plasma cortisol in mares or geldings. Mean (± SD) plasma concentrations o f cortisol 
were 7.3 + 3.4 and 12.6 ± 9.2 ng/ml in mares and geldings, respectively.
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plasma cortisol concentrations for horse #20 (gelding), #108 (gelding), #135 (gelding), 
#16 (mare), #59 (mare), #83 (mare) and #138 (mare) were 5.5 ± 0.5, 23.8 ± 6.9, 8.4 ± 
3.1, 7.6 ± 1.6, 10.9 ± 4.6, 5.6 ± 0.7 and 5.0 +1.1 ng/ml, respectively.
D. Discussion
Concentrations o f plasma glucocorticoids are determined by a balance between 
secretion from the adrenal cortex and removal by the liver. In horses, the adrenal 
cortex secretes large amounts o f cortisol and small amounts o f corticosterone (James et 
al., 1970). A small amount of circulating cortisol is converted by peripheral tissues to 
cortisone. In horses, free cortisol can be rapidly removed from the circulation by 
metabolism and the biologic half life o f equine cortisol is about 126 minutes which is 
longer than the 80 minute half-life of this steroid in humans (Slone, 1983). This 
species difference probably reflects different activity of hepatic enzymes which 
catabolize cortisol (Freestone & Melrose, 1995).
The diurnal rhythm in mean plasma cortisol concentrations has been related to 
changes in episodic secretion o f cortisol by the adrenal cortex (Weitzman et al., 1971). 
Each episode or pulse o f cortisol release is characterized by a very rapid rise in 
circulating cortisol concentrations, followed by a slower decline. Pulses o f cortisol 
release occur more frequently in the early morning hours, leading to the characteristic 
diurnal rhythm of cortisol secretion. The frequency of episodic secretion is regulated 
by intrinsic changes in the synthesis and secretion o f corticotropin releasing hormone 
(CRH) by the hypothalamus, light-dark cycles, feeding cycles and inherent
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rhythmicity in the adrenal, possibly mediated by sympathetic innervation o f the 
adrenal gland (Dallman, 1984; Follenius et al., 1982; Krieger et al., 1979).
Most mammals exhibit a peak in plasma glucocorticoids at the onset of the 
normal period o f wakefulness and a trough 12 hours later. In horses, concentrations of 
plasma cortisol have previously been reported to be relatively constant during the 
morning and lower in the afternoon (Bottoms, 1972; James et al., 1970). Published 
reports indicate mean morning concentrations o f plasma cortisol are approximately 70 
ng/ml and concentrations later in day should be approximately 68% of cortisol 
measured in samples collected during the morning (James et al., 1970). Similarly, 
Thornton (1985) reported that, in horses, the circulating levels o f plasma cortisol are 
highest from 6 to 8 AM and lowest from 4 to 10 PM.
The diurnal rhythm of plasma cortisol in the unconditioned horses used for our 
experiments was similar to that previously reported. Specifically, the highest level of 
circulating cortisol was observed from 6 to 9 AM and concentrations at these time 
points were significantly greater than concentrations of plasma cortisol measured at 6,
7, 10 and 11 PM. Mean plasma cortisol from 6 AM to 9 AM was 67.7 ± 18.2 ng/ml 
which was similar to the value reported by James and coworkers (1970).
Previous reports have indicated that there is not a gender difference in 
circulating glucocorticoid concentrations (James et al., 1970). Similarly, clinical 
ranges for normal glucocorticoid concentrations in horse mares and geldings support 
the conclusion that there is not a real sex difference in plasma cortisol concentrations. 
Results for the two hour sampling period used to test for an effect of gender on
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plasma glucocorticoids in our experiment suggest that the concentration o f plasma 
cortisol may be effected by gender. This result may be due to the small number of 
samples collected and the limited number of horses used in our experiments.
The normal range o f plasma cortisol concentrations reported for horses depends 
primarily on specificity o f primary antibodies used in various radioimmunoassays, 
assay methodology and whether or not the assay used is validated for samples 
collected from the equine species. The radioimmunoassay method and reagents that 
we used in our experiments were previously validated for analysis o f cortisol in equine 
plasma samples (Thompson et al., 1988). The antibody used in this assay is quite 
specific for cortisol and it has low cross-reactivity with corticosterone and does not 
cross-react with other steroids. Assayable concentrations o f plasma cortisol measured 
using our methodology are similar to results obtained when replicate samples were 
assayed with a commercially available cortisol assay kit that has been validated for the 
equine species (Thompson et al., 1988). Thompson and coworkers (1988) have also 
reported that the primary antibody that we used reacts with a single band when plasma 
extracts are resolved using thin layer chromatography. Some laboratories have 
reported that mean plasma cortisol in horses ranges from 1690 to 2600 ng/ml 
(Zolovick et al., 1966). Other laboratories have reported that normal mean plasma 
cortisol concentrations in horses are less than 130 ng/ml (James et al., 1970). In a 
review article, Thornton (1985) reported that the highest plasma cortisol concentration 
ranged from 10'8 M to 10'7 M from 6 to 8 AM and the lowest was 10'8M or less from 
4 to 10 PM. Plasma cortisol concentrations in the horses used for our experiments
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ranged from 5.0 ± 1.1 to 57.4 ± 22.8 ng/ml and these concentrations are within the 
range o f 10'8 M to 10‘7 M reported by Thornton (1985). Thus, we believe that horses 
used in our experiments have normal plasma cortisol concentrations. Further, diurnal 
fluctuations in plasma cortisol concentrations indirectly suggest that hormone 
concentrations are being regulated in a physiological fashion.
CHAPTER 4: EFFECTS OF INTRAVENOUS CORTISOL INJECTION ON
ASSAYABLE PLASMA GLUCOCORTICOID CONCENTRATIONS 
A. Objectives
This experiment was performed as part o f a collaborative project aimed at 
determining whether acute increases in plasma cortisol would result in changes in 
immune functions similar to that which occur in exercise-stressed horses. Our specific 
goal was to inject cortisol intravenously (IV) in order to try to produce 
radioimmunoassayable plasma steroid concentrations similar to those measured in 
exercise-stressed horses.
B. Materials and Methods
A preliminary trial was performed in order to try to establish the amount o f 
cortisol that would be injected intravenously to mimic stress-induced changes in the 
circulating concentrations o f this steroid. A single eight year old gelding was used for 
this trial. The dose of cortisol used to treat this animal was calculated based on 
information provided by the clinician that collaborated with us on neuroendocrine- 
immune experiments. Specific information (Freestone, personal communication) 
included the average body weight of adult horses (501 kg), total blood volume (72 
ml/kg) and plasma volume (48 ml/kg).
The gelding used for this experiment weighed 1165 pounds (545 kg). His 
basal plasma cortisol concentration was approximately 30 ng/ml. Summaries of data 
(n=8) from an acute exercise stress test (2/17/92) indicated that peak cortisol 
concentrations during exercise should be at least 100 to 110 ng/ml higher than baseline 
concentrations (data not shown in this chapter). It was calculated that the gelding used
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for preliminary experiments had a blood volume of 39.27 liters and that we wanted a 
peak cortisol concentration 120 ng/ml over baseline following IV cortisol injection.
Cortisol (Sigma Chemical Co., St Louis, MO) was dissolved in absolute 
ethanol (4.7 pg cortisol/50 pi ethanol) and diluted further with 1.95 ml o f sterile 
saline. This 2 ml dose was based on blood volume. The treatment was injected at 
9:40 AM on March 10, 1992. Blood samples were collected using an indwelling 
catheter in the jugular vein. Samples were collected 60 minutes and immediately 
before cortisol treatment and subsequently at 5, 10, 15, 30, 45, 60 and 120 minutes 
following cortisol treatment. Blood was collected into heparinized tubes. The tubes 
were capped, gently inverted two to three times and placed on ice. Plasma was 
separated by centrifugation and frozen on dry ice. The cortisol was extracted and 
assayed as described in Chapter 3.
Radioimmunoassayable cortisol in plasma peaked at approximately 5 ng/ml 
over baseline. The gelding started sweating and become quite nervous at 5 minutes 
post-treatment and continued to exhibit these symptoms until 15 minutes following 
injection.
Seven unconditioned horses were used to test the effects o f IV cortisol or 
vehicle treatment on assayable plasma hormone concentrations. Each horse was 
weighed the day before they were to be treated. Mean (± SD) weight o f the horses 
was similar (1100 ± 50 lbs). Three horses were injected intravenously with 4.7 mg of 
cortisol and four controls received vehicle. Cortisol (69.5 mg)was dissolved in 1 ml 
o f absolute ethanol and this was diluted with sterile saline to obtain a final cortisol
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concentration o f 2.35 mg/ml. Vehicle was prepared by mixing similar volumes of 
ethanol and saline. Each horse was injected intravenously with 2 ml o f diluted cortisol 
or vehicle.
The experiment was done as a random split plot design and it was started at 7 
AM on August 3rd of 1992. Peripheral blood samples were collected 60 minutes prior 
to injection and at 0, 5, 10, 15, 30, 45, 60 and 120 minutes after injection. Samples 
from each horse were used to measure levels o f the circulating cortisol using RIA as 
described previously (Chapter 3). Blood samples for recovery o f PBMCs were 
collected by a collaborator 60 minutes prior to cortisol or vehicle injection and 20 and 
120 minutes after injection in order to analyze LAK cell activity (Keadle, 1992).
The exercise stress test was started at 6 AM and it consisted of a 2 minutes 
walk at 1.5 meters per second (m/s), a 3 minutes trot at 3.5 m/s, a 3 minute gallop at 
8 m/s, a 5 minute gallop at 8 m/s on a 7% incline and a 2 minute trot at 3.5 m/s.
This test was done to characterize increases in plasma cortisol related to physical 
exercise. Samples for cortisol RIA were collected at -60, 0, 5, 10, 15, 30, 45, 60 and 
120 minutes relative to the beginning of exercise.
Concentrations o f plasma cortisol as a percentage o f the pretreatment 
concentration and in ng/ml were analyzed using ANOVA for repeat measure and 
pairwise comparisons.
C. Results
Circulating concentrations o f cortisol in horses that were injected with cortisol 
or vehicle are listed in Table 3 as a percentage of the pretreatment concentration.
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Table 3: Plasma Cortisol Concentrations in Unconditioned Horses
Following Intravenous Injection o f Cortisol or Vehicle: Hormone 
Concentrations as a Percentage of the Basal Concentration
Time
(minutes)
Cortisol Concentration 
(% pretreatment) P Value for 
Pairwise 
ComparisonCortisol Trt. (Mean + SD)
Vehicle Trt. 
(Mean ± SD)
Basal (- 60, 0) 100.0 ± 40.9 100.0 + 35.2
5 176.7 ± 14.3* 97.8 ± 12.8 P < 0.05
10 139.7 + 9.0 85.3 ± 19.6 P < 0.05
15 148.0 ± 26.7 84.8 + 14.1 P < 0.05
30 132.0 ± 29.7 83.3 + 21.6 P < 0.05
45 127.7 ± 27.8 94.5 ± 34.0 P > 0.05
60 117.0 ± 19.1 106.5 ± 36.2 P > 0.05
120 148.7 ± 37.0 86.8 + 22.7 P < 0.05
Three unconditioned horses were injected intravenously with 4.7 mg o f cortisol in 2 
ml o f saline and four were injected with the same amount of vehicle. Blood samples 
were collected 60 minutes prior to injection and at 0, 5, 10, 15, 30, 60 and 120 
minutes after injection. Plasma concentrations o f cortisol were determined using 
radioimmunoassay (RIA). Basal concentrations o f plasma cortisol (14.1+ 5.8 ng/ml in 
cortisol treated horses or 16.1+ 5.7 ng/ml in vehicle treated horses) were determined 
based on the values in samples collected at -60 and 0 minutes relative to the time of 
treatment. There was a significant effect of treatment based on ANOVA. In cortisol 
treated horses, plasma cortisol 5 minutes after injection was greater (P<0.05) than the 
basal level when means were compared using Dunnett's t-test. Levels o f circulating 
cortisol at 5, 10, 15 and 30 minutes after injection of cortisol were significantly higher 
than values in vehicle treated horses. Within each column, values marked with an 
asterisk (*) are significantly greater than the basal concentration. The P value for 
comparison o f means at a specific time point is listed in the right column. A P value 
of less than 0.05 indicates that plasma concentrations of assayable cortisol were 
greater in cortisol treated horses than in vehicle-treated horses at a specific time point. 
Trt. = treated.
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Mean (+ SD) pretreatment cortisol concentrations were 16.1 ± 5.7 ng/ml for vehicle 
injected horses and 14.1 ± 5.8 ng/ml for cortisol injected horses. When data were 
analyzed as a percentage o f the pretreatment concentration there was a main effect 
(P<0.05) o f cortisol injection on levels o f plasma cortisol. The circulating 
concentration of cortisol in the cortisol-treated group rapidly reached a peak value of 
179% of the pretreatment concentration immediately after injection and then it rapidly 
decreased to 139% of the pretreatment concentration. Analysis o f the data using 
Dunnett's t-test indicated that the concentration o f plasma cortisol at 5 minutes after 
intravenous injection o f cortisol was significantly greater than the pretreatment value.
In contrast, the vehicle treated group had plasma concentrations of cortisol that were 
relatively steady throughout the 2 hour sampling period and there was no significant 
change in plasma cortisol concentrations after intravenous injection of vehicle.
Circulating concentrations of cortisol in horses treated with cortisol were higher 
(P<0.05) then that measured in the horses treated with vehicle. Pairwise comparisons 
of cortisol concentrations in the two groups, at each time point, indicated that plasma 
cortisol concentrations in cortisol-treated horses were significantly higher than that in 
vehicle-treated horses at 5, 10, 15 and 30 minutes after injection. Data for cortisol 
concentrations in ng/ml of plasma are summarized in Table 4. There was a main 
effect (P<0.05) of cortisol injection on concentrations of plasma cortisol. The 
concentrations o f plasma cortisol at 5, 10 and 15 minutes after IV injection o f cortisol 
were significantly greater than the pretreatment concentration. In the vehicle-treated
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Table 4: Plasma Cortisol Concentrations (ng/ml) in Unconditioned Horses 
Following Intravenous Injection of Cortisol or Vehicle
Time
(minutes)
Cortisol Concentration 
(ng/ml) P Value for 
Pairwise 
ComparisonCortisol Trt. 
(Mean ± SD)
Vehicle Trt. 
(Mean ± SD)
Basal (- 60, 0) 14.1 ± 5.8 16.1 ± 5.7 P>0.05
5 24.8 ± 10.4* 16.1 ± 7.2 P < 0.05
10 19.3 ± 6.7* 14.2 ± 8.1 P < 0.05
15 19.8 ± 4.3* 13.7 ± 5.3 P < 0.05
30 14.1 ± 0.1 15.4 ± 4.8 P > 0.05
45 16.8 ± 3.0 15.9 ± 9.6 P > 0.05
60 15.8 ± 3.8 17.4 ± 8.9 P > 0.05
120 19.6 ± 3.1 14.3 ± 6.1 P < 0.05
Three unconditioned horses were injected intravenously with 4.7 mg of cortisol 
dissolved in 2 ml o f sterile saline and four horses were injected with 1.5 ml of vehicle. 
Blood samples were collected 60 minutes prior to injection and at 0, 5, 10, 15, 30, 60 
and 120 minutes after injection. Plasma concentrations of cortisol were determined 
using radioimmunoassay (RIA). There was a main effect (P<0.05) o f treatment on 
plasma cortisol when data were analyzed using ANOVA. In cortisol treated horses, 
plasma cortisol at 5, 10 and 15 minutes after injection was significantly greater than 
the basal level when data were analyzed using Dunnett's t-test. Levels o f circulating 
cortisol at 5, 10 and 15 minutes after cortisol injection were also significantly greater 
than hormone concentrations in vehicle treated horses. Means within a column that 
were marked with an asterisk (*) are significantly greater than the basal concentration 
o f cortisol. The P value for specific time points is listed in the right column. A P 
value o f less than 0.05 denotes differences for data in a given row. Trt. = treated.
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group, plasma concentrations o f cortisol did not change (P>0.05) in the 2 hour 
sampling period.
Concentrations o f plasma cortisol in the cortisol-treated group were compared 
with stress-induced elevations o f circulating cortisol in the same horses (Tables 5 and 
6). Mean (± SD) pretreatment cortisol concentrations were 46.6 ± 12.5 ng/ml for 
exercise-stressed horses and 14.1 ± 5.8 ng/ml for cortisol-treated horses.
Concentrations o f plasma cortisol at other time points were transformed to a 
percentage o f the pretreatment cortisol concentration for each treatment group in order 
to compare effects o f treatments on plasma cortisol at each time point. Dunnett's t-test 
indicated that concentrations o f plasma cortisol at 5, 10, 15, 30, 45 and 60 minutes 
after the beginning o f exercise-stress were significantly greater than the pretreatment 
cortisol concentration. Pairwise comparison demonstrated that concentrations of 
plasma cortisol in cortisol-treated horses were significantly lower than stress-induced 
circulating levels o f cortisol at all time points except 120 minutes after the beginning 
of exercise or cortisol injection.
Statistical analysis o f plasma cortisol concentrations in ng/ml showed that 
exercise-stress resulted in increased (P<0.05) concentrations o f plasma cortisol at all 
time points from 5 to 120 minutes as compared to the concentration of cortisol in 
plasma before the beginning of exercise. Concentrations o f plasma cortisol in cortisol- 
treated horses were significantly lower than that measured in exercise-stressed horses 
at all time points (Table 6).
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Table 5: Plasma Cortisol Concentrations in Unconditioned Horses
Following Intravenous Injection of Cortisol and in Exercise-Stressed 
Horses: Hormone Concentrations as a Percentage of the Basal 
Concentration
Time
(minutes)
Cortisol Concentration 
(% pretreatment) P Value for 
Pairwise 
ComparisonCortisol Trt. (Mean ± SD)
Stressed 
(Mean ± SD)
Basal (- 60, 0) 100.0 ± 40.9 100.0 ± 26.4
5 176.7 ± 14.3* 258.0 ± 44.4* P < 0.05
10 139.7 ± 9.01 324.3 ± 75.8* P < 0.05
15 148.0 ± 26.7 277.8 ± 47.2* P < 0.05
30 132.0 ± 29.7 338.7 ± 38.9* P < 0.05
45 127.7 ± 27.8 254.3 ± 53.5* P < 0.05
60 117.0 + 19.1 246.5 ± 44.2* P < 0.05
120 148.0 ± 37.0 167.8 ± 44.2* P > 0.05
Three unconditioned horses were injected intravenously with 4.7 mg of cortisol 
dissolved in 2 ml o f saline. Blood samples were collected 60 minutes prior to cortisol 
treatment or the beginning of the stress test and at 0, 5, 10, 15, 30, 60 and 120 
minutes after cortisol treatment or the start of the stress test. Plasma concentrations of 
cortisol were determined using radioimmunoassay (RIA). Basal concentrations of 
plasma cortisol were determined based on values in the -60 and 0 minute samples and 
values for other time points were calculated as a percentage o f the basal concentration. 
Basal hormone concentrations (mean ± SD) in cortisol-treated and exercise-stressed 
horses were 14.1 ± 5.8 and 46.6 ± 12.5 ng/ml, respectively. Data were analyzed by 
ANOVA for repeated measure. Means within a column were compared to the basal 
concentration using Dunnett's t-test. Means within a column that were significantly 
different from the basal level are marked with an asterisk (*). In cortisol-treated 
horses, plasma cortisol measured at 5 minutes after injection was greater (P<0.05) than 
the basal level. In stressed horses, plasma cortisol concentrations at 5, 10, 15, 30, 45, 
60 and 120 minutes were significantly greater (P<0.05) than the basal level.
Circulating cortisol at 5, 10, 15, 30, 45 and 60 minutes after injection in cortisol- 
treated horses were lower (P< 0.05) than values in stressed horses. The P value for 
specific time points is listed in the right column. A P value of less than 0.05 denotes 
differences for data in a given row. See text for specific conditions used for the 
exercise stress. Trt. = treated.
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Table 6: Plasma Concentrations of Cortisol (ng/ml) in Unconditioned Horses 
Following Intravenous Injection o f Cortisol and in Exercise-Stressed 
Horses
Time
(minutes)
Cortisol Concentration 
(ng/ml) P Value for 
Pairwise 
ComparisonCortisol Trt. Stressed
Basal (- 60, 0) 14.1 ± 5.8 46.6 ± 12.5 P < 0.05
5 24.8 ± 10.4* 118.6 ± 26.9* P < 0.05
10 19.3 ± 6.7 146.5 + 29.9* P < 0.05
15 19.8 ± 4.3. 129.1 + 37.0* P < 0.05
30 14.1 ± 0.1 138.1 ± 22.3* P < 0.05
45 16.8 ± 3.0 115.2 ± 22.8* P < 0.05
60 5.8 ± 3.8 115.1 ± 37.8* P < 0.05
120 19.6 + 3.1 78.1 ± 32.7* P < 0.05
Three unconditioned horses were injected intravenously with 4.7 mg o f cortisol 
dissolved in 2 ml o f saline. Blood samples were collected 60 minutes prior to 
injection or the beginning of the stress test and at 0, 5, 10, 15, 30, 60 and 120 minutes 
after injection or the beginning o f exercise stress. For each group, cortisol 
concentrations within a column were compared to the basal concentration using 
Dunnett's t-test. Means that were significantly different from the basal level are 
marked with an asterisk (*). In cortisol treated horses, plasma cortisol 5 minutes after 
injection was significantly greater (P<0.05) than the basal level. In stressed horses, 
plasma cortisol concentrations at 5, 10, 15, 30, 45, 60 and 120 minutes were greater 
(P<0.05) than the basal level. Circulating cortisol concentrations in cortisol-treated 
horses at 5, 10, 15, 30, 45, 60 and 120 minutes after injection were lower (P< 0.05) 
than the concentrations at the same time points for stressed horses. The P value for 
specific time points is listed in the right column. A P value of less than 0.05 denotes 
differences for data in a given row. See text for a description o f methods used for the 
exercise stress test. Trt. = treated.
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D. Discussion
The experiment described in this section was part of a large collaborative study 
aimed at determining whether intravenous cortisol injection would alter immune 
functions that we had found to be effected by exercise stress. Our data have 
previously been summarized in a preliminary report by one o f our collaborators 
(Keadle, 1992).
Exercise is a kind of physiological stress which activates the neuroendocrine 
system and the autonomic nervous system (Cotman et al., 1987; Goetzl & Spector, 
1989). Exercise and other stressors reportedly induce secretion of multiple hormones 
and transmitters including cortisol, adrenocorticotropic hormone (ACTH), corticotropin 
releasing hormone (CRH), vasopressin, P-endorphin, epinephrine and nonepinephrine 
(Alexander et al., 1991; Hamra, 1990; Keadle, 1992; Potla et al., 1994a,b).
The relationship between glucocorticoids and immune functions is complex. In 
addition to the well known inhibitory effects of pharmacologic dosages of 
glucocorticoids on immune processes, some evidence suggests that physiologic levels 
o f cortisol, normally produced by the adrenal cortex, are necessary for the 
development and maintenance o f normal immunity (Munck et al., 1984). This 
suggestion is consistent with the general rule of effects of glucocorticoids on immune 
functions; where at high levels, glucocorticoids suppress body defense mechanisms 
while at low levels they are required to permissively enhance the activity o f the body's 
defense mechanisms (Munck & Naray-Fejes-Toth, 1992).
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Glucocorticoids may exert a wide variety of inhibitory effects on the immune 
system. They have been reported to act on multiple target cells, tissues and organs 
through multiple mechanisms. The major cell targets for glucocorticoid effects on the 
immune system are lymphocytes, monocytes/macrophages and mononuclear 
leukocytes. Glucocorticoids may affect the distribution, proliferation, differentiation 
and function o f these cells. The major route by which glucocorticoids influence many 
immune responses is through their effects on cytokine production. Specifically, it has 
been reported that glucocorticoids inhibit the production of granulocyte-macrophage 
colony-stimulating factor (GM-CSF), interferon-y (INF-y), tumor necrose factor-a 
(TNF-a), interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-3 (IL-3) and interleukin 
(IL-6) by T cells and monocytes/macrophages (Kunicka et al., 1993; Paliogianni et al., 
1993a).
In vivo LAK cell activity is regulated by multiple factors including cellular 
factors and soluble factors. High dose glucocorticoids have been demonstrated to 
inhibit LAK cell activity in vitro (McVicar et al., 1989). Recently, it was reported 
that low dose cortisol may enhance LAK cell activity and it has been proposed that 
cortisol may mediate exercise-induced increases in LAK cell activity (Keadle, 1992; 
Melrose et al., 1993). To test this possibility, unconditioned horses were challenged 
with 4.7 mg of cortisol injected intravenously. Then PBMCs were collected at 
different time points and stimulated with IL-2 for 3 days (Keadle, 1992). The 
generated LAK cell activity was determined by measurement o f species-specific lysis 
o f EqT8888 target cells. Changes in plasma cortisol did not affect IL-2-induced LAK
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cell activity. This may be due to the fact that cortisol concentrations at the time 
points when PBMCs were collected did not reach the same level which would be 
induced by exercise stress. Specifically, LAK cell activity was analyzed for cells 
collected 60 minutes prior to hormone injection and 20 and 120 minutes after cortisol 
injection. The concentrations o f plasma cortisol at 20 and 120 minutes had already 
decreased to the pretreatment concentrations and these values were significantly lower 
than that which was induced by exercise. In contrast to effects on LAK cell activity, 
the cortisol treatment used for this experiment induced leukocytosis, relative and 
absolute neutrophilia, and relative and absolute lymphopenia (Keadle, 1992). Previous 
reports from our collaborative studies have indicated that exercise-induced changes in 
LAK cell activity of equine PBMCs do not involve a redistribution of cells (Horohov 
et al., 1996). Thus, increased LAK cell activity in samples collected from the stressed 
horses is likely to be due to increased activity of cells already in the circulation. 
Whether this is due to independent effects of a single compound or to combined 
effects of multiple hormones is an area of contemporary research interest.
The plasma concentration o f cortisol is affected by synthesis and secretion from 
the adrenal cortex and metabolism by the liver and kidney. Normally, in horses, 
plasma cortisol is highest in the morning (10'8 - 10"7 M) and cortisol is present in the 
circulation at approximately 10'8 M concentrations in the afternoon (Thornton, 1985). 
Most cortisol in the circulation is free or bound by albumin since horses do not have a 
significant amount of cortisol-binding globulin (Freestone & Melrose, 1995; Irvine & 
Alexander, 1987). Free cortisol can diffuse into tissues rapidly. The present
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experiment was performed in the morning and total cortisol was measured by RIA.
The results from this experiment demonstrated that pretreatment concentrations of 
plasma cortisol in the vehicle control and cortisol injected group were within the range 
o f normal values. There was no significant change in concentrations o f plasma 
cortisol in the vehicle-treated group whereas cortisol concentrations in the cortisol- 
treated group significantly increased within 15 minutes. However, according to a pilot 
experiment, intravenous injection o f 4.7 mg o f cortisol should have produced greater 
increases in circulating levels o f cortisol than the values obtained in the present 
experiment. Injection of 4.7 mg o f cortisol did not produce plasma levels o f cortisol 
similar to stress-induced increases in this hormone. One reason for this may be that 
the cortisol which was injected rapidly diffused into tissues. It is more likely that data 
from the preliminary trial was not adequate for us to calculate an appropriate dose. 
Results from this experiment may allow for a more accurate calculation o f cortisol 
doses that would produce the magnitude of exercise-induced changes in this 
glucocorticoid. Whether these treatments would mimic the effect of exercise-stress on 
LAK cell activity requires further study.
CHAPTER 5: IMMUNOREACTIVE GLUCOCORTICOID RECEPTOR, 
C-FOS AND C-JUN IN PERIPHERAL BLOOD MONONUCLEAR 
CELLS COLLECTED FROM RESTING HORSES
A. Objectives
Experiments reported in this chapter were conducted in order to determine 
whether equine peripheral blood mononuclear cells (PBMCs) contained 
immunoreactive (ir) proteins necessary for a functional interaction between hormone- 
bound glucocorticoid receptors (GR) and protein subunits o f activator protein-1 (AP- 
1).
Specific objectives o f the experiments were to:
1. Determine if ir-GR could be detected in extracts o f PBMCs.
2. Estimate the molecular weight o f ir-GR in order to determine if the 
ir-material was similar in size to GR from other species.
3. Determine whether PBMCs collected from resting horses contained 
detectable ir-Jun and/or ir-Fos.
4. Establish the number of equine PBMCs and the amount o f cell 
protein that were needed to consistently detect ir-Jun and/or ir-Fos.
5. Establish the sensitivity of assays used to detect ir-Jun and ir-Fos by 
using known amounts of commercially available standards.
6. Determine whether the detection o f ir-Jun and ir-Fos in extracts from 
equine PBMCs would be abolished by pre-absorbing primary 
antibodies with excess amounts o f purified Jun and Fos standards.
1 0 2
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7. Determine if the immunoreactivity o f Jun and Fos standards and 
extracts from equine PBMCs was abolished by heat treatment.
B. Materials and Methods
1. Isolation of Peripheral Blood Mononuclear Cells
Peripheral blood mononuclear cells were prepared from whole blood collected 
from three resting horses in January of 1992. These three horses were #138 (mare, 6 
years old), #83 (mare, 7 years old) and #106 (mare, 8 years old). They were housed 
in open-air stalls and fed 10 quarts of Omalene pellets (Purina Mills, St. Louis, MO) 
at 8 AM and 4 PM. These horses were sampled on multiple occasions in order to 
complete experiments described in this chapter.
Blood was collected by jugular venipuncture into heparinized sterile tubes and 
spun at 800Xg for 30 minutes in order to obtain a buffy coat layer. The buffy coat 
was resuspended in calcium and magnesium free phosphate-buffered saline (PBS) and 
underlayered with Ficoll-Plaque (Pharmacia Fine Chemicals, Piscataway, NJ). Then 
the tubes were centrifuged at 400Xg for 20 min. The interface cells were collected 
and washed twice with PBS. After a final buffer wash, the PBMCs were resuspended 
in PBS and transferred to eppendorfs for proteins extraction.
2. Extraction Methods Used to Recover Immunoreactive Proteins
Isolated PBMCs were pelleted and washed once with 1 ml o f ice-cold buffer A
[10 nM N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid (HEPES; pH 7.9), 1.5 
mM MgCL, 10 mM KC1, 0.5 mM dithiothreitol (DTT)]. Then the cells were lysed in 
buffer A by gently and repeatedly passing the cell suspension through a 28-gauge
needle. The nuclei were collected by centrifugation at lOXg for 8 seconds in an 
Eppendorf microcentrifuge and the supernatant was discarded. Crude nuclei were 
extracted with ice-cold buffer C [20 mM HEPES (pH 7.9), 25% (v/v) glycerol, 420 
mM KC1, 1.5 mM MgCl2, 0.2 mM ethylenediaminetetra-acetate (EDTA), 0.5 mM 
phenylmethylsulfonyl fluoride (PMSF), 0.5 mM DTT], For protein extraction, 60 pi 
o f buffer C was used for each 100 pi of cell pellet and extractions were done for at 
least 15 minutes on ice. An equal volume o f buffer D [20 mM HEPES (pH 7.9), 20% 
(v/v) glycerol, 0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT] was added to each tube. 
The mixture was spun in an Eppendorf microcentrifuge at lOXg for at least 10 
minutes at 4°C. Supernatants were collected and stored at -80°C. The protein 
concentration o f each preparation was determined using the Micro BCA Protein Assay 
Reagent Kit (Pierce, Rockford, Illinois 61105).
3. Methods Used to Detect Immunoreactive Glucocorticoid Receptor
Protein extracts were treated with reductant (2-(3-mercaptoethanol) and heated 
prior to loading on an 8% SDS-PAGE gel. Heat-treated protein samples and high 
range prestained standards (Bio-Rad Laboratories, Richmond, CA) were resolved using 
Tris-SDS buffer (pH 8.3) as previously described by Laemmli (1970). Proteins were 
then transferred to nitrocellulose membranes (Schleicher and Schuell Inc, Keene, NH) 
using electroblotting with the gel and nitrocellulose sandwich submerged in Tris buffer 
[25 mM Tris (pH 8.3), 192 mM glycine, 20% (v/v) methanol] at 0°C. To determine if 
detectable ir-GR was present, non-specific binding to the membrane was blocked with 
10% (w/v) bovine serum albumin (BSA) (Fraction V, Sigma Chemical Co, St Louis,
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MO) in TBS buffer [20 mM Tris (pH 7.5), 150 mM NaCl] for 1 hour at room 
temperature. Membranes were incubated in all reagents while being gently agitated on 
an orbital shaker. After blocking non-specific binding, the membrane was washed 
with 0.05% TBST buffer [TBS buffer with 0.05% (v/v) Tween-20]. Then the 
membrane was incubated with monoclonal mouse anti-GR IgG (Affinity Bioreagents, 
Inc. Neshanic Station, NJ) overnight at 4°C. This particular monoclonal antibody was 
produced by immunization of BALB/c mice with partially purified rat GR. It has been 
shown to react with a single epitope in the DNA-binding domain o f the GR. A 
control membrane was incubated without primary antibody. This membrane was 
prepared and processed in a manner similar to that used for the duplicate membrane. 
Both membranes included replicate equine PBMC extracts.
On the second day, the membranes were washed with TBST buffer and 
incubated with alkaline phosphatase-conjugated secondary antibody (Strategene, La 
Jolla, CA) for 1 hour at room temperature. Finally, the immunoreactive complex was 
visualized with alkaline phosphatase substrate and 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP)/nitro blue tetrazolium (NBT) chromogen (Strategene, La Jolla, CA). 
The molecular weight of protein was calculated using a linear plot o f mobility versus 
log of the molecular weight for protein standards .
4. Methods Used to Detect Immunoreactive c-Jun and c-Fos 
To determine the quantity o f AP-1 proteins in resting horse PBMCs and the 
sensitivity and specificity of the method used to detect AP-1 proteins, c-Fos and c-Jun 
standards, and the extracts from PBMCs of resting horses, were pipetted on to
nitrocellulose membranes. Specificity of antibody binding was tested using denatured 
c-Fos and c-Jun standards and the extracts from PBMCs of resting horses. Samples 
were denatured by submerging eppendorf tubes in a boiling water bath for 15 minutes 
before applying samples and standards to the membrane. All membranes were air 
dried for 10 minutes and non-specific binding to the membrane was blocked with 10% 
(w/v) BSA in TBS buffer for 1 hour at room temperature. Membranes were incubated 
with all reagents which being gently agitated. They were washed with 0.05% TBST 
buffer. Membranes were subsequently incubated overnight at 4°C with 10 ml of 2 
pg/ml monoclonal anti-c-Fos antibody (Oncogene Science, Inc. NY), 10 ml o f 2 pg/ml 
polyclonal anti-c-Jun antibody (Oncogene Science, Inc. Uniondale, NY), pre-absorbed 
monoclonal anti-c-Fos antibody or pre-absorbed polyclonal anti-c-Jun antibody.
Primary antibodies were incubated for 18 to 24 hours with an excess o f standard in 
order to pre-absorb specific immunoreactivity. On the second day, the membranes 
were washed with TBST buffer and incubated with alkaline phosphatase-conjugated 
secondary antibodies (Strategene, La Jolla, CA) for 1 hour at room temperature. 
Finally, the immunoreactive complex was visualized by adding the chromogen, 
BCIP/NBT (Strategene, La Jolla, CA).
C. Results
1. Immunoreactive Glucocorticoid Receptor
On the membrane incubated with anti-GR antibody, a single band was found 
on the third lane including whole cell protein extract from horse PBMCs while no 
band was visualized on the second lane which was loaded with nuclear protein extract
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from horse PBMCs (Figure 12). The molecular weight o f the band was about 100 KD 
as calculated using a plot o f mobility o f known compounds subjected to 
polyacrylamide-sodium dodecyl sulfate gel electrophoresis versus log of the molecular 
weight of the protein standards. The membrane incubated without primary antibody 
did not have a band at that position (Figure 12).
2. Immunoreactive c-Jun and c-Fos
Protein extracts from PBMCs collected from all three horses contained 
immunoreactivity when dot blots were incubated with the anti-c-Fos monoclonal 
antibody or anti-c-Jun polyclonal antibody. Density o f the reaction product appeared 
to decrease in proportion to the amount of protein. The minimum amount of the 
protein extract required to detect ir-AP-1 protein subunits was about 90 ng for each 
horse (Figures 13 and 14). The number o f PBMCs needed to detect ir-Jun proteins 
was 6 x 103 cells and detectable ir-Fos proteins were found when extracts were 
prepared from a minimum of 9 x 104 cells.
Serial dilution of c-Fos and c-Jun protein standards suggested that the 
minimum detectable quantity o f ir-proteins was 31.2 and 3.9 ng, respectively (Figures 
15 and 16). This experiment was repeated 3 times with the same result.
Membranes were incubated with pre-absorbed primary antibody or untreated 
primary antibody in order to determine if  reaction products associated with PBMC 
extracts would be abolished when standards were used to saturate the binding sites on 
the antibodies. Samples on membranes incubated with the untreated primary antibody 
showed specific binding activity with the anti-c-Fos monoclonal antibody or anti-c-Jun
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Figure 12. Basal Expression of Glucocorticoid Receptor in Resting Horse PBMCs. 
High range molecular weight prestained SDS-PAGE standards (lane 1), nuclear protein 
extract (lane 2) and whole cell protein extract (lane 3) were resolved on an 8 % SDS- 
PAGE gel and transferred to a nitrocellulose membrane by electroblotting. Then the 
membranes were incubated with or without mouse anti-GR antibodies. They were 
subsequently incubated with anti-mouse secondary antibody conjugated to alkaline 
phosphatase. Bound antibody was visualized with chromogen. A band at the position 
corresponding to a molecular weight of 100 KD was found in the lane of whole cell 
protein extract while no band was found on the lane of nuclear protein extract. 
Membrane that was processed without primary antibody did not have any discemable 
bands (data not shown).
Figure 13: Basal Expression o f Immunoreactive c-Jun in Extracts From Resting Florse 
(n=3) PBMCs. Protein extracts were pipetted on to nitrocellulose membrane in ng 
amounts listed as in Table 7. Then the membrane was incubated with rabbit anti-Jun 
polyclonal IgG. This was followed by incubation with alkaline phosphatase- 
conjugated goat anti-rabbit secondary antibody and chromogen. The last lane included 
a primary antibody control in order to test whether reaction conditions resulted in 
visible reaction product.
Table 7: Amount o f Protein Used to Detect Immunoreactive-Jun in Serially Diluted 
c-Jun Standards and the Nuclear Extracts Prepared From PBMCs o f Three 
Horses
c-Jun protein standard (ng) 500 250 125 62.5 31.2 15.6
Nuclear extract (ng) (horse 138) 362 181 90.5 45.2 22.6 11.3
Nuclear extract (ng) (horse 83) 382 191 95.5 47.7 23.9 11.9
Nuclear extract (ng) (horse 108) 334 167 83.5 41.7 20.9 10.4
Polyclonal anti-c-Jun Ab control (ng) 200 100 50 25 12.5 6.25
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Figure 14: Basal Expression o f Immunoreactive c-Fos in Extracts From Resting Horse 
(n=3) PBMCs. Protein extracts from PBMCs were pipetted onto nitrocellulose 
membrane in ng amounts as listed in Table 8. Then the membrane was incubated with 
mouse anti-Fos monoclonal IgG. This was followed by incubation with alkaline 
phosphatase conjugated goat anti-mouse secondary antibody and chromogen. The last 
lane included a primary antibody control in order to have a color reaction control on 
each nitrocellulose membrane.
Table 8: Amount o f Protein Used to Detect Immunoreactive Fos in Serially Diluted 
c-Fos Standards and Nuclear Extracts Prepared From PBMCs o f Three 
Horses.
c-Fos protein standard (ng) 500 250 125 62.5 31.3 15.7
Nuclear extract (ng) (horse 138) 362 181 90.5 45.3 22.6 11.3
Nuclear extract (ng) (horse 83) 382 191 95.5 47.8 23.9 11.9
Nuclear extract (ng) (horse 108) 334 167 83.5 41.7 20.9 10.4
Monoclonal anti-c-Fos Ab control (ng) 200 100 50 25 12.5 6.3
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Figure 15: Sensitivity of the Method Used to Detect c-Jun Protein. Serially diluted c- 
Jun protein standards were spotted on nitrocellulose membrane in ng o f total peptide 
as listed in Table 9. Then the membrane was incubated with rabbit anti-Jun 
polyclonal IgG followed by incubation with alkaline phosphatase conjugated anti­
rabbit secondary antibody and chromogen. The minimum detectable amount of c-Jun 
was 3.9 ng.
Table 9. Amount o f Protein Used to Determine the Minimal Amount of 
Immunoreactive Jun That Can Be Detected
c-Jun protein standard (ng) 2000 1000 500 250 125 62.5
c-Jun protein standard (ng) 31.25 15.60 7.80 3.90 1.95 0.98
c-Jun protein standard (ng) 0.49 0.24 0.12 0.06 0.03 0.02
Polyclonal anti-c-Jun Ab control (ng) 200 100 50 25 12.5 6.25
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Figure 16: Sensitivity o f the Method Used to Detect c-Fos Protein. Serially diluted c- 
Fos protein standards were spotted on nitrocellulose membrane in ng o f total peptide 
as listed in Table 10. Then the membrane was incubated with mouse monoclonal anti- 
Fos IgG, followed by incubation with alkaline phosphatase conjugated anti-mouse 
secondary antibody and chromogen. The minimum detectable amount of c-Fos was 
31.2 ng.
Table 10: Amount o f Protein Used to Determine the Minimal Amount of 
Immunoreactive Fos That Can Be Detected
c-Fos protein standard (ng) 2000 1000 500 250 125 62.5
c-Fos protein standard ( ng) 31.25 15.60 7.80 3.90 1.95 0.98
c-Fos protein standard (ng) 0.49 0.24 0.12 0.06 0.03 0.02
Monoclonal anti-c-Fos Ab control (ng) 200 100 50 25 12.5 6.25
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polyclonal antibody (Figures 17 and 18). These two control membranes were run at 
the same time and with the same reagents that were used to test whether visible color 
was found on membranes incubated with pre-absorbed primary antibodies. Pre­
absorption o f both primary antibodies abolished detectable color reactions for ir-Jun 
and Fos proteins.
Antibody specificity also was demonstrated using denatured AP-1 protein 
standards and the nuclear protein extracts from horse PBMCs (Figure 19). The results 
from this experiment demonstrated that denatured c-Jun protein standard and protein 
extracts from horse PBMCs failed to produce a color reaction when they were 
processed with anti-c-Jun antibody.
D. Discussion
A prerequisite for a cellular response to glucocorticoids is the presence o f GR 
in the cell. However, the hormone sensitivity o f GR-containing cells may be affected 
by a number of factors and there is a great variation in glucocorticoid effects as a 
function o f cellular differentiation (Ballard et al., 1979), receptor activity (Northrop et 
al., 1986), receptor modifying factors (Housley et al., 1984) and receptor concentration 
(Bourgeois & Newby, 1979; Gehring et al., 1984; Vanderbilt et al., 1987). Cellular 
GR levels have been shown to vary as a result o f endocrine status (Cidlowski & 
Cidlowski, 1981), neural influence, cell contact (Antakly et al., 1985), different stages 
in the cell cycle (Cidlowski & Michaels, 1977; Cidlowski and Cidlowski, 1982), state 
o f development, aging (Chang & Roth, 1979) and receptor heterogeneity. 
Glucocorticoid receptor levels may also vary in response to a number of exogenously
Figure 17A
1 1 4
Figure 17B
Figure 17: Specificity o f the Methods Used to Detect Immunoreactive Jun I. Serially 
diluted c-Jun standards and nuclear extracts were spotted on nitrocellulose membranes 
in ng quantities as listed in Table 11. Then the membranes were incubated with rabbit 
anti-Jun polyclonal IgG ( Figure 17A) or with pre-absorbed anti-Jun antibodies (Figure 
17B), followed by incubation with alkaline phosphatase conjugated anti-rabbit 
secondary antibody and chromogen. There was no detectable immunoreactivity on the 
membranes incubated with pre-absorbed primary antibodies. The primary antibody 
control lane on blots incubated with pre-absorbed primary antibody did stain with 
alkaline phosphatase conjugated anti-rabbit secondary antibody and chromogen.
Table 11: Amount of Protein Used to Detect Immunoreactive Jun with Polyclonal
Anti-Jun Antibody and Primary Antibody Pre-absorbed with Excess c-Jun 
Standard
c-Jun protein standard  (ng) 50 25 12.5 6.25 3.13 1.56 0.78
N uclear ex tract (ng) (horse 138) 2000 1000 500 250 125 62.5 31.25
Polyclonal anti-c-Jun A b (ng) 12.50 6.25 3.13 1.56 0.78 0.39 0.20
Figure 18A
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Figure 18B
Figure 18: Specificity of the Methods Used to Detect Immunoreactive Fos. Serially 
diluted c-Fos standards and nuclear extracts were spotted on nitrocellulose membranes 
in ng quantities as listed in Table 12. Then the membrane was incubated with mouse 
anti-Fos monoclonal IgG (Figure 18A) or pre-absorbed anti-Fos antibodies (Figure 
18B), followed by incubation with alkaline phosphatase conjugated anti-mouse 
secondary antibody and chromogen. There was no detectable immunoreactivity in 
samples or standards on the membranes incubated with pre-absorbed primary 
antibodies. The antibody control lane on blots incubated with pre-absorbed primary 
antibody did stain with alkaline phosphatase conjugated anti-mouse secondary antibody 
and chromogen.
Table 12: Amount o f Protein Used to Detect Immunoreactive Fos with Monoclonal 
Anti-Fos Antibody and Primary Antibody Pre-absorbed with Excess c-Fos 
Standard
c-Fos protein standard (ng) 50 25 12.5 6.25 3.125 1.563 0.78
N uclear extract (ng) (horse 138) 2000 1000 500 250 125 62.5 31.25
M onoclonal anti-c-Fos A b (ng) 12.5 6.25 3.125 1.563 0.78 0.39 0.195
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Figure 19: Specificity o f the Methods Used to Detect Immunoreactive Jun II. The c- 
Jun protein standards and nuclear protein extracts were reduced with 2-P- 
mecaptoethanol and heated to boiling for 10 min. Then, serially diluted c-Jun protein 
standards, nuclear protein extracts, denatured c-Jun protein standards and denatured 
protein extracts were pipetted onto the membrane in the ng amount listed in Table 13. 
The membrane was incubated with rabbit anti-Jun polyclonal IgG followed by 
incubation with alkaline phosphatase conjugated anti-rabbit secondary antibody and 
chromogen. There was no detectable immunoreactivity on rows loaded with denatured 
c-Jun protein standards or denatured protein extracts.
Table 13: Amount o f Protein Used to Determine if Heat Denatured Standard and 
Samples Contain Immunoreactive c-Jun
c-Jun protein standard (ng) 50 12.5 6.25 3.1 1.6
Protein extract (ng) (horse 138) 143 71.5 35.75 17.88 8.94
D enatured c-Jun protein standard (ng) 50 12.5 6.25 3.1 1.6
D enatured protein extract (ng) (horse 138) 143 71.5 35.75 17.88 8.94
Polyclonal anti-c-Jun A b control (ng) 50 12.5 6.25 3.1 1.6
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added compounds, such as concanavalin A and other mitogens and cyclophosphamide, 
sodium butyrate, retinoids, androgens and glucocorticoids themselves (Cidlowski & 
Cidlowski, 1981). The homologous down-regulation o f GR by glucocorticoids 
involves transcriptional, post-transcriptional and post-translational mechanisms 
(Burnstein & Cidlowski, 1992).
Glucocorticoid receptors exist in cytosolic fractions and in the nucleus of 
nucleated cells in horses and most other vertebrate species (Feldman, 1989; Jones & 
Phillips, 1986; Potla et al, 1993a, b). Without stimulation by steroid hormones, 
inactive GR exist as multimers which are phosphorylated and associated with heat 
shock proteins. Once bound by cortisol, the receptors dissociate into monomers. The 
subsequent dephosphorylation o f receptors and release of heat shock proteins activate 
the receptors so that they are translocated into the nucleus. The protein extracts used 
for this experiment were prepared from untreated resting horse PBMCs; thus, they 
should contain inactivated multimers of phosphorylated glucocorticoid receptors 
associated with heat shock proteins. However, the samples were treated with 
mercaptoethanol and heated before loading on the gel. These treatments should result 
in dissociation of the receptor multimers, release of heat shock protein and formation 
o f GR monomers. In addition, these treatments may disturb the conformation of 
monomers o f GR and result in exposure o f the DNA-binding domain. The 
monoclonal antibody used in this experiment has been shown to react with a single 
epitope in the DNA-binding domain o f rat GR. The DNA-binding domain o f GR is 
very conserved among species (Danielsen et al., 1986; Giguere et al., 1986;
Hollenberg et al., 1985). Although this monoclonal antibody was raised against rat 
GR, it was expected to react with horse GR. Monomers in treated protein extracts 
from horse PBMCs should show up as a band located between standards with a 
molecular weight is 80 KD to 116.5 KD. The western blot showed a single band at 
about 100 KD in the lane of whole cell extracts. There was no detectable band in the 
lane o f nuclear extract from resting horse PBMCs. Therefore, GR was probably 
located on the outer nuclear membrane and thus in the cytosolic fraction of samples 
from unstimulated horse PBMCs. Membrane incubated with all reagents except 
primary antibody did not have a detectable reaction product. These results suggest 
that ir-GR is limited to cytosolic fractions. These results would probably be 
repeatable for PBMCs stimulated with cortisol since hormone bound-GR has a higher 
affinity for DNA and the primary antibody used in this experiment is specific for the 
DNA binding domain of GR. This assumption is supported further by the fact that 
specific binding o f radiolabeled cortisol has been demonstrated at various times of the 
day for both nuclear and cytosolic fractions from equine PBMCs (Potla et al., 1993).
Studies from rats and humans have shown that the molecular weight of the 
monomer o f GR is about 90 KD. There are several possible explanations for the 
molecular weight o f ir-GR obtained from equine PBMCs. Firstly, there may be a 
species variation in the structure o f GR or species differences in phosphorylation 
forms o f the receptor. The difference may also be due to a difference in the method 
used to calculate the molecular weight o f the band. Accordingly, the 
mobility/molecular weight ratio variation usually is about 3%. In addition, the
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molecular weight standards used in this experiment were prestained proteins. The 
addition o f the dye may cause the proteins to migrate at a rate different (± 10%) than 
their true molecular weights. Thus, further studies are needed to verify identity o f the 
100 KD ir-GR protein found in this experiment. The isolation and purification o f this 
protein and subsequent sequencing and functional assays will provide this verification.
The AP-1 proteins are the product of a group o f proto-oncogenes which are the 
immediate early genes. Studies from other species have demonstrated that there is 
normally a low level of AP-1 proteins in unstimulated cells. Most cycling cells 
express basal levels o f Jun proteins, but lack detectable c-Fos and FosB (Kovary & 
Bravo, 1991, 1992). However, these genes can be induced rapidly and transiently in 
response to the activators o f protein kinase C (PKC) in various tissues.
The induction of AP-1 proteins is involved in proliferation, differentiation and 
transformation o f cells. Horse PBMCs contain large granule lymphocytes which are 
the major source of LAK cell activity. The induction of LAK cell activity by IL-2 
involves two processes, activation and subsequent proliferation (Hormanski et al.,
1992; Siegel et al., 1987). Results from other species have suggested that AP-1 
proteins may be involved in the induction o f LAK cell activity by IL-2. Experiments 
described in this chapter were done to detect ir-proteins which may be related to these 
effects and validate assays which could be used to subsequently study treatment effects 
o f phorbol ester and cortisol on LAK cell activity o f equine PBMCs.
Experiments described in this chapter analyzed a dot blot method to detect 
AP-1 activity in equine PBMCs. Results from the present experiment showed that
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resting horse PBMCs contain detectable Jun and c-Fos proteins. The low animal 
variation in the minimum amount of nuclear protein needed to detect AP-1 activity 
suggests that the basal level o f the AP-1 proteins in horse PBMCs is normally 
expressed in a constitutive fashion.
The sensitivity of these assays was determined by testing the minimum amount 
o f c-Fos and c-Jun protein standards that could be detected. The difference in 
sensitivity of the method for c-Fos and c-Jun was likely due to the sensitivity of the 
primary antibody to the c-Fos and c-Jun protein standards, respectively. The anti-c- 
Fos antibody used in this experiment was a mouse monoclonal antibody which was 
raised against a peptide corresponding to amino acid residues 128 to 152 o f v-Fos and 
this antibody reacts with viral forms o f Fos and cellular Fos o f humans and rodents. 
The antibody to c-Jun was a rabbit affinity-purified polyclonal antibody raised against 
a synthetic peptide corresponding to amino acids 209 to 225 in the DNA binding 
domain o f v-Jun. The protein standards used in this experiment were synthetic 
peptides which were used to immunize the animals and produce corresponding 
antibodies as mentioned above. Thus, the sensitivitys our assays may not be the same 
for intact c-Jun and c-Fos proteins extracted from horse PBMCs.
Specificity o f our immunoreactive staining method was evaluated using pre­
absorbed primary antibodies and denatured protein standards and nuclear extracts. 
Pre-absorbed primary antibody solutions were prepared by incubating specific 
antibodies with the c-Fos and c-Jun protein standards. There was no specific antigen- 
antibody reaction and no color reaction for either of these controls. In contrast to the
pre-absorbed primary antibodies, untreated anti-c-Fos and anti-c-Jun antibody bound to 
the immunoreactive c-Fos and c-Jun proteins. Specificity o f our method was also 
tested by using denatured AP-1 protein standards and nuclear extracts from horse 
PBMCs. Immunoreactivity was abolished when samples were heat-treated and 
contemporary control blots had detectable immunoreactive proteins.
Results from this series of experiments collectively demonstrate that equine 
PBMCs contain ir-proteins necessary for functional interactions between GR and AP-1 
proteins subunits.
CHAPTER 6: THE RELATIONSHIP BETWEEN IMMUNOREACTIVE 
JUN EXPRESSION AND GLUCOCORTICOID EFFECTS ON 
LYMPHOKINE-ACTIVATED KILLER CELL ACTIVITY
A. Objectives
The overall goal of this experiment was to determine whether phorbol ester or 
cortisol treatments act individually or together to modify lymphokine activated killer 
(LAK) cell activity of equine peripheral blood mononuclear cells (PBMCs) stimulated 
with 250 Units of interleukin-2 (IL-2) per milliter (ml) o f media. We also 
characterized immunoreactive (ir)-Jun in equine PBMCs in order to determine whether 
any treatment effects were related to differences in the amount o f this nuclear protein.
Specific objectives o f this experiment were to:
1. Treat equine PBMCs with phorbol ester concentrations that would 
induce a significant increase in ir-Jun.
2. Determine whether cortisol treatments effected the amount o f ir-Jun 
in nuclear extracts from PBMCs.
3. Determine whether ir-Jun concentrations induced by phorbol ester 
treatment were modified by various doses of cortisol.
4. Characterize the effect o f phorbol ester, cortisol or cortisol and 
phorbol ester treatments on detectable ir-Jun measured at various 
time points during generation of equine LAK cell activity.
5. Determine the effect of phorbol ester treatment on IL-2 induced 
LAK cell activity.
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6. Verify stimulatory effects of low cortisol doses and the inhibitory
effects o f high dose cortisol treatment on LAK cell activity.
7. Determine whether combined treatment with phorbol ester and 
cortisol alters effects of the individual compounds on LAK cell 
activity.
B. Materials and Methods
1. Cell Culture and Experiment Design
The PBMCs were isolated from whole blood collected from resting horses 
(n=3), as described previously (Chapter 3). Cells were resuspended in RJPMI-1640 
media (Gibco) supplemented with 1% (v/v) 10,000 U/ml penicillin, 1% (v/v) 10 mg/ml 
streptomycin, 1% (w/v) glutamine, 2-mercaptoethanol and 5% (v/v) fetal calf serum. 
Ten ml of cells were cultured in 25 ml flasks at a concentration of 1 X 107 cells per
10 ml for 72 hours. The PBMCs from each horse were divided into 9 groups. Each
group included two replicates. One replicate was used for measurement o f LAK cell 
activity at 72 hours and the other replicate flask was used for measurement o f nuclear 
proteins. All treatments were added at the same time for PBMCs collected from an 
individual animal. Therefore, the experimental protocol depicted in Table 14 was 
repeated three times in order to evaluate samples from each horse.
Treatments o f IL-2, IL-2 plus phorbol ester (TPA), IL-2 plus cortisol or IL-2 
plus TPA and cortisol were added to media at the beginning o f culture (Table 14). All 
cultures were incubated at 39°C in a humidified incubator with 5% C 0 2 and 95% 0 2. 
The dose for each treatment was determined based on assays routinely performed as
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Table 14: Treatments Used to Test for Effects of Cortisol and Phorbol Ester on 
Lymphokine Activated Killer Cell Activity and the Expression of 
Immunoreactive c-Jun
Group Flask Treatments
1 1 & 2 Media
2 3 & 4 IL-2 (250 U/ml)
3 5 & 6 IL-2 plus TPA (0.1 mg/ml)
4 7 & 8 IL-2 plus cortisol (10'4 M)
5 9 & 10 IL-2 plus cortisol (10'8 M)
6 11 & 12 IL-2 plus cortisol (10'10 M)
7 13 & 14 IL-2 plus TPA and cortisol (10'4 M)
8 15 & 16 IL-2 plus TPA and cortisol (10'8 M)
9 17 & 18 IL-2 plus TPA and cortisol (10'10 M)
Blood samples were collected from resting horses (n=3) and peripheral blood 
mononuclear cells (PBMCs) were recovered by Ficoll density gradient centrifugation. 
Cells from each horse were divided into 9 treatment groups and all treatments were 
added at the beginning o f culture. Each treatment group included two replicate flasks. 
Odd numbered flasks were used to measure lymphokine activated killer (LAK) cell 
activity after culture for 72 hours. Even numbered flasks were used to recover nuclear 
proteins to measure immunoreactive-Jun.
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part o f collaborative studies on neuroendocrine-immune interactions in the equine 
species. Doses were also based on previously reported data. Equine PBMCs treated 
with 125 U o f IL-2 per ml have previously been tested in conjunction with various 
hormones and animes to characterize effects on LAK cell activity (Keadle, 1992; 
Melrose et al., 1993). In the present study, optimal concentrations of IL-2 (250 U/ml) 
were used to generate LAK cell activity. This dose o f IL-2 was used to treat all 
cultures except the media controls. The phorbol ester dose was based on literature 
which demonstrated that this concentration produced specific time-dependent increases 
in Jun protein collected from human PBMCs (Jonat et al., 1990). The same report 
indicated that this dose of TPA had a significant effect on immune function and that 
the effectiveness o f treatment was related to glucocorticoid effects that are independent 
o f direct binding to glucocorticoid response elements (GREs). In the present 
experiment, all TPA-treated cultures were incubated with 0.1 mg/ml TPA.
The concentration of cortisol added to each culture was based on previous tests. 
Stimulation o f IL-2 induced LAK cell activity has been reported for lower hormone 
concentrations (Keadle, 1992). However, the exact concentration that is stimulatory 
seems to vary with animal, time o f day and day of sample collection (Bu & Melrose, 
unpublished). When in vitro cortisol treatments stimulate equine LAK cell activity, 
cortisol concentrations are typically 10'8 or 10'10 M. We tested both hormone doses in 
the present study so that we could determine whether either concentration stimulated 
LAK cell function induced by optimal concentrations o f IL-2.
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2. Methods for Measurement of Immunoreactive c-Jun
To measure ir-Jun in nuclear extracts from PBMCs, 2 ml o f cells were 
collected from even numbered flasks for each treatment group at 0, 12, 24, 48 and 72 
hours. Cell protein was extracted as described in Chapter 5. Extracts were stored at - 
80°C until the analysis of c-Jun protein. The c-Jun protein levels in PBMCs treated 
with IL-2, phorbol ester and various doses o f cortisol for 0, 12, 24, 48 and 72 hours 
were determined by dot blot and autoradiography techniques as well as by counting 
radioactivity bound to each sample. Standard Jun proteins and nuclear extracts from 
PBMCs were pipetted onto nitrocellulose membranes (2 pl/dot) as indicated in Table 
15 and membranes were air-dried for 10 minutes. A single nitrocellulose membrane 
was used for each horse. Each membrane was marked so that it was subdivided in 64 
squares o f equal size (Table 15). Rows and columns o f squares were numbered in 
order to maintain orientation o f the membrane. All o f the squares in the first row and 
the first square in the second row contained serially diluted c-Jun standards ranging 
from 50 ng to 0.2 ng per dot. The second square in row 2 included 4 ng of primary 
polyclonal anti-Jun antibody. This sample was included as a control to ensure that 
bound or immobilized antibody was detected in each reaction. The next set o f boxes 
(row 2, lane 3 through row 7, lane 7) included nuclear extracts from PBMCs collected 
at various time points and from each of the 9 treatment groups. Finally, the last 9 
boxes were left as blanks so that non-specific binding o f radioactivity to the membrane 
could be determined for each experiment.
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Table 15: Key for the Identification and Location of Immunoreactive Samples on Dot 
Blots Prepared for Each Horse (See text for additional details)
1 2 3 4 5 6 7 8
1
c-Jun
Std
50 ng
c-Jun 
Std 
25 ng
c-Jun
Std
12.5 ng
c-Jun
Std
6.25 ng
c-Jun 
Std 
3.1 ng
c-Jun 
Std 
1.6 ng
c-Jun 
Std 
0.8 ng
c-Jun 
Std 
0.4 ng
2
c-Jun 
Std 
0.2 ng
c-Jun 
Ab 
4 ng
0 Hour 
C ontrol
0 Hour 
IL-2
250 ll/m l
0 Hour
IL-2
TPA
0 Hour 
IL-2 
Cort. 
(10J M)
0 Hour 
IL-2 
Cort. 
(10‘“M)
0 H our
IL-2
Cort.
( 10‘I,IM)
3
0 Hour
IL-2
TPA
Cort.
(10 '4M)
0 H our
IL-2
TPA
Cort.
(10 '“M)
0 Hour
IL-2
IP A
Cort.
(10‘"'M)
12 Hour 
Control
12 Hour 
IL-2
250 U/ml
12 Hour
IL-2
TPA
12 Hour 
IL-2 
Cort. 
(lO-'M )
12 H our 
IL-2
Cort.
(10*M )
4
12 Hour 
IL-2 
Cort. 
(1 0 " 'M )
12 Hour
IL-2
TPA
Cort.
(10-'M )
12 H our
IL-2
IPA
Cort.
(10"M )
12 Hour
IL-2
TPA
Cort.
(10'"'M )
24 Hour 
Control
24 H our 
IL-2
250 U/ml
24 Hour
IL-2
IP A
24 H our 
IL-2 
Cort. 
(10J M)
5
24 Hour 
IL-2 
Cort. 
(10"M )
24 H our 
IL-2 
Cort. 
(10" 'M )
24 H our
IL-2
TPA
Cort.
(lO-’M)
24 Hour
IL-2
TPA
Cort.
(10*M )
24 Hour
IL-2
TPA
Cort.
(10 '"M )
48 Hour 
Control
48 Hour 
IL-2
250 U/ml
48 H our
IL-2
IPA
6
48 Hour 
IL-2 
Cort. 
(1 0 'M )
48 H our 
IL-2 
Cort. 
(10'"M)
48 H our 
IL-2 
Cort. 
(10" 'M )
48 Hour
IL-2
TPA
Cort.
(lO-'M )
48 Hour 
IL-2 
TPA 
Cort.
(10 *M)
48 Hour
IL-2
TPA
Cort.
(10-'"M)
72 Hour 
Control
72 H our 
IL-2 
250 
U/ml
7
72 Hour
IL-2
TPA
72 Hour 
IL-2 
Cort. 
(10-'M )
72 H our 
IL-2 
Cort. 
(10"M )
72 Hour 
IL-2 
Cort. 
(10 '"’M)
72 Hour
IL-2
TPA
Cort.
(10-'M )
72 Hour 
IL-2 
TPA 
Cort.
(10 *M)
72 Hour
IL-2
TPA
Cort.
(10 '"M )
Blank
8
Blank Blank Blank Blank Blank Blank Blank Blank
Membranes were incubated with 10% (v/v) bovine serum albumin (BSA) in 
TBS buffer [20 mM Tris (pH 7.5), 150 mM NaCl] for 60 minutes at room temperature 
in order to limit non-specific binding. All incubations and rinses were performed 
while the free-floating membranes were being gently agitated on an orbital rotator.
The membranes were incubated with 2 pg/ml o f polyclonal rabbit anti-c-Jun IgG 
overnight at 4°C. On the next day the membranes were incubated with 10 ml of 
diluted (1:1000) 125I-labeled anti-rabbit IgG in 10% (w/v) BSA-TBS buffer for 60 
minutes at room temperature. The dilution of radiolabeled IgG was done as 
recommended by the supplier and preliminary experiments (data not shown) 
demonstrated that radiolabeled second antibody could be effectively substituted for the 
alkaline-phosphatase conjugated antibody used in previous experiments (Chapter 5). 
Membranes were rinsed repeatedly in TBST buffer [TBS buffer with 0.05% (v/v) 
Tween-20] and a Geiger counter was used to monitor radioactivity left on a blank 
nitrocellulose membrane that had been processed with the membrane containing 
known and unknown ir-Jun protein. When background activity of the blank membrane 
was reduced to relatively low and constant levels, the experimental membrane was air 
dried and processed for autoradiography using Kodak X-OMAT diagnostic film and 
Kodak X-Omatic regular intensifying screens. Films were exposed for 48 hours at - 
80°C. The resulting films were developed using automated equipment operated by 
staff in the radiology department in the School of Veterinary Medicine.
Once autoradiography was completed, the membranes were cut up into the 64 
squares depicted in Table 15. Radioactivity in each square was counted using a LKB
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gamma counter. Mean non-specific binding was calculated for blank membranes and 
specific binding was recorded as the CPM measured over CPM for blank squares. 
When tests were completed for all horses, the mean CPM at time zero and the mean 
CPM for control cultures were calculated. Treatment effects at 72 hours were 
evaluated after the CPM for treated cultures were calculated as a percent o f the media 
control CPM. These data were analyzed using ANOVA and Tukey's test. Data for 
CPM measured at various time points was transformed so that CPM measured for cells 
harvested at 12, 24, 48 and 72 hours are presented as a percent o f the CPM measured 
at 0 hours for an individual treatment group. These data were analyzed using 
ANOVA and means at various time points were compared to results at 0 hours using 
Dunnett's t-test.
3. 51 Chromium Release Cytotoxicity Assay
The PBMCs used for LAK cel! activity assays were cultured for 72 hours.
Then cells were collected by centrifugation and cell pellets were resuspended in fresh 
media without IL-2. Lymphokine activated killer cell activity was measured by 
assaying treated PBMCs for cytolytic activity against an equine tumor cell line, 
Eqt8888, using a standard 51Cr release cytotoxicity assay (Hormanski et al., 1992).
The cultured PBMCs were collected from the flask by centrifugation and they were 
resuspended in fresh media at a concentration o f 3.3 xlO6 cells per ml. Then 200 pi 
volumes o f the cell suspension were placed into each o f 4 replicate wells on 96 well 
round bottom plates. This was followed by serial dilution o f cells to yield final 
effector:target ratios o f 250:1, 55:1 and 19:1. The log growth phase target cells were
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labeled for 2 hours with 100 pCi of Na251CrO4/106 cells. These cells were then 
washed three times with media and resuspended at a final concentration o f 2 x l0 4 cells 
per ml. They were added to 96-well U-bottomed plates containing the serially diluted 
LAK cells. The plates were gently centrifuged at 800 rpm for 2 minutes and 
incubated for 4 hours at 39°C. Supernatants were collected using a supernatant 
collection system (Skatron, McClean, VA). Lysis o f the Eqt8888 cells was measured 
by quantitating the release of the radioisotope into the culture supernatant with a LKB 
quattro gamma counter. Percent specific lysis was calculated by the formula: 
(experimental release - spontaneous release)/(total release - spontaneous release). Data 
were analyzed using ANOVA and Tukey test.
C. Results
1. AP-1 Protein Expression in LAK Cells
The effect o f phorbol ester and cortisol treatment on ir-Jun in the IL-2-induced 
LAK cell cultures was determined by preparing autographs of dot blots that included 
extracts from the PBMCs. A representative autoradiograph is shown in Figure 20.
The detectable radioactivity of c-Jun protein standards appeared to decrease in 
proportion to the amount o f protein. There was little difference in the visible intensity 
o f radioactivity among protein extracts prepared from PBMCs cultured for 0, 12 and 
24 hours. However, there was a visible difference in the intensity of radioactivity 
among samples treated for 48 and 72 hours. The intensity of radioactivity for samples 
prepared from PBMCs treated with IL-2 plus TPA and IL-2 plus TPA and cortisol 
(10'8 and 10'10 M) appeared to be greater than the intensity of radioactivity associated
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Figure 20: Effects o f Phorbol Ester and Cortisol Treatments on Expression o f c-Jun 
Proteins in Horse PBMCs Stimulated with IL-2: Autoradiography. PBMCs isolated 
from resting horse peripheral blood samples were cultured with IL-2, IL-2 plus 
phorbol ester, IL-2 plus cortisol and IL-2 plus phorbol ester and cortisol. A 2 ml 
aliquot o f cells was harvested from each flask at 0, 12, 24, 48 and 72 hours. Nuclear 
proteins extracted from cultured cells were pipetted on to nitrocellulose membranes. 
The amount of protein and the source o f each protein sample or standard in each dot 
was summarized in Table 15. Membranes were incubated with rabbit anti-c-Jun 
polyclonal antibodies and 125I-labeled anti-rabbit IgG. Radioactivity was detected by 
autoradiography.
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with other treatment groups and other time points. High dose cortisol treatment 
appeared to decrease the intensity of radioactivity associated with immunoreactivity 
induced by TPA when protein extracts were prepared from PBMCs cultured for 48 and 
72 hours.
Radioactivity bound to each protein sample was counted using a gamma- 
counter. There was a main effect of treatment (p<0.05) on measurable radioactivity. 
Results (mean ± SD) obtained for the cells which were cultured for 72 hours are 
shown in Figure 21. The IL-2 treatment did not significantly affect immunoreactive c- 
Jun protein whereas TPA significantly increased (p<0.05) the detectable amount of ir- 
Jun. In contrast, high (10‘4 M) or low dose (10'8 and 10‘1H M) cortisol treatments alone 
did not significantly affect the amount of ir-Jun protein. However, high dose cortisol 
treatment did abolish TPA-induced increases in ir-Jun protein. Low dose cortisol 
(10'8 M, 10'1U M ) treatments had no significant effect on TPA induced ir-Jun.
Results for radioactivity bound to ir-Jun in extracts o f PBMCs cultured for 0, 
12, 24, 48 and 72 hours are summarized in Figure 22. There was no significant effect 
o f time on ir-Jun for cultures incubated with media, 250 U/ml of IL-2 or IL-2 plus 
cortisol. However, ir-Jun was increased (P<0.05) by TPA treatment at 48 and 72 
hours as compared to the mean CPM measured at 0 hours. The stimulatory effect of 
TPA treatment was not altered (P>0.05) when TPA-treated cultured were also treated 
with 10'8 M or 10'10 M concentrations of cortisol. However, stimulatory effects of 
TPA treatment on time-dependent increases in ir-Jun were abolished (P>0.05) by 
incubating TPA-treated cells with 10'4 M cortisol.
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Figure 21: Effects o f Phorbol Ester and Cortisol Treatments on Expression o f c-Jun 
Proteins in Horse PBMCs Stimulated With IL-2: Radioactivity. PBMCs isolated from 
resting horses (n=3) were cultured with IL-2, IL-2 plus phorbol ester, IL-2 plus 
cortisol and IL-2 plus phorbol ester and cortisol. A 2 ml aliquot of cells was 
harvested from each flask at 0, 12, 24, 48 and 72 hours. Proteins extracted from 
cultured cells were immobilized on nitrocellulose membranes. Then, the membrane 
was incubated with rabbit anti-c-Jun polyclonal antibodies and 125I-labeled anti-rabbit 
IgG. The radioactivity was quantitated with a gamma counter. The mean (± SD)
CPM for samples collected at 72 hours is shown as a percentage of CPM measured for 
media control samples. All values were corrected for non-specific radioactivity by 
subtracting CPM measured in blank nitrocellulose squares (n=3). Then, the data were 
analyzed using ANOVA and Tukey's test. Bars marked with different letters were 
significantly different.
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Figure. 22: Measurable Amounts of Immunoreactive (ir)-Jun Extracted From Peripheral Blood Mononuclear Cells (PBMCs) 
Treated with Interleukin-2, Phorbol Ester (TPA) and Cortisol. The PBMCs were harvested from blood that was collected from 
resting horses (n=3). Each panel depicts results for cells cultured in media or with 250U/ml IL-2 with or without 0.1 mg/ml TPA 
alone or in combination with various cortisol concentrations. The. mean (± SD) CPM associated with ir-Jun in each treatment 
group is presented as a percent of the CPM measured at the beginning of culture and for each group. Data for each treatment is 
included in a single panel. Results were analyzed with ANOVA and mean ir-Jun at 12, 24, 48 and 72 hours after the beginning 
of culture were compared to mean CPM measured at 0 hours using Dunnett's t-test. Means which were significantly different 
from the 0 hour sample are marked with an asterisk (*). See text for additional details.
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2. LAK cell activity
Results from cytotoxicity assays which tested effects o f phorbol ester and 
cortisol treatments on lL-2-induced LAK cell activity are summarized in the Figure 23. 
Lytic activity at an effector to target ratio o f 250:1 was analyzed using Tukey's test. 
Lytic activity for effectontarget ratios of 55:1 and 19:1 were not analyzed statistically 
due to the extremely low LAK cell activity measured for these samples (data not 
shown). Lytic activity measured for the media control cultures was 7% and 
interleukin-2 treatment o f PBMCs for 72 hours increased (P<0.05) lytic activity to 
31%. This effect was abolished (P>0.05) by treatment of PBMCs with TPA and 
treatment with 10‘4 M cortisol. There was no significant effect o f 10'8 and 10'10 M 
cortisol treatments on IL-2 induced LAK cell activity. Specific lytic activity was 27% 
in the IL-2 plus 10'8 M cortisol treated group and 33% in the IL-2 plus 10'IQ M 
cortisol treated group. Finally, the inhibitory effect of TPA on IL-2-induced LAK cell 
activity was not significantly effected by any of the doses of cortisol tested in this 
experiment.
D. Discussion
Lymphokine activated killer cell activity is defined as cytolytic activity 
mediated by lymphocytes that is not restricted by MHC expressed on target cells. In 
human and murine species, LAK cell activity is derived from the LGL population 
which contains virtually all active NK cells (Herberman et al., 1987). Incubation of 
equine PBMCs, containing LGL and small granular lymphocytes, with a relatively
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Figure 23: Effects o f Phorbol Ester and Cortisol Treatments on IL-2-Induced LAK 
Cell Activity for PBMCs Collected From Resting Horses (n=3). PBMCs isolated from 
resting horse blood samples were incubated for 72 hours with IL-2, IL-2 plus phorbol 
ester, IL-2 plus cortisol or IL-2 plus phorbol ester and cortisol. LAK cell activity 
(mean ± SD) was measured against the species specific EqT 8888 cell line at an 
effector:target ratio of 250:1 using a standard 51Cr release assay. Phorbol ester and 
high dose cortisol treatment significantly inhibited IL-2-induced specific lysis. Low 
dose cortisol treatments did not affect IL-2-induced LAK cell activity. Phorbol ester 
plus high dose or low dose cortisol treatments significantly inhibited EL-2-induced 
LAK cell activity. Bars marked with the same letters were not significantly different.
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high dose o f IL-2 (125-250 U/ml) results in species-specific LAK cell activity against 
the Eqt 8888 cell line (Hormanski et al., 1992).
Lymphokine activated killer cell activity is regulated by multiple factors 
including cellular factors and soluble factors. High doses o f cortisol has been shown 
to inhibit in vivo LAK cell activity (McVicar, 1989; Papa et al., 1986) and in vitro 
results, as well as studies on exercise stress-induced changes in immune functions of 
horses, have suggested that low dose cortisol treatments may enhance LAK cell 
activity and mediate the exercise-induced increase in LAK cell activity (Keadle, 1992; 
Melrose et al., 1993).
Evidence from other species suggests that the effects of high dose 
glucocorticoids on the immune system are mediated by binding of the hormone- 
receptor complex to glucocorticoid response elements (GRE) on target DNA and 
related changes in transcription o f responsive genes. The mechanisms responsible for 
stimulatory effects of low dose cortisol effects likely involve interference with nuclear 
proteins necessary for transcriptional effects of the AP-1 complex or other protein 
interactions. Thus, it is possible that the inhibitory effect o f high dose cortisol on IL-2 
induced LAK cell activity in horses is mediated by direct interaction o f the GR with 
the GRE in the target genes while the stimulatory effect o f the low dose may involve 
interaction o f the GR with AP-1 proteins. To test this hypothesis, two endpoints were 
measured in this part o f the project. The first experimental endpoint tested for an 
interaction between phorbol ester and cortisol treatments on IL-2-induced LAK cell 
activity. The second analysis o f experimental data was based on an AP-1 protein
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expression assays. Objectives o f the latter experiment were to characterize the effect 
o f cortisol on AP-1 protein expression in LAK cells and determine whether the 
induction o f AP-1 protein would modify the effects o f cortisol on IL-2-induced LAK 
cell activity. These analyses were expected to demonstrate that AP-1 proteins were 
involved in induction o f equine LAK cell activity by IL-2 and that the stimulatory 
effects of glucocorticoids on IL-2-induced LAK cell activity were mediated by an 
interaction between multiple stimuli related to glucocorticoid effects and activators of 
protein kinase C (AP-1 proteins).
Activator protein-1 proteins are products o f immediate early genes, jun  and fas. 
They can be induced by phorbol esters. Phorbol ester treatments activate protein 
kinase C. Activated PKC causes phosphorylation o f cellular proteins which, in turn, 
may lead to phosphorylation o f amino acid residues within the transactivation residues 
o f c-Jun and result in an increase in transcriptional activity of c-Jun. Alternatively, 
dephosphorylation o f residues located directly upstream of the basic DNA binding 
domain results in an increase in the DNA binding activity o f c-Jun. Then, the 
activated c-Jun homodimers or heterodimers bind to AP-1 sites within the c-jun 
promoter or other target genes and induce gene transcription. The induction of c-jun 
gene expression leads to signal amplification and conversion o f transient signals into a 
long term transcriptional response (Angel et al., 1988a). Interaction between AP-1 
protein subunits and GR results in inhibition of DNA-binding activity o f both the AP- 
1 complex and GR. If  low dose cortisol regulates IL-2-induced LAK cell activity 
through protein-protein interactions with AP-1 protein subunits, the addition of phorbol
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ester should alter the effect o f low dose cortisol treatment on LAK cell activity 
induced by IL-2. Low dose cortisol treatment should also affect the measurable 
amount o f c-jun induced by phorbol ester. However, our results from the LAK cell 
activity assay suggested there was no interaction between low dose cortisol and 
phorbol ester treatment on IL-2 induced LAK cell activity since there was no 
significant difference in LAK cell activity for cultures treated with low dose cortisol, 
low dose cortisol plus phorbol ester or phorbol ester alone.
The measurable amount o f ir-c-Jun protein in extracts from PBMCs treated 
with low doses of cortisol were not different from ir-c-Jun in cultures treated with 
IL-2. Cultures incubated with IL-2 plus low dose cortisol and phorbol ester or IL-2 
plus phorbol ester had similar amounts of ir-Jun. Therefore, it is likely that AP-1 
proteins are not involved in the effects of low dose cortisol on IL-2-induced LAK cell 
activity expressed by horse PBMCs.
The published literature suggests that there are a number o f other mechanisms 
which may mediate effects o f low dose cortisol on LAK cell activity. In particular, 
cortisol may interfere with IL-2 receptor signal transduction by effecting 
phosphorylation or cortisol may interact with nuclear transcriptional factors other than 
AP-1. Stimulation of IL-2 receptors activates tyrosine kinase pathways including the 
p56lck pathway, the c-myc induction pathway and the be 1-2 induction pathway 
(Miyazaki et al., 1995). Activity o f lek is regulated by phosphorylation and 
dephosphorylation of the tyrosine residue at the carboxyl terminus. The elevation of 
cAMP occurs within minutes following exposure to cortisol and does not require
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protein synthesis (Wheeler et al., 1981). Thus, cAMP may mediate effects o f low 
dose cortisol on IL-2-induced LAK cell activity observed in previous experiments by 
our laboratory. Increased cAMP can activate cAMP-dependent protein kinases which 
may cause phosphorylation/dephosphorylation of the tyrosine residue at the carboxyl 
terminus o f lck and modify activity of the lck. Alternatively, GR may interact with c- 
myc or bcl at the transcriptional level.
The amount o f ir-Jun measured in this experiment also demonstrated that 
higher doses of cortisol significantly inhibited the stimulatory effect of TPA treatment.
The amount o f ir-Jun measured for the IL-2 plus high dose cortisol treatment group 
was not significantly different from that for cells treated with IL-2 alone or PBMCs 
cultured only in media. Immunoreactive-Jun from PBMCs treated with IL-2 plus 
phorbol ester and with higher dose cortisol was significantly different from that for 
PBMCs treated with IL-2 plus phorbol ester. Although high dose cortisol treatments 
inhibited the amount of ir-Jun induced by phorbol ester treatment, there was no 
relationship between the measurable amount of ir-Jun and LAK cell activity for these 
two groups.
Results on LAK cell activity measured in this experiment demonstrated that 
phorbol ester treatments inhibit IL-2-induced LAK cell activity. This suggests that 
there may be an interaction between the PKC pathway and tyrosine kinase pathway in 
induction of LAK cell activity. However, it is unlikely that AP-1 proteins play a role 
in the inhibitory effects of phorbol esters on IL-2-induced LAK cell activity.
Therefore, the PKC pathway may proximally interfere with the tyrosine kinase
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pathway activated by IL-2 through induction o f phosphorylation or dephosphorylation 
o f cellular proteins which are involved in the signaling of IL-2 receptors.
CHAPTER 7: SUMMARY AND CONCLUSIONS
Glucocorticoids are steroid hormones that are synthesized by the adrenal cortex. 
They have profound effects on immune functions. As primary effectors o f cellular and 
humoral immune responses, lymphocytes and macrophages are the major target for 
glucocorticoids. Pharmacological doses o f glucocorticoids suppress a wide variety of 
nonspecific inflammatory responses and specific immunologic processes. They inhibit 
the growth, differentiation and functions o f monocytes and lymphocytes, the 
distribution o f various cell types and the production of cytokines. In contrast, low 
physiologic concentrations of glucocorticoids enhance some immune functions.
Glucocorticoids affect immune functions through multiple mechanisms. 
Molecular mechanisms involved in glucocorticoid effects on the immune system may 
involve regulation o f gene transcription by binding of glucocorticoid receptors to 
glucocorticoid response elements on the target DNA or interaction with AP-1 proteins, 
or other nuclear proteins.
Lymphokine-activated killer cells have been defined as cytotoxic lymphocytes 
capable of lysing fresh autologous solid tumor target cells in short-term 5lCr-release 
assays (Yang, et al., 1986). Lymphokine activated killer cell activity is MHC- 
nonrestricted cytotoxicity and it is generally limited to killing by lymphocytes as 
measured in short-term (4 hr) chromium release assays. The majority o f LAK cell 
activity is derived from IL-2-activated LGL/NK cells whereas little or no activity is 
generated from resting T cells. In the equine species, LAK cell activity is associated 
with the EqT3+ population (Hormanski, et al., 1992) which includes small T cells and
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large granular lymphocyte (LGL) fractions of peripheral T lymphocytes. The LGL 
fraction requires less IL-2 to achieve maximal cytolytic activity and also exhibits more 
potent cytotoxic activity on a per cell basis.
Inhibitory effects of high dose glucocorticoids on NK cell activity are well 
established (Gatti, et al., 1987). Similarly, studies have shown that high doses of 
glucocorticoids inhibit LAK cell activity and LAK cell generation (Vetto, et al., 1987). 
On the other hand, recent studies have indicated that low dose cortisol treatment may 
enhance LAK cell activity in horses (Keadle, 1992; Melrose, et al., 1993).
Controversial reports on the effect of glucocorticoids on the immune system are 
likely due to differences in susceptibility to glucocorticoids among species, the 
maturation and activation status of lymphoid cells, different model systems (in vivo or 
in vitro), dose o f glucocorticoids and use of synthetic glucocorticoids. In most studies 
on inhibitory effects of glucocorticoids, suprapharmacological doses o f synthetic 
corticosterone and glucocorticoid sensitive species have been used.
To interpret results correctly, we used unconditioned horses which have normal 
plasma cortisol concentrations, variable concentrations o f cortisol ranging from low 
physiological concentrations to suprapharmacological doses and both in vivo and in 
vitro approaches to address effects o f glucocorticoids on LAK cell activity and related 
molecular mechanisms. Adrenal function and plasma concentrations in horses are well 
defined. Previous studies have shown that incubation o f PBMCs with IL-2 induces 
species-specific LAK cell activity and a target cell line that allows for measurement of 
IL-2-induced LAK cell activity has been established (Hormanski, et al., 1992). In
1 4 4
addition, previous studies have shown that low dose cortisol (10‘10 M) treatment 
enhanced IL-2-induced LAK activity in resting horses (Keadle, 1992). Assayable 
concentrations o f cortisol measured for horses included in this experiment were 1 O'7 to 
10'8M. This is considered to be physiologically normal.
We found that resting horse PBMCs express detectable basal levels of 
immunoreactive AP-1 proteins and glucocorticoid receptor. This provided the basis 
for the studies on the role o f AP-1 proteins in immune responses and the mechanisms 
o f glucocorticoid actions on immune functions o f these cells. In vitro studies on the 
effects o f cortisol treatments showed that the high dose glucocorticoid treatment 
inhibited LAK cell activity. The concentration o f cortisol which produced this effect 
is considered to be a pharmacological dose. We also demonstrated that in vitro 
phorbol ester treatments inhibited IL-2-induced LAK cell activity in horse PBMCs but 
phorbol ester treatment did not alter effects o f cortisol on IL-2-induced LAK cell 
activity. Furthermore, our results demonstrated that there is no direct relationship 
between phorbol ester induced AP-1 protein expression and LAK cell activity in 
horses since the expression o f AP-1 proteins was induced in LAK cells whose 
cytotoxic activity was inhibited by phorbol ester while the expression o f AP-1 proteins 
was inhibited in LAK cells whose cytotoxic activity was also inhibited by cortisol. In 
addition, our results indicated that AP-1 proteins are not involved in effects o f cortisol 
treatments on IL-2-induced LAK cell activity in horses since induction o f AP-1 
proteins did not alter effects o f high or low dose cortisol treatments on IL-2-induced
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LAK cell activity. Therefore, AP-1 proteins do not appear to be involved in 
glucocorticoid regulation o f LAK cell activity in the equine species.
Based on our results and the results from previous studies, it seems that low 
dose cortisol modulates IL-2-induced LAK cell activity in an IL-2 concentration- 
dependent manner. Low dose cortisol may cooperate with lower concentrations o f IL- 
2 to induce expression of the high affinity IL-2 receptor by regulating activity of 
protein kinases involved in IL-2 receptor signaling through cAMP. To test this 
hypothesis, several studies need to be done including tests on the effects o f low dose 
cortisol on intracellular cAMP levels, phosphorylation/dephosphorylation o f cellular 
protein kinases which are involved in IL-2 receptor signaling and IL-2 receptor 
expression, modulation o f the effects of low dose cortisol by cyclic adenylase inhibitor 
and relationship o f cAMP and phosphorylation/dephosphorylation o f these cellular 
protein kinases to IL-2 receptor expression and LAK cell activity. However, the 
significance of such studies is questionable since stimulatory effects o f cortisol on 
equine LAK cell activity are observed with hormone concentrations below normal 
physiological concentrations. Furthermore, it is unlikely that IL-2 concentrations are a 
limiting factor in stressed animals since large amounts of cytokines are released from 
the adrenal gland o f stressed animals (Bartfai et al., 1990)
Low dose cortisol treatments may regulate activity o f the gene coding the IL-2 
receptor. Since AP-1 proteins do not seem to be involved in effects o f glucocorticoids 
on IL-2-induced LAK cell activity, other unknown proteins may mediate effects of 
low dose cortisol on IL-2-induced LAK cell activity in horses. This hypothesis can be
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examined by studying effects o f low dose cortisol on IL-2 receptor mRNA levels in 
PBMCs by Northern blot or polymerase chain reactions (PCR) followed by Southern 
blot analysis. Further, studies on effects o f low dose cortisol treatment on protein 
binding to the promoter of the IL-2 receptor gene using footprinting may help to 
identify the target sequence of cortisol and nuclear factors which interact with GR.
We conclude that there is no direct relationship between AP-1 proteins and IL- 
2-induced LAK cell activity in horses. Pharmacological doses o f glucocorticoids may 
inhibit IL-2-induced LAK cell activity by a transcriptional effects o f the glucocorticoid 
receptor. Low dose cortisol treatments did not affect the IL-2-induced LAK cell 
activity in our experiments. Given the physiological range in normal glucocorticoid 
concentration we do not feel that exercise-induced changes in LAK cell activity are 
related to cortisol effects. Subsequent studies should concentrate on one or more of 
the many compounds that are released in response to exercise stress and their, effects 
on LAK cell activity.
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